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CHAPTER 1:  GENERAL INTRODUCTION 
 
Overview 
 The genus Brucella includes eight species which infect numerous mammalian 
hosts as well as humans.  In the natural animal hosts the brucellae infect the 
lymphoreticular and reproductive organs.  These infections often lead to 
pyogranulomatous lesions in numerous organs.  In humans the disease has been 
historically referred to as undulant fever and is characterized by recurrent pyrexia, 
malaise, myalgia, abortion in pregnant females, and pyogranulomatous lesions in male 
reproductive organs, joints, and parenchymatous organs.   
The first isolation of Brucella was made by David Bruce in 1887 on the island of 
Malta from the spleens of infected British soldiers and was originally named 
Micrococcus melitensis.2, 6  Later work on Malta found that the organism which Bruce 
identified was also found in the milk of goats.10  The genus was later renamed Brucella in 
honor of Bruce’s contribution to discovering the etiologic agent of undulant fever.  The 
first isolation of Brucella in animals, however, was made by Bang in Denmark in 1897.1  
Bang also was the first to fulfill Koch’s postulates by reproducing abortion in pregnant 
cattle with the organism which he isolated.  The first isolation of Brucella in swine 
occurred in 1914 in Indiana and was accomplished by Traum.8  Traum isolated the 
organism from an aborted fetus and identified the organism as a unique strain of Brucella 
abortus, which was at that time known as Bacillus abortus.  The causative agent of swine 
brucellosis was later recognized and classified as a separate species in the genus Brucella 
by Huddleson in 1929, and was renamed Brucella suis.4
The first eradication program for brucellosis in the United States was initiated for 
cattle in 1934.  This program was started subsequent to a major drought and the great 
depression more as an effort to reduce cattle numbers within the country as part of an 
economic recovery program rather than to control brucellosis.7  Since its inception, this 
program has relied on identification of seroreactive animals, identification of herds of 
origin, and elimination of seroreactive cattle or herds.  This program in cattle was aided 
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by the introduction of vaccination with the B. abortus strain 19 in 1940 and B. abortus 
strain RB51 in 1996. 
The US State-Federal Brucellosis Eradication Program for swine was organized in 
the 1960’s.  Like its cattle counterpart, this program has relied on serological 
surveillance, epidemiological investigation, trace back to originating herd, and 
elimination of seroreactive herds.  Vaccination has never been a part of the swine 
eradication program; however, research into the application of Brucella vaccines to swine 
occurred in the 1940’s and 1950’s prior to the initiation of the program.  The success of 
the program was undoubtedly aided by the drastic changes in swine production and 
management which have occurred in the industry since the program’s inception.  These 
changes have lead to the institution of biosecurity practices and record keeping which can 
only be rivaled by the poultry industry.   
The successful elimination of swine brucellosis from domestic swine herds in the 
US and Europe through testing and slaughter programs lead to a general paucity of swine 
brucellosis research in recent decades.  Most literature in the swine brucellosis field was 
published between 1930 and 1960.  However, within the last decade there has been a 
renewed interest in swine brucellosis which has lead to a small revival in research related 
to swine brucellosis and B. suis.  This renewed interest at a time of near eradication of 
Brucella from the US was sparked by an initiative to deal with wildlife reservoirs of 
Brucella.  Feral swine are enzootically infected with B. suis in the US and are responsible 
for the remaining outbreaks of brucellosis in domestic swine.  Another reason for general 
renewed interest in Brucella related research has been the inclusion of B. suis, as well as 
B. melitensis and B. abortus, on the US Centers for Disease Control and USDA Select 
Agents list due to their perceived potential use as biological agents of terrorism and war.9
 Virtually all publications dealing with feral swine brucellosis have been mere 
serological surveys in selected populations. Recent Brucella vaccine studies in domestic 
swine have suggested that the naturally rough mutant cattle vaccine B. abortus RB51 
(RB51) would be effective in controlling swine brucellosis; however, controlled 
challenge studies had not been attempted.3, 5  The research reported herein was designed 
to investigate basic characteristics of brucellosis in feral swine and to investigate possible 
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vaccine candidates for the control of swine brucellosis.  Work in this dissertation 
addressed microbiological and pathological aspects of brucellosis in a feral swine herd.  
Also, studies in this dissertation assessed the usage of RB51 in domestic and feral swine 
as well as a newly described naturally rough mutant of B. suis as a vaccine in domestic 
swine.  
 
Dissertation Organization 
 This dissertation is presented in the alternative format and includes a review of 
the pertinent literature, four manuscripts submitted to three different journals, and general 
conclusions.  Chapter 2 is a review of historical and recent literature dealing with 
brucellae, swine brucellosis, B. suis, Brucella vaccines, and feral swine.  Chapter 3 is a 
manuscript submitted to the Journal of Veterinary Diagnostic Investigation.  This 
manuscript characterizes a feral swine herd enzootically infected with Brucella and 
attempts to provide information regarding characteristics of isolated Brucella, culture and 
seroprevalance, and lesions of Brucella infected animals.  Chapter 4 is a manuscript 
submitted to the journal Research in Veterinary Science and reports the results of a 
vaccine trial with RB51 in an enzootically infected feral swine herd.  Chapter 5 is a 
manuscript published in the American Journal of Veterinary Research.  This paper 
reports the results of experiments designed to assess the distribution, clearance, 
immunogenicity, and efficacy of RB51 in domestic swine.  Chapter 6 is a manuscript 
submitted to the American Journal of Veterinary Research which characterizes a newly 
recognized naturally rough mutant of B. suis, B. suis 353-1, with respect to its 
pathogenicity, distribution, clearance, immunogenicity, and efficacy as a vaccine in 
domestic swine.  Chapter 7 includes general conclusions.  References cited within each 
chapter are listed at the end of the respective chapter, and Chapters 3 to 6 are formatted 
according to the respective journals to which they were submitted.    
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CHAPTER 2:  LITERATURE REVIEW 
 
Introduction 
 The brucellae are gram-negative, coccobacillary, aerobic, facultative intracellular 
alpha-proteobacteria which are known to infect over 80 mammalian species.107  The 
genus Brucella is composed of 8 highly genetically homogeneous species.117, 231, 232  B. 
melitensis was the first species identified and infects primarily goats and sheep.35, 170   B. 
abortus was first identified in cattle15 but enzootically infects a number of large ruminant 
species including North American bison (Bison bison)73 and elk (Cervus elaphus 
nelsoni).225  B. suis was first isolated from swine,226 but other members of the species 
infect reindeer and caribou (Rangifer tarandus) and murine species.160  B. ovis primarily 
infects sheep and is of lower virulence than the other Brucella species.37  B. canis is 
enzootic in canid species,82, 134 and B. neotomae has been identified in the desert wood rat 
(Neotoma lepida) of the American West.218  The most recently identified Brucella species 
are those which infect marine mammals.  Strains which infect seals, sea lions, and related 
species have been organized into the species B. pinnipediae, and those which infect 
dolphins and related species are now part of the species B. cetaceae.51, 54  The genomes of 
3 of the species (B. melitensis,76 B. suis,195 and B. abortus117) have been completely 
sequenced, and due to the marked genetic similarity of these three species and sequenced 
segments of the other five, some have suggested that there should be only one species, B. 
melitensis. 162, 231, 232  Four members of the genus, B. melitensis, B. suis, B. abortus, and 
B. canis are zoonotic causing disease in humans referred to as undulant fever.111 
Swine brucellosis occurs at widely variable incidence rates throughout the world 
in domestic or feral swine populations except in Great Britain and the Scandinavian 
peninsula where the disease has been eradicated.63, 146  The highest incidence rates of 
swine brucellosis in domestic swine occur in Central and South America, Asia, 
particularly China and Southeast Asia, and sub-Saharan Africa.86, 143, 156, 200  B. suis has 
been essentially eradicated from domestic populations in the US, northern Europe, and 
Australia; however, B. suis is enzootic in feral populations in these locations.2, 112, 151, 245  
Sporadic outbreaks of swine brucellosis in domestic herds in these areas are related to 
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contact with infected feral swine.56, 206  Occasional outbreaks of brucellosis in cattle also 
occur due to B. suis infection from feral swine.93  Pyogranulomatous prostatitis and 
epididymitis in dogs17 and cases of fistulous withers in horses61 have both been caused by 
B. suis infection in areas with enzootic feral swine brucellosis. 
 
Brucella suis – biovars and microbiological characteristics 
 B. suis, like the other Brucella species, are carboxyphilic, nonmotile, 
nonhemolytic, partially acid-fast, catalase positive pathogenic bacteria which are easily 
propagated on nutrient agar, and their propagation is enhanced by enrichment with blood 
or serum.7, 199 The strong, almost immediate urease activity of B. suis easily allows its 
differentiation from B. abortus and most B. melitensis isolates. 7, 199  Lysis by the Tbilisi 
phage can also be used to differentiate B. suis from B. abortus and B. melitensis.  B. 
melitensis is resistant to lysis by the Tbilisi phage at both the recommended test dilution 
(RTD) and 104 × RTD. 7, 199  B. suis exhibits intermediate sensitivity to the Tbilisi phage 
by being resistant to lysis at the RTD but sensitive at 104 × RTD. 7, 199  B. abortus is the 
most sensitive of all the brucellae to the Tbilisi phage in that it is lysed at the RTD. 7, 199  
B. ovis and B. canis only exist as rough strains lacking the O-polysaccharide side-chain of 
the lipopolysaccharide (LPS) molecule. 7, 199  Rough strains of B. suis exist and can be 
differentiated from B. ovis due to the obligate carboxyphilic nature of B. ovis. 7, 199  B. 
suis can also be easily differentiated from B. canis because, like B. melitensis, B. canis is 
resistant to lysis by the Tbilisi phage at the RTD. 7, 199  The microbiological 
characteristics of B. neotomae are highly similar to those of B. suis; however, these two 
species can be distinguished by the inability of B. neotomae to grow on nutrient agar 
containing 20 μg/ml thionin. 7, 199
B. suis is subclassified into 5 biovars based on dominant antigens, growth 
characteristics, and the animal species which they primarily infect.  B. suis biovar 1, 
which is found worldwide, is the only biovar to produce hydrogen sulfide, expresses the 
A antigen, and infects primarily swine.7, 199 B. suis biovar 2 is differentiated from biovar 
1 in that it does not produce hydrogen sulfide and is differentiated from biovar 3 in that it 
does not grow on basic fuchsin containing media. 7, 199  Biovar 2 is primarily found in 
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Europe, is generally considered to not be infectious to humans, and is maintained in 
European hares (Lepis capinensis) which are considered to be able to transmit the 
organism from farm to farm.24, 49, 222, 223   Biovar 3 primarily infects swine and is also 
widely distributed throughout the world.  Biovar 3 is the only biovar to consistently grow 
on agar containing basic fuchsin and expresses the A antigen dominantly. 7, 199   Biovar 4 
is maintained in reindeer and caribou herds in the subarctic regions of the Northern 
Hemisphere, and natural infection of biovar 4 has never been recognized in swine.  
Biovar 4’s distinguishing bacteriological characteristic is that it coexpresses the A and M 
antigens. 7, 199  Biovar 5 is a minor biovar of B. suis which has been isolated from several 
rodent species and is distinguished from the other biovars by dominantly expressing the 
M antigen . 7, 60, 62, 199  
 
Brucella suis infection:  clinical disease and pathogenesis 
 B. suis is largely still thought of as a primarily abortifacient organism.  Abortion 
is indeed associated with epizootics of swine brucellosis; however, abortion is a minor 
component of the disease presentation of B. suis infection. As early as 1931, it was 
recognized by Johnson and Huddleson132 that swine brucellosis was not primarily an 
“abortion disease”.  Johnson and Huddleson blame this misconception on the fact that B. 
suis was first isolated from an aborted pig fetus,226 “Since Brucella was isolated by 
Traum from fetuses expelled prematurely from sows, the belief has been widely prevalent 
that Brucella disease in swine is essentially an abortion disease.  Our studies of the 
natural course of the disease in several large groups of hogs in the state of Michigan have 
failed to confirm this belief.”132  Hutchings128 also realized that a great emphasis was 
being placed on reproducing abortions in the experimental evaluation of B. suis 
infections.  He suggested that evaluating resistance to infection rather than preventing 
abortions which were extremely difficult to produce with experimental infection, was 
more important in evaluating control measures of B. suis transmission. 
 B. suis can infect swine by a variety of exposure routes.  Unlike the other species 
of  Brucella, B. suis is venereally transmitted.146, 149  Ingestion of infected material is the 
other major route of natural exposure; however, inhalatory exposure is also capable of 
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causing infection.146, 149  Several studies have addressed the minimal infectious dose of B. 
suis.  Models using B. suis biovar 3 (strain 644) found that dosages of 105, 107, and 109 
colony forming units (CFU) were all capable of infecting 100% of animals challenged 
while reduced infection rates were achieved with a dose of 103 CFU.44  Experimental 
studies managed to transmit B. suis to swine, as well as B. abortus to cattle, via insect 
vectors (Stomoxys calcitrans);237 however, there is little evidence that vector transmission 
occurs with natural infection. 
 After initial exposure to B. suis, there is uptake of bacteria and delivery to 
draining lymph nodes, both via an incompletely understood process.  Bacteremia then 
occurs, and the persistence of the bacteremia is quite variable and has been demonstrated 
to last 1 week to 34 months in infected sows.77, 79, 80  Systemic infection of lymphoid 
organs closely follows bacteremia.77  Initial infection is not associated with fever except 
in some boars which eventually succumb to severe pyogranulomatous lesions.77, 148  
Changes in leukograms also do not occur with acute and chronic B. suis infection.77  
 Reproductive losses in sows have been recognized to occur as early as 22 days 
after successful insemination with B. suis contaminated semen, and irregular return to 
estrus presents in those cases 30 to 45 days after insemination. 149  When abortions occur 
in mid to late gestation, they are associated with the B. suis infection being acquired after 
day 40 of pregnancy. 149  Uterine infection and vaginal shedding of B. suis is highly 
variable and has been reported to occur from one to 30 months after initial infection. 149  
Infertility in infected sows has been shown to be related to the duration of infection and 
the extent of lesions in the uterus. 59, 71, 126, 149, 222
 B. suis is often found in the semen from infected boars.10  Boars shedding B. suis 
in their semen frequently are associated with lower conception rates and lower live pigs 
born per litter than noninfected boars.10   This decrease in reproductive efficiency is not 
necessarily associated with decreases in semen quality. 10  Infection in reproductive 
organs of males has been shown to persist for at least three to four years in some 
individuals.148  The extent of infertility in boars is related to the distribution of infection 
and lesions.149  Individuals with unilateral involvement of the accessory sexual organs 
rarely exhibit decreases in fertility or libido yet disseminate large numbers of organisms 
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in their semen.  Individuals with testicular involvement or bilateral involvement of the 
accessory sexual organs exhibit marked decreases in fertility and possibly libido.126   
 Clinical signs associated with B. suis infection in prepubescent swine are rare and 
include swollen joints and lameness which are associated with bacteremia.  Pigs born to 
infected sows are often infected with B. suis and exhibit markedly high neonatal mortality 
rates.68, 128, 129  Most pigs which survive have been shown to become blood culture 
negative by 3 months of age and achieve systemic clearance by six months of age.109, 127  
In larger studies, however, low numbers of animals were found to become chronically 
infected with B. suis when exposed as nursing pigs.147  Manthei found that about 8% of 
230 pigs exposed to B. suis while nursing were blood culture positive beyond 3 months of 
age, and about 2.5% were tissue positive at slaughter after two years of age.150   Systemic 
clearance appears to be more protracted in sexually mature swine.  In sexually mature 
females, systemic clearance appears to occur between two and six months after infection 
as the Brucella recovery rate from necropsy tissue declined from 94.4% to 23.5% in this 
period.80  However, there was no change in recovery rate thereafter with recovery rates 
remaining around 25% through 42 months after infection.80   Sexually mature males 
become chronically infected at a significantly higher rate than females.  Six months after 
initial experimental infection 66.7% of sexually mature males remained infected as 
determined by Brucella recovery from necropsy samples.80  This rate only declined to 
50% at 42 months after initial infection. 80   
 Natural resistance to B. suis infection has been reported in certain lines of 
swine.39, 40  Some have suggested that this is related to genetic differences related to the 
natural resistance associated macrophage protein (NRAMP1). 228  The Nramp1 gene has 
been cloned in pigs, and it has been shown that NRAMP1 is strongly expressed in 
macrophages and neutrophils following nonspecific stimulation with LPS.244 
 The cellular events of Brucella infections have been explored in both phagocytic 
and nonphagocytic cells.110  The events involved with mucosal penetration are poorly 
understood, but after penetration Brucella cells are taken up by M cells, macrophages, 
and neutrophils via a zipper-like phagocytosis.1  This phagocytosis is mediated by 
complement or Fc receptors, and lectin and fribronectin receptors mediate uptake in 
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nonprofessional phagocytic cells.41  Internalization of Brucella also appears to be 
dependent on the brucellar two component system BvrS-BvR which encodes for a 
histidine kinase sensor and its regulator protein. 110  This system seems to regulate the 
expression of several outer membrane proteins.115, 214  Once internalized, intracellular 
survival of Brucella is dependent on avoiding lysosome fusion with the phagosome. 110, 
196  After internalization the phagosome membrane contains both lysosomal-associated 
membrane protein 1 (LAMP1) as well as sec61β and calreticulin, both endoplasmic 
reticulum markers. 110, 196  The phagosome is, however, deficient of lysosomal hydrolase 
cathepsin D a luminal marker of lysosomes.110  Early acidification of the phagosome, 
although detrimental to the short term replication of Brucella, has been shown to be 
necessary for the ultimate survival of Brucella within macrophages.140, 198  The final 
replicative compartment of Brucella is considered to be the endoplasmic reticulum as 
LAMP1 is lost but sec61β labeling remains. 110, 196   
 
Immunity 
 Most of what is known about the immune response to natural Brucella infection 
and responses to Brucella vaccines has been discovered through studies in mice, cultured, 
cells, and isolated peripheral cells from humans with brucellosis.  Early infection of 
macrophages with B. suis induces an innate response of cytokine production. Interleukin-
(IL)1, IL-6, and IL-10 as well as the neutrophil-stimulating chemokine IL-8 are produced 
early in the infection of the macrophage.43, 84 Apoptosis is downregulated in human 
macrophages which are infected with B. suis.113  Intracellular survival and replication of 
the B. suis appears to be necessary for this downregulation.113  An upregulation of the 
antiapoptotic gene bcl-2 has been shown to be associated with this occurrence; however, 
a soluble factor appears to be involved in the signaling process as supernatant from 
infected cells can downregulate apoptosis in noninfected cells. 113  B. suis infection of 
macrophages also decreases their responsiveness to Fas ligand (FasL) and interferon 
gamma (IFN-γ) induced apoptosis.84  Within B. suis infected macrophages there is also a 
downregulation of tumor necrosis factor-alpha (TNFα) production which has been 
reported to be dependent on the 25 kDa outer membrane protein (Omp25).43, 135 
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Downregulation of TNF-α appears to make the cells less responsive to IL-12 and IFN-
γ.84, 166  Humans infected with B. suis have a dramatic increase in circulating γ/δ T cells 
which are activated by soluble factors from B. suis.27 After activation, the T cells produce 
TNF-α and IFN-γ.189, 190  Natural killer (NK) cells from humans have also been shown to 
decrease intramacrophagic replication of B. suis via a contact dependent mechanism 
which is enhanced by IL-2. 85  In addition to the contact-dependent mechanism, NK cells 
appear to be activated as they produce IFN-γ and TNF-α which also likely enhances their 
activity and the activity of the macrophages in clearing B. suis.8   
Murine models of Brucella infection have shown that a type 1 T helper (Th1) cell 
cytokine response is necessary for clearance of infection.13, 97  This Th1 response has 
been shown to be elicited by triggering toll-like receptor 9 (TLR9).125  The ligand for 
TLR9 is unmethylated DNA, and heat-killed B. abortus has been shown to simulate 
TLR9 and induce a Th1 cascade.  TLR2 and TLR4 which are stimulated by LPS have 
been shown to not be necessary for clearance of B. abortus.236  The Th1 response to 
Brucella infection in mice is characterized by a strong IFN-γ response in splenocytes.98  
Blockage of the Th1 cytokine cascade did not shift the response of mice to a Th2 
response as IL-4 production was not elevated in the mouse splenocyte.97   Studies in 
BALB/c mice, which have a marked lag in the upregulation of the Th1 response after 
Brucella infection, show that CD8+ T cells and TNF-α contribute to the control of 
Brucella infection but are not satisfactory in themselves in inducing full clearance of the 
organism.97, 174  However, despite a lack of measurable IL-4, blockage of both IL-4 and 
IL-10 pathways resulted in decreases in Brucella infection.13, 96   
Like other species of Brucella in their respective animal hosts, there is little 
evidence that humoral immunity is protective in preventing infection or reinfection with 
B. suis.14, 130, 164, 239  Sows with low serum agglutination titers by the standard tube test 
(STT) were easily infected with B. suis when given a dose of 107 CFU by the 
conjunctival route.44  
 Cell-mediated immune responses of swine to B. suis infection have not been 
thoroughly investigated.  Cultured peripheral blood mononuclear cells (PBMCs) from 
swine naturally infected with B. suis were shown to proliferate with stimulation from 
  12 
soluble B. suis antigens.137  PBMC proliferative responses were not correlated to 
serological titers on an individual animal basis; however, the two had a high degree of 
correlation on a group basis. 137  Although there is little information on immune responses 
related to Brucella infection in swine, IFN-γ has been shown to be the most central factor 
in Th1 immune responses related to clearance of intracellular pathogens in swine.74, 75  
 
Lesions associated with Brucella suis infection 
 Lesions in lymph nodes are frequently reported in swine infected with B. suis.  
Variable degrees of lymphadenopathy are usually the only gross lesion evident in lymph 
nodes; however, occasionally purulent exudate or organized abscesses are recognized.34 
Microscopically, lymph nodes have variable numbers of inflammatory cells consisting of 
neutrophils, epithelioid macrophages, and multinucleated giant cells and foci of 
coagulative, liquefactive, or caseous necrosis.78  Lymphoid hyperplasia has also been 
reported in culture positive lymph nodes. 78  For all lymph node lesions, the most 
commonly reported affected lymph nodes are gastrohepatic, medial retropharyngeal, 
parotid, mandibular, tracheobronchial, and splenic. 78  Pyogranulomatous and necrotizing 
lesions similar to those reported in lymph nodes have also been reported in spleens of B. 
suis infected swine.9  Reported hepatic lesions range from microscopic random or portal 
accumulations of lymphocytes, plasma cells, macrophages, and neutrophils to grossly 
visible foci of caseous necrosis which are microscopically characterized as multifocal 
granulomas or pyogranulomas with central necrosis. 34, 78   Fibrosing perihepatitis has also 
been reported to be associated with B. suis infection.34  
Lesions in male reproductive organs of swine are well documented with B. suis 
infection. 34, 77, 78, 81, 129  Gross lesions are most commonly reported in seminal vesicles.  
Affected seminal vesicles are markedly enlarged due to an increase in fibrous connective 
tissue separating individual lobules which may contain purulent exudate.77, 81 More acute 
lesions may be mere abscesses without fibrosis.  Histologically affected seminal vesicles 
contain abundant fibrous tissue and numerous lymphocytes, plasma cells, macrophages, 
and multinucleated giant cells with some lesions being neutrophil rich. 77, 78, 81, 149  The 
epithelium of ducts within affected seminal vesicles is often necrotic or totally denuded, 
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and there are occasional areas of caseous or liquefactive necrosis throughout the 
parenchyma. 77, 78, 81, 149  Similar lesions may also be found in the prostate, bulbourethral 
gland, epididymis, and testis.77  With chronicity, lesions in the male secondary 
reproductive organs progress to a markedly atrophic and fibrotic appearance.149  
Testicular inflammation rages from mild infiltrates of lymphocytes, plasma cells, 
macrophages, and neutrophils to well organized pyogranulomas.129  Large areas of 
necrosis have also been noted in infected testes.129 Seminiferous tubules in affected testes 
may be normal or exhibit marked atrophy with limited spermatozoa formation.129  
Lesions in female reproductive organs are recognized most frequently with B. suis 
biovar 2.  The classical gross lesion associated with B. suis biovar 2 has been termed 
miliary metritis due to its marked multifocal, widely disseminated distribution and has 
been reported to be present in as much as 47% of sows and gilts during an epizootic.25 
The grossly visible nodules are composed of caseous necrosis surrounded by abundant 
numbers of neutrophils alone or neutrophils with epithelioid macrophages and 
multinucleated giant cells.  Similar lesions are described in the kidneys and spleens of B. 
suis biovar 2 infected swine.23  The swine lesions are highly similar to the lesions 
observed in the European hare which is considered a natural host reservoir and 
responsible for European outbreaks of swine brucellosis.  Affected hares exhibit nodules 
of caseous necrosis surrounded by pyogranulomatous inflammation in the spleen, lung, 
liver, sacculus rotundus, uterus, testis, epididymis, and mammary gland.24  Natural and 
experimental infection with biovars 1 and 3 in sows and gilts occasionally produce 
grossly visible purulent to fibrinopurulent endometritis although frank vaginal purulent 
discharge is rarely recognized.146  Cystic endometritis and catarrhal endometritis have 
also been reported to be features of B. suis biovar 1 infection.149  Microscopically uterine 
lesions with B. suis biovars 1 and 3 range from multifocal endometrial aggregates of 
lymphocytes, plasma cells, neutrophils, and macrophages with or without necrosis to 
diffuse purulent endometritis with necrosis.148, 149
Lesions in placentas and tissues from aborted fetuses have been reported to be 
rare.149  Lesions which have been reported include grossly visible hyperemia, edema, 
and/or hemorrhages within placenta, increased subcutaneous and peritoneal fluids which 
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may be hemorrhagic, and microscopically observable purulent placentitis with or without 
necrosis.149   
 Bone lesions have been reported commonly in vertebrae and less commonly in 
long bones.  Vertebral lesions are often grossly visible and consist of pyogranulomatous 
osteomyelitis with marked necrosis and with or without intervertebral disk involvement.95   
When diskospondylitis is present, there is often accompanying impingement of the spinal 
cord with marked atrophy of particularly white matter tracts.  Diskospondylitis 
development from B. suis infection in swine appears to have a predilection for the lumbar 
and lumbosacaral areas.95  Bone lesions also have been reported to have notable 
neovascularization, bone sequestra are common.78  Less frequent lesions associated with 
B. suis infection in swine include subcutaneous abscesses,77, 81 lymphohistiocytic 
inflammatory aggregates in the lung,78 pyogranulomatous meningoencephalitis,11 and 
lymphocytic and purulent adrenalitis.78   
 
Diagnosis of swine brucellosis 
Serological assays 
 All standard serological assays used in the diagnosis of B. suis infection utilize O-
polysaccharide side-chain of the lipopolysaccharide (LPS) molecule from B. abortus; 
thus, none are designed specifically for B. suis.7  However, limited early studies with 
serological assays utilizing B. suis specific antigens reported no appreciable differences 
over assays which utilized the standard B. abortus antigens.146  The O side-chain also 
contains the A and M antigens which are utilized for Brucella speciation and biotyping.   
The O side-chain is a homopolymer of approximately 100 residues of 4-formamido-4, 6-
dideoxymannose linked solely in an α-1, 2 conformation in the A dominant strains and in 
an α-1, 2 conformation with every fifth residue linked in an α-1, 3 conformation in the M 
dominant strains.38  The 4-amino-4, 6 dideoxymannose epitope is responsible for the 
Brucella antigenic crossreactivity with LPS from Yersinia enterocolitica O:9, 
Escherichia coli O:157; Escherichia hermanni, Salmonella O:30 serogroup; Vibrio 
cholerae O:1, and Stenotrophomonas maltophila.38  Rough mutants of Brucella express 
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LPS in which the O side-chain is totally absent or greatly reduced; therefore infection 
with these mutants results in seronegative animals.180   
The literature has great discrepancies in the utility of serology in the diagnosis of 
B. suis infection.  Certainly as a herd diagnostic tool, standard serological techniques are 
adequate; however, their ability to identify individual, infected animals appears to be 
poor.  Most studies dealing with determining sensitivity of individual serological assays 
utilize sera from acutely infected individuals.  Sensitivity rates reported for individual 
assays are as follows:  STT:   51.1%-100%;103, 206  mercaptoethanol test (2-ME):  38.5%- 
100%);103, 143, 194 rivanol test:  23.1%-100%;99, 103, 143, 152 complement fixation test:  
49.1%-100%99, 103, 143, 206, 173  card test:  20%-100.0%;103, 143, 206 and buffered plate antigen 
(BPA) test: 61.0%-77.1%.99, 152, 173  Specificity rates are as follows:  STT: 62.0%-
100%;99, 143, 206 2-ME:  81.1%-100%;143, 194 rivanol test 74.0%-100%;99, 143, 152 
complement fixation test: 86.0%-100;99, 143, 152, 206 card test 76.0%-92.0%;99, 152, 206 and 
BPA test:  90.0%-95.9%.99, 173  The specificity of all standard serological assays is 
considered to be low with the presence of confounding infections particularly infections 
with Yersinia enterocolitica serogroup O:9.241  The fluorescent polarization assay (FPA) 
is the most recently developed serological tool for Brucella serological diagnosis.172  The 
reported sensitivity of the FPA assay is 63.0%-98.9%, and the specificity is reported to be 
55.0%-99.9%.152, 173, 194   The FPA studies utilized sera which was previously determined 
to be positive by the BPAT or 2-ME assays; therefore, the sensitivity values are likely 
inappropriately high. 
Delayed-type hypersensitivity 
 Intradermal skin testing has been used to diagnose swine brucellosis and has been 
reported to be as effective on a herd basis as serological evaluation.213  Original 
brucellins were prepared from smooth strains of B. melitensis and B. abortus.191  Manthei 
examined three brucellins prepared from B. suis in swine:  a phosphatide fraction, a 
purified culture filtrate, and a soluble nucleoprotein fraction.149  The sensitivity of the 
delayed-type hypersensitivity skin test using these three fractions was reported to be 
slightly higher than standard serological assays; however, like the serological assays, the 
skin test was not successful in identifying all individually infected animals. 149  Newer 
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brucellins have been prepared from rough strains of B. melitensis with reports of higher 
specificities compared to the smooth brucellins.133   
Bacteriological culture 
Bacteriological culture is, of course, the definitive method for diagnosis of swine 
brucellosis.  Deyoe and Manthei cultured necropsy tissue samples from 147 swine 
experimentally infected with B. suis biovar 1 and euthanized one to 52 months after 
infection.81  Lymph nodes were the most consistently culture positive organs (75.2%), 
and the most consistently positive lymph nodes were mandibular, gastrohepatic, internal 
iliac, medial retropharyngeal, and parotid; however, all lymph nodes examined yielded 
Brucella growth at some incidence rate. 81  Bacteriological culture of only the 
mandibular, medial retropharyngeal, gastrohepatic, and internal iliac lymph nodes would 
have identified 91% of the total culture positive animals. 81  Male reproductive organs 
(37.2%) were more consistently positive than uterus (28.9%).  Other culture positive 
tissues and fluids included:  spleen (38.7%), lung (36.8%), liver (31.8%), blood (30.1%), 
bone marrow (25.0%), joint fluid (23.9%), urine (20.8%)tonsil (14.8%), kidney (14.5%), 
salivary gland (12.2%),adrenal (11.7%), brain (7.5%), and ileocecal valve (3.7%).81
Molecular techniques 
 Polymerase chain reaction (PCR) techniques have been employed for culture 
identification and Brucella species differentiation.31  These techniques have been used 
mostly to identify Brucella which has first been cultured.  While several studies have 
incorporated PCR to identify Brucella directly from tissue, there has been limited 
investigation into the sensitivity of PCR identification of Brucella tissues, blood, or fluids 
from infected animals.8, 69, 114, 220  In the few studies which have looked at sensitivity of 
PCR assays, sensitivity was often low compared to bacteriologic culture.243    
PCR assays have been developed that are Brucella genus specific.  These assays 
have been based on the omp2A,100 omp43,94 16S rRNA,119, 207 16S-23S intergenic 
region,202  and BCSP31 genes.12  PCR assays which allow species and biovar 
differentiation have been developed based on the insertion sequence (IS) 711.33, 118  The 
IS711 has allowed differentiation of B. abortus biovars 1, 2, and 4; B. abortus strain 
RB51; B. melitensis, B. ovis, and B. suis biovar 1.32, 33, 92  The omp2A gene can be 
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targeted by PCR to distinguish B. abortus from other Brucella species.142  Omp2A PCR 
combined with restriction fragment length polymorphism (RFLP) analysis can 
discriminate most species of Brucella.54  Additional PCR-RFLP assays which can 
discriminate Brucella species have targeted the omp25,52 dnaK,53 and omp31 genes.233  
The vaccine strain B. abortus S19 contains a stable deletion in the eri gene which allows 
its differentiation by PCR from other Brucella possible.209   
Immunochemical techniques 
Immunochemical techniques have been applied to the diagnosis of B. suis 
infection in swine; however, these techniques have been found to be far inferior to 
bacteriological culture.161  Meador reported an immunohistochemical assay for the 
diagnosis of B. abortus in cattle, goats, and mice; however, it has never been applied to 
Brucella infected swine.159  The sensitivity of a similar immunohistochemical technique 
was determined to be 82% when applied only to lochial smears.3  Deyoe reported a 
sensitivity rate of 14.3% for immunofluorescence techniques utilizing polyclonal 
antibodies applied to a variety of frozen tissue sections.80   
 
Experimental infection of swine with other Brucella species 
 Limited studies of experimental infection of swine with B. suis biovar 4 have 
shown that swine develop an infection of draining lymph nodes which does not progress 
to a similar distribution and disease as B. suis biovars 1, 2, or 3.18, 79, 80, 149  The results of 
various studies of experimental infection of swine with B. abortus are contradictory 
exhibiting widely variable results.  Most studies show that the majority of swine do not 
succumb to systemic infection with B. abortus.18, 188  Although natural infections of swine 
with B. abortus have been reported,70, 154, 155 when experimentally infected, B. abortus 
can usually only be recovered from the draining lymph node from a variable number of 
animals for a short duration of time.146  Additional experimental infection studies with B. 
abortus in swine showed that most swine do not seroconvert to smooth strains of B. 
abortus when orally challenged.18  A low percentage of swine challenged with a smooth 
strain of B. abortus seroconverted when infected by subcutaneous, intramammary, or 
intravenous routes.18, 163  Experimentally exposing swine to naturally infected cattle or 
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feeding swine with B. abortus contaminated milk produced a very low rate of 
seroconversion and infection with only recovery of B. abortus from draining lymph 
nodes.108  
 There are several early reports of natural B. melitensis in swine;72, 155 however, 
most, if not all of these isolates were actually B. suis biovar 3.  The characteristics of the 
swine B. melitensis isolates described in the early literature are exactly those of B. suis 
biovar 3 and really do not fit those of classical B. melitensis organisms as all the swine 
isolates are fast urease positive.20  Therefore, the early artificial infection study of B. 
melitensis in swine is suspect; in that study, swine were infected with swine isolates of B. 
melitensis which were undoubtedly B. suis biovar 3.121 Subsequent experimental 
infections of swine with B. melitensis by oral and subcutaneous routes  produced similar 
results as experimental infections with B. abortus; B. melitensis was only isolated from 
20% or less of infected animals and only from a single lymph node, presumably the 
draining node, from each culture positive animal.20, 188   Some gilts experimentally 
infected with high doses of B. melitensis did develop bacteremia which lasted seven to 13 
weeks after initial infection.20   
 Experimental, intravenous infection of swine with B. neotomae produced 
seroconversion; however, experimentally infected animals failed to develop infection of 
lymphoid organs which lasted the nine weeks of the study.19   
 
Brucella vaccines used to control brucellosis 
Brucella abortus strain 19 
 B. abortus strain 19 (S19) has been the most widely used vaccine for the 
prevention and control of cattle brucellosis.212  S19 was first isolated from the milk of a 
Jersey cow in 1923, and its reduced virulence was apparently attained from the isolate 
being kept at room temperature for over one year.36  S19 is a smooth, biovar 1 strain 
which is sensitive to penicillin and cannot grow in the presence of 1.0 mg/ml erythritol, 
both properties which allow it to be differentiated from field strains of B. abortus; 
however, there is a high reversion rate for growth on erythritol.7  Being a smooth strain, 
vaccination with S19 induces a humoral response which causes vaccinated animals to be 
  19 
seroreactors on standard Brucella serological assays.  However, when S19 is employed as 
only a calfhood vaccine, serum antibodies decline by the time sexual maturity is reached 
allowing the vaccine to be an integral part of brucellosis control without preventing the 
detection of animals infected with field strains of B. abortus in the cow herd.  Although 
S19 is of reduced virulence, it can induce abortion at a variable rate (1-14%) when 
pregnant animals are vaccinated.22, 147, 165, 168  S19 may also fail to be cleared in a very 
low percentage of vaccinated animals.  These S19-chronically infected animals may 
succumb to abortion in adulthood.224  S19 can be cultured from placenta and fetal tissues 
from abortions from S19-chronically infected cows. 224  Type III hypersensitivities 
expressed as multicentric arthropathy/arthritis has also been reported as a side-effect of 
S19 vaccination.64, 65, 141, 171   
 Numerous trials have examined the efficacy the S19 vaccine in cattle.169  
Experimental efforts were made to determine the minimal effective dosage and minimal 
age of vaccination.  These trials all evaluated vaccine efficacy based on the pregnant 
female challenge model which evaluates efficacy on the basis of abortion and Brucella 
recovery from maternal and fetal/neonatal tissues; although there is great discrepancy in 
the results of these studies, they suggest that abortion may be prevented when calves are 
vaccinated as young as four months of age but not one month of age.  Protection based on 
fetal infection is much more variable, and the optimal vaccine dose and age of 
vaccination is much more difficult to determine in light of the variable challenge 
dosages.57, 141, 197, 219  S19 has been used in elk (Cervus elaphus nelsoni) as a ballistically 
administered parenteral vaccination in Wyoming since the 1980s.120, 139  The biobullet 
vaccine system used in elk delivered dosages of 5.6-7.6 × 109 CFU . 120, 139    Several 
experimental trials have shown a decrease of approximately 30% in the abortion rate in 
vaccinates compared to nonvaccinated controls.120   
Brucella abortus strain 45/20 
 The parent strain of B. abortus 45/20, 45/0, was originally isolated from a cow in 
Great Britain in 1922.158  B. abortus strain 45/20 is a rough strain which was derived 
from 20 passages of strain 45/0 in guinea pigs.157, 158 However, recent monoclonal 
antibody studies suggest that the rough variants of 45/20 produce O-side chain.210, 211  As 
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a rough strain, 45/20 was attenuated; however, when used as a vaccine 45/20 was found 
to revert to smooth phenotype which had increased virulence.90, 221  This led to the 
decreased usage of live 45/20 as a vaccine; however, killed, adjuvanted 45/20 became a 
preferred vaccine in certain cattle brucellosis control programs.205  Despite being derived 
from rough 45/20, approximately 1% of cattle vaccinated with the killed, adjuvanted 
45/20 vaccine become serological reactors to standard Brucella serological assays.205  The 
induction of Brucella agglutinating antibodies was more marked in animals which had 
been previously vaccinated with S19,205 and the overall incidence rate of developing 
Brucella agglutinating antibodies after 45/20 vaccination was reported to be highly 
variable among lots of vaccine.212  Vaccine protocols which employed killed, adjuvanted 
45/20 usually used 2 doses of the vaccine at an interval of six weeks to 3 months with 
yearly booster vaccination considered necessary by some.116, 169  However, studies with 
single dose protocols found similar protection to the two dose protocol.6  The induction 
of cell-mediated immune responses by killed, adjuvanted 45/20 vaccine has been reported 
to be superior to that of S19,50 and protective responses have been reported to be at least 
equal those of S19.116, 205  Killed, adjuvanted 45/20 vaccine has also been used in 
protocols with S19; S19 was used as a calfhood vaccine and 45/20 was used to boost 
adult cattle.169   
Killed Brucella vaccines have been investigated in reindeer for the prevention of 
B. suis biovar 4 transmission.83  Killed, adjuvanted preparations of B. abortus strain 
45/20 were found to be efficacious when vaccinated reindeer were challenged 90 days 
after vaccination.  Efficacy was assessed on the basis of a delay in seroconversion, 
decreased abortion rate, and decreased Brucella culture from necropsy tissues from 
vaccinated females and their offspring. 83
Brucella abortus strain RB51 
 B. abortus strain RB51 (RB51) is a naturally rough mutant of the challenge strain 
B. abortus 2308.  RB51 is rifampimycin resistant, a trait which allows its selective 
isolation from mixed or contaminated culture samples.123  Being a rough strain, RB51 
does not induce the production of antibodies which react in standard Brucella serological 
assays180, 216 despite recent evidence showing that RB51 synthesizes a low level of M-like 
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O-side chain.55  However, there is evidence that animals may become serological reactor 
to standard Brucella serological assays after an anamnestic response from booster 
vaccination.180  RB51 is of low virulence as determined by experimental infection of 
cattle, mice, and guinea pigs and does not induce abortion when pregnant cattle and bison 
are vaccinated.182, 192, 193, 229  RB51 can also be distinguished from other strains of B. 
abortus by molecular methods due to positions of IS711 elements.230
 The standard vaccine dosage of RB51 used in the US is 2.0 × 1010 CFU RB51.  
This dosage is associated with clearance in most animals by week 14 after vaccination, 
significant humoral responses, and strong cell-mediated immune responses in both cattle 
and bison (Bison bison).48, 175, 176, 177, 178, 179, 180, 183, 184, 184, 185, 187   These responses have 
been associated with significant protection from challenge with virulent B. abortus.  
Studies dealing with RB51 in nontarget species indicate that it is relatively safe for black 
bears (Ursus americanus), Richardon’s ground squirrels (Spermophilus richardsonii), 
deer mice (Peromyscus maniculatus), prairie voles (Microtus ochrogaster), ravens 
(Corvus corax), bighorn sheep (Ovis Canadensis), pronghorn antelope (Antilocapra 
americana), mule deer (Odocoileus heminonus), moose (Alces alces shirasa), and 
coyotes (Canis latrans);131, 186 thus, there is great interest in utilizing this vaccine as a 
wildlife vaccine, particularly in bison.  The induction of protective immunity by oral 
administration of RB51 in mice217 and cattle91 has also spiked interest in utilizing RB51 
as an oral wildlife vaccine.  
When elk are vaccinated with RB51, they respond with a very intense antibody 
production but appear to have an increased clearance time and increased time of 
bacteremia compared to other species.138, 181  Cell mediated immune responses to RB51 
and to lymphocyte mitogens were largely due to proliferation of B lymphocytes in elk, 
and vaccinated elk showed a lack of protection when challenged with virulent B. abortus. 
138, 181, 235
Brucella melitensis strain Rev 1 
 B. melitensis strain Rev 1 (Rev 1) is a smooth, attenuated strain which is resistant 
to streptomycin and has been used as a vaccine in goats and sheep.  Rev 1 is avirulent in 
rams; however, it will induce abortion in does and ewes if the vaccine is administered 
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during pregnancy.4, 16, 28  Like S19, vaccination with Rev 1 produces serological reactors 
which may interfere with surveillance if vaccination is not limited to a defined age group.  
Although never employed to control cattle brucellosis as part of a large scale control 
program, studies indicate that Rev 1 offers better protection than S19 in cattle.101, 124  
 
Brucella vaccine trials in swine 
 Several vaccine trials have been performed with B. abortus strain 19 (S19) in 
swine.122 146  Manthei evaluated subcutaneous dosages of 1.0 × 1011 and 2.0 × 1011 CFU 
in gilts.146 The vaccinated gilts were challenged with virulent B. suis six months after 
initial vaccination.  There was no protection noted on the basis of bacterial recovery from 
sow tissues, and vaccinated sows actually had a 21.2% increase in Brucella recovery 
compared to nonvaccinated controls.146  Hoerlein conducted several studies using S19 
which was commercially available; his results were consistent with Manthei in that there 
was no apparent protection induced by S19 in preventing infection with virulent B. 
suis.122  Additional studies evaluated the S19 vaccine in the control of swine brucellosis 
under natural field exposure.136  S19 failed to show improvement of vaccinated animals 
on the basis of serological conversion, bacteriological culture of B. suis, and reproductive 
efficiency. 136  Swine vaccinated with S19 were shown to seroconvert to B. abortus 
antigens with both IgM and IgG production.201  
 Several studies were performed with a compound vaccine consisting of live B. 
abortus strain Old Bang and LPS antigen from B. suis.45, 46, 47  The vaccine was reported 
to be nonpathogenic in swine and transmission of the vaccine strain among swine was not 
detected.47  Vaccine trials with the B. abortus Old Bang/B.suis LPS vaccine concluded 
that it was significantly efficacious based on reduction in Brucella recovery and 
abortion.45, 46, 47  More controlled experiments with defined challenge doses of virulent B. 
suis in guinea pigs failed to show any efficacy of the B. abortus Old Bang/B. suis LPS 
vaccine compared to nonvaccinated controls.102   
 Manthei also evaluated the King 8 strain of B. suis biovar 1 which originated in 
Australia and was reported to be a reduced virulence strain.146  Gilts received 
subcutaneous dosages of 1.0 × 1011 CFU and 2.0 × 1011 CFU.  When challenged at six 
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months after initial vaccination, vaccinated gilts had a 45.8% reduction in Brucella 
recovery. 146  Manthei concluded that immunity was too short-lived for the vaccine to be 
useful because in a second similar experiment where gilts were challenged at 24 months 
after initial vaccination there was no difference in Brucella recovery between vaccinated 
and control groups. 146  However, the challenge in the long term King 8 experiment 
appeared to be stronger as Brucella was recovered from 100% of the controls as 
compared to 45.4%-80.0% in Manthei’s previous swine vaccine experiments. 146  Others 
claimed that further experiments with the King 8 strain were not pursued due to concerns 
that it would revert to full virulence and concerns about its likely pathogenicity to 
humans.71, 79   
 Edens and Foster examined LPS containing extracts of B. suis as vaccine 
preparations in swine.88  Vaccines were prepared from LPS extracts which were treated 
or not treated with lysozyme. 88  An additional vaccine was prepared by conjugating the 
lysozyme treated LPS extract to bovine gamma globulin. 88 Vaccinated swine were 
challenged with virulent B. suis 42 days after initial vaccination. 88  All vaccine 
preparations were found to protect the swine from virulent challenge based on Brucella 
recovery from necropsy tissues. 88  The group receiving the gamma globulin conjugated 
preparation of lysozyme treated LPS showed the most drastic reduction in Brucella 
recovery. 88  Despite initial favorable results using B. suis LPS extracts as a vaccine, it 
appears that further investigations were not pursued.  
B. suis strain 2 is a vaccine strain which has been reported to have been used in 
swine, sheep, goats, and cattle in China since 1971;242 however, there is very little 
knowledge or experience with this vaccine outside of that country.  Strain 2 was reported 
to be attenuated by serial passage on culture media for a year attaining a virulence similar 
to S19, but it is a smooth strain of B. suis biovar 1. 242   Strain 2 was reported to be 
nonpathogenic in swine and was reported to be cleared in both males and females by 45 
days after vaccination; however, Strain 2 induced abortions in sheep and goats with 
parenteral administration but not with oral administration. 242  The attenuation of Strain 2 
for swine and guinea pigs was also reported to be very stable with no reversion of 
virulence when serially passaged in swine, guinea pigs, sheep, and goats. 242  Subsequent 
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studies in mice found that Strain 2 was of lower virulence than either S19 or Rev 1 as 
measured by vaccine strain recovery.30  Strain 2 has been used in brucellosis control 
programs for swine, ovine, and caprine brucellosis in China.  In swine it has been 
investigated as part of a multifactorial control program. Vaccination with Strain 2 was 
accompanied by culling of all females which aborted.  The serological prevalence rates 
on the test farms were reported to drop from 62.8% to 2.4% on one farm and from 75% to 
0% on another farm. 242   Others who have paraphrased Chinese studies of Strain 2 in 
swine stated that Strain 2 was protective in swine which were challenged conjunctivally 
with virulent B. suis, but offered no protection when vaccinated gilts were challenged 
with naturally infected boars.5  Strain 2 protection studies in mice found that Strain 2 
induced equal protection of mice when challenged with virulent strains of B. suis, B. 
melitensis, or B. abortus 45 days after vaccination.30  The level of protection was similar 
when vaccinated mice were challenged 150 days after vaccination except for the virulent 
B. melitensis challenge model in which there was no significant difference in total splenic 
weight or Brucella recovery compared to nonvaccinated controls. 30  Studies executed in 
Spain with Strain 2 failed to support the Chinese reports which stated that Strain 2 was 
efficacious in preventing ovine brucellosis.29   
 With RB51 having showed great efficacy in controlling bison and cattle 
brucellosis, there has been great optimism for this vaccine to aid in the control of swine 
brucellosis in both feral and domestic populations.  Initial studies with RB51 reported 
that it induced a humoral immune response in swine when administered parenterally or 
orally.89  Lord and colleagues evaluated the efficacy of RB51 in vaccinated gilts as 
compared to gilts vaccinated with killed B. suis strain 1330 (biovar 1), extracts containing 
the O-side chain of the LPS from B. suis, and non vaccinated controls.144    Oral and 
parenteral routes at various dosages were examined for all vaccine preparations.  Single 
and multiple administrations of each vaccine were also examined. 144  Lord concluded 
that oral and parenteral administration of either a single or multiple doses of both RB51 
and the O-side chain vaccine preparation gave 100% protection in a natural challenge 
model utilizing naturally infected boars as the method of challenge for vaccinated gilts. 
144  Lord, however, did not evaluate culture recovery of Brucella from all animals.  
  25 
Bacteriologic culture was only performed on vaginal swabs and fetal tissues from gilts 
which aborted.  Therefore, the criteria for protection for this study centered around 
protection from abortion. 144  
 
Feral swine 
 Little attention was paid to documenting the establishment, distribution, and 
propagation of feral swine during the early history of North America after European 
habitation; therefore, most of what has been written on the historical perspective of this 
animal is based on historical inference as well as oral tradition.  Feral swine are believed 
to have existed in the territory which is now the continental United States since 1542 
when the explorer Hernando DeSoto introduced swine into short-lived Spanish 
settlements.26  Feral swine on the Hawaiian islands are estimated to have originated with 
Polynesian bringing swine from Tahiti around 1000 AD.240  This population undoubtedly 
intermingled with European stock which was brought by Cook to the islands in 1778. 240 
Animals which are referred to as feral or wild swine are all members of the species Sus 
scrofa and consist of animals with at least 3 distinct phenotypes.  The animal which is 
traditionally referred to as the feral hog or “razorback” is a descendent of those animals 
which went feral during the early stages of colonialism in North America.  These early 
feral swine intermingled with “captive” swine which were free-range raised in the 
woodland and open areas of the southern US through the early part of the twentieth 
century.   The Eurasian boar is the second phenotypically distinct wild pig in North 
America.  These animals were imported from Europe first to the state of New Hampshire 
in the latter part of the nineteenth century.  Established populations of “pure” Eurasian 
boars are recognized in New Hampshire and the southern Appalachian region of 
Tennessee and North Carolina.  Domestic pigs which have been accidentally or 
intentionally released in recent years comprise the third phenotypic distinction.   Of 
course, interbreeding among these three phenotypic groups exists.   
Feral swine populations are established in at least 31 states in the US (Figure 1), 
21, 66, 67, 87, 104, 105, 106, 153 ,167, 204, 208, 234, 240  and feral swine are the only mammalian species 
on the Federal Invasive Species List.  This makes it illegal on a federal scale to 
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intentionally transport and release feral swine for the purpose of establishing a new 
population in an area which was previously free of feral swine.  Despite this federal 
restriction, feral swine distribution continues to drastically increase.  This increase is 
most often due to intentional release of wild swine for the purpose of establishing 
populations for hunting or to enhance animal numbers or characteristics which are 
desirable for “trophy” animals in preexisting populations.104, 105, 106, 153, 234  Additional 
factors which have contributed to the increased distribution and population of feral swine 
include:  escape of wild swine from shooting preserves, natural movement and 
proliferation of established feral swine populations, abandonment of wild swine by agents 
unable to market them to shooting clubs, purposeful release of domestic swine for 
hunting, escape of domestic swine from confinement operations, and escape or 
abandonment of pet swine.105
Feral swine impose numerous documented negative impacts on the environments 
which they inhabit.  In the southern US, feral swine populations are extremely costly to 
the timber and pulpwood industries.  After an area has been timbered, feral swine often 
move into new growth pine forests and feed on the delicate roots of the pine species.238  
Feral swine have also been shown to virtually destroy the delicate bog environments of 
Hawaii.  Ground nesting birds and other wildlife populations have been negatively 
impacted by feral swine predation, and native collared peccary populations which 
compete with the feral swine for food and territory in Texas and the Southeast are also 
negatively impacted by the increasing numbers of feral swine.204  
Documentation of brucellosis in feral swine populations has been almost solely 
based on serological surveys as well as anecdotal evidence based on outbreaks of 
brucellosis in domestic swine and cattle populations which had contact with feral swine.  
When Brucella serological reactors were necropsied and their tissue cultured, B. suis was 
identified.21  Through this data, brucellosis has been documented in 15 states within the 
US (Figure 1).58, 66, 67, 106, 112, 167, 208, 227  Serological prevalence in infected feral swine 
populations ranges from 0.6%-53%.21, 87  Feral swine have also been a source of B. suis 
infection for hunters and feral swine slaughterhouse workers in both the US and 
Australia.58, 203, 215  Feral swine also serve as a source of Trichinella spiralis and 
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pseudorabies virus, thus, threatening the US pseudorabies eradication effort.66, 112 
Although brucellosis has not been documented in collared peccaries (Tayassu tajacu) in 
the US, collared peccaries have been found to be infected with B. suis by bacteriological 
culture and serology in South America.145   
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Figure 1.  Feral swine and feral swine brucellosis within the United States.  All states 
which contain their respective state abbreviations have documented feral swine 
populations.  States shaded in red contain feral swine with documented brucellosis.  
States shaded in green contain feral swine, but there was no detectable brucellosis within 
those feral swine based on serological surveys.  States shaded in yellow contain feral 
swine, but there have been no studies to document the presence of brucellosis within 
those populations.  States shaded in white contain no known feral swine. 
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Abstract 
 Eighty feral swine were trapped from a herd which had been documented to be 
seropositive for Brucella and which had been used for Brucella abortus RB51 vaccine 
trials on a 7,100 hectare tract of land in South Carolina.  The animals were euthanized 
and complete necropsies were performed.  Samples were taken for histopathology, 
Brucella culture, and Brucella serology.  Brucella was cultured from 62 (77.5%) animals.  
Brucella suis was isolated from 55 animals (68.8%), and all isolates were biovar 1.  
Brucella abortus was isolated from 28 animals (35.0%), and isolates included field strain 
biovar 1 (21 animals; 26.3%), vaccine strain Brucella abortus S19 (8 animals, 10.0%), 
and vaccine strain Brucella abortus RB51 (6 animals, 7.5%).  Males were significantly 
more likely to be culture positive than females (92.9% vs. 60.6%).  Thirty-nine animals 
(48.8%) were seropositive.  Males also had a significantly higher seropositivity rate than 
females (61.9% vs. 34.2%).  The relative sensitivity rates were significantly higher for 
the standard tube test (44.6%) and fluorescence polarization assay (42.6%) than the card 
agglutination test (13.1%).  Lesions consistent with Brucella infection were commonly 
found in the animals surveyed and included inflammatory lesions of the lymph nodes, 
liver, kidney, and male reproductive organs which ranged from lymphoplasmacytic to 
pyogranulomatous with necrosis.  This is the first report of an apparent enzootic Brucella 
abortus infection in a feral swine herd suggesting that feral swine may serve as a 
reservoir of infection for Brucella abortus as well as Brucella suis for domestic livestock. 
Introduction 
The genus Brucella composes a group of genetically very similar, Gram negative, 
facultative intracellular, pathogenic bacteria which are known to infect over 80 domestic 
and wild mammalian species.14, 16, 33, 34  In animal hosts, Brucellae commonly are 
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associated with infection of reproductive tissues of the male and female and 
lymphoreticular tissues as well as pyogranulomatous lesions of multiple tissues.20  Four 
members of the Brucella genus, B. melitensis, B. suis, B. abortus, and B. canis are 
zoonotic agents and produce a disease in humans referred to as undulant fever which is 
characterized by recurrent pyrexia, infection of lymphoreticular tissues, bacteremia, and 
purulent and pyogranulomatous lesions in multiple organs in infected humans.15, 36  B. 
melitensis, B. abortus, and B. suis are also on the US Centers for Disease Control and 
USDA Select Agents list due to their perceived potential use as biological agents of 
terrorism and war.36
The US has had a concerted effort to eliminate both cattle and swine brucellosis 
from its livestock populations through cooperative programs between the states and 
USDA Animal Plant Health Inspection Service (APHIS).23  Both programs have been 
based on the principle of serological testing and elimination of seroreactive herds.  The 
eradication program in cattle has been aided by the implementation of calfhood 
vaccination with reduced virulence vaccine strains S19 and RB51.  The swine program 
never implemented the use of a vaccine, but dramatic changes in swine management 
practices since the 1950s undoubtedly aided the elimination of swine brucellosis in 
domestic herds.  With the near total eradication of brucellosis from the US livestock 
population, there is an increased effort to address the issue of Brucella infected wildlife 
populations.8  Within the 48 contiguous states of the US, feral swine (Sus scrofa), elk 
(Cervus elaphus nelsoni), and bison (Bison bison) are the major wildlife reservoirs of 
Brucella.24  Today only sporadic outbreaks of brucellosis occur in both domestic swine 
and cattle within the US, and most recent outbreaks have been associated with contact 
with Brucella infected feral swine or elk.9   
Within the US B. abortus is maintained enzootically within elk (Cervus elaphus 
nelsoni) and bison (Bison bison) within the Greater Yellowstone Area of Wyoming, 
Montana, and Idaho.  Brucellosis has been reported in the bison of Yellowstone National 
Park since 1917, and current studies from the Greater Yellowstone Area report 
seroprevalence rates of 76-90% with 46% of seropositive females being culture positive.6, 
26, 35  The bison herds have been managed to remain on federal land and likely have had 
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limited contact with cattle.  However, elk numbers in the area are much higher.  Brucella 
infected elk have a much larger geographic distribution than bison, and elk often come 
into close contact with cattle in the area.  Recent brucellosis seroprevalence rates among 
elk herds associated with winter feed ground has been reported to be 25-54%.7, 18  
However, seroprevalence rates of elk herds not associated with feed ground has been 
reported to be 0-1%.25   
Feral swine herds have been reported in 27 of 50 states in the USA. The numbers 
and population distribution of feral swine have increased dramatically in recent decades 
partially due to natural population dynamics but mostly due to the establishment of new 
populations for the purpose of hunting in areas which were previously feral swine free.  
Brucellosis has been documented in feral swine populations in 14 states.37  In addition to 
the infection of domestic swine with B. suis, feral swine are also responsible for infecting 
cattle with B. suis.10  Due to their popularity as a game species and the widespread 
distribution of brucellosis within these populations, feral swine are also a significant 
threat for zoonotic infections.28                                                                                                                      
Materials and Methods 
This study was conducted on a 7,100 hectare tract of land on a peninsula between 
the Atlantic Ocean and the Winyah Bay in Georgetown County, South Carolina, USA 
(33° 20’ N, 79° 13’ W).  The study was conducted between October 2002 and February 
2003.  A total of 80 sexually mature feral swine (42 males and 38 females) were trapped 
using box traps and fermented shelled corn as bait.  This population had been used to 
evaluate the efficacy of parenteral administration of B. abortus RB51 (RB51) in feral 
swine.   
Necropsies: 
After euthanasia, 30 ml of blood was obtained via cardiac puncture.  Blood was 
divided for serology (10 ml) and for Brucella culture (20 ml). Urine, nasal swabs, and 
vaginal swabs were collected for bacteriological culture.   The following tissues were 
harvested for bacteriological culture and histologic examination: liver, spleen, lung, 
kidney, uterus, mammary tissue, testis, seminal vesicle, bulbourethral gland, prostate, and 
lymph nodes including prescapular, medial retropharyngeal, sternal, tracheobronchial, 
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gastrohepatic, prefemoral, popliteal, mandibular, and parotid. All samples for 
bacteriological evaluation were frozen at -70° C until processed for culture. Tissues 
collected for histologic evaluation were immediately placed in neutral-buffered 10% 
formalin, processed by routine paraffin embedding techniques, cut in 4 μm sections, and 
stained with hematoxylin and eosin.  Selected tissue sections were also stained by Ziehl-
Neelsen (acid-fast), periodic acid-Schiff (PAS), and Hucker-Twordt (silver) methods 
Serologic Evaluation 
 After collection, blood samples were allowed to clot and serum was separated by 
centrifugation.  Serum was divided into 1 ml aliquots, and stored at -70° C until assays 
were performed.  Brucella serologic status of all animals was determined by fluorescence 
polarization (FPA)22, standard tube agglutination (STT)1, and card agglutination assays1 
by previously described methods. Animals which had a positive reaction on at least one 
of the three serologic assays were considered positive seroreactors. 
Bacteriologic Culture: 
After thawing, tissues were individually ground in approximately 10% (w/v) 
sterile phosphate buffered saline (PBS, pH=7.2) using sterile glass grinders. Aliquots 
(100 μl) of each tissue homogenate were plated on tryptose agar containing 5% bovine 
serum as well as three Brucella selective media including brilliant green agar (BGB132; 
tryptose agar base with 5% bovine serum, .001 μg/ml brilliant green, 25 U/ml bacitracin, 
100 μg/ml cycloheximide, 100 U/L nystatin, 20 μg/ml vancomycin, 50 μg/ml 
trimethoprim, and 100 μg/ml EDTA), Kudzas Morse agar (KM; tryptose agar base with 
5% bovine serum, 25 U/ml bacitracin, 6 U/ml polymyxin B, 100 μg/ml cycloheximide, 
and 1.4 μg/ml ethyl violet), and RBM agar, a selective medium for SRB51.17  Inoculated 
plates were incubated at 37˚C in 5% CO2 for 7 days. 
Culture Identification: 
Brucella suspect cultures were identified on the basis of colony morphology, 
growth characteristics, and growth on selective media.1  Isolates were identified as 
Brucella spp. by a polymerase chain reaction technique (PCR) using Brucella-specific 
primers to the omp2A region of the Brucella genome.  Reactions consisted of 50 μl and 
contained 5 μl of suspect culture in tris-EDTA and 45 μl of reaction mixture consisting of 
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200 μM each of dATP, dCTP, dGTP, and dTTPa, 1 X PCR Buffer IIb, 1.5 mM MgCl2, 
1.25 U AmpliTaq Gold polymeraseb, and 0.2 μM of each upstream and downstream 
primers (Table 1) selected from the omp2A sequences of B. abortus.13  The primers had 
100% conservancy within the genomes of B. suis and B. melitensis according to BLAST 
analysis.  Tris-EDTA and a culture of Yersinia enterocolitica O:9 served as negative 
controls, and B. suis strain 3B, a biovar 1 laboratory challenge strain, served as a positive 
control. Following a 10 minute activation at 95˚C, reaction preparations were cycled in a 
thermocyclerc for 40 cycles consisting of 30 sec. at 95˚ C, 30 sec. at 44˚ C, and 60 sec. at 
72˚ C.  Products were analyzed by electrophoresis on 1.5% agarose gels stained with 
ethidium bromide.  Animals were considered culture positive if at least one sample 
yielded a positive Brucella culture. 
 Cultures which were positive by the omp2A PCR assay were run in a second 
multiplex PCR which could discriminate B. suis, B. abortus RB51, B. abortus S19, and 
B. abortus/B. melitensis field strains.  This PCR assay utilized RB51 specific primers 
targeted toward the insertion sequence 711 (IS711).4, 32  Each reaction mixture consisted 
of a volume of 25 μl containing 2.5 μl of suspect culture in Tris-EDTA, 1X PCR reaction 
buffer containing 50 mM Tris, 1.5 mM MgCl2, 10 mM KCl, 50 mM (NH4)2SO4, 
pH=8.3d, 200 μM each of dATP, dCTP, dGTP, and dTTPa; 1X GC rich solutiond; 1.0 U 
of FastStart DNA polymerasee; and 0.2 μM of the following primers:  IS711 specific, 
RB51-3 , eri multiplex forward, eri multiplex reverse, 42797 forward, and 42797 reverse 
(Table 1).  Thermocycling consisted of a single 5 min. incubation at 95˚ C followed by 40 
cycles consisting of 15 sec. at 95°C, 30 sec. at 52°C, and 90 sec. at 72°C.  Tris-EDTA 
and B. suis strain 3B, SRB51, S19, and B. abortus strain 2308 served as the positive 
control.  Products were analyzed by electrophoresis on 2.0% agarose gels stained with 
ethidium bromide. 
 In order to determine the degree of genetic homogeneity among the feral swine 
isolates found in this study and to aid in the positive identification of B. abortus vaccine 
strains, a variable nucleotide tandem repeat (VNTR) assay (“HOOF-Prints” assay) was 
employed as previously described.2, 3 Isolates were assayed for the number of copies of 
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the 8 bp repeat (5’-AGGGCAGT-3’) at loci 1-8 as reported in the original paper 
describing the technique.3  
S19 Confirmation and Sequencing 
Isolates which were S19 based on the multiplex PCR were selected to determine 
if the deletion in the eri gene was the same as was previously reported by the reference 
strain of S19.27  S19 isolates were subjected to a PCR reaction which flanked the deletion 
in the eri gene.27  Each reaction consisted of 50μl and contained 5 μl of suspect culture in 
tris-EDTA and 45 μl of reaction mixture consisting of 200 μM each of dATP, dCTP, 
dGTP, and dTTPa, 1 X PCR Buffer IIb, 1.5 mM MgCl2, 1.25 U AmpliTaq Gold 
polymeraseb, and 0.2 μM of each eri sequencing forward and reverse primers (Table 1).  
Thermocycling consisted of a 10 minute activation at 95˚C followed by 40 cycles 
consisting of 60 sec. at 95˚ C, 30 sec. at 57˚ C, and 30 sec. at 72˚ C.  Laboratory 
propagated S19 and B. abortus strain 2308 served as positive controls and Yersinia 
enterocolitica O:9 served as a negative control.  Products were analyzed by 
electrophoresis on 1.5% agarose gels stained with ethidium bromide.  PCR products were 
purified in a silica matrixf prior to sequencing.  Products were quantitated using the Pico 
Green assay for dsDNAg .  The appropriate quantity of dsDNA was labeled in both 
directions using Big Dye terminator chemistries and sequenced using an ABI 3100 
genetic analyzerh.  Primers used for sequencing were identical to those used in the 
primary PCR reaction and were used at a concentration of 0.13 μM.  Resulting sequences 
were assembled and edited using Sequencher 3.0i.  Alignment of gene segments was 
performed with the program CLUSTALX.31   
Statistical Analysis 
 For all statistical analyses a level of P<0.05 was used to determine differences 
between vaccinates and controls.  Chi square analysisj was used to determine differences 
between males and females within the population for serologic positivity and serologic 
sensitivity, differences among serology assays for sensitivity rates, and differences 
between culture positive and culture negative animals for histologic lesions which were 
not sex specific. 
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Fisher’s Exact Testj was used to determine differences between males and females 
within the population for culture positivity, the isolation of multiple Brucella species, and 
the isolation of specific Brucella species as well as differences between culture positive 
and culture negative males for sex specific histologic lesions. 
Results 
Necropsy findings and gross lesions 
 Of the 38 females which were trapped, 15 (39.5%) were gestating and 7 (18.4%) 
were lactating.  In utero litter size ranged from 2 to 7 (mean = 4.6; median = 5).   
 The seminal vessicles of one male were diffusely enlarged, fibrotic, and contained 
an abundant amount of purulent exudates. B. suis was subsequently cultured from the 
affected seminal vessicle.  Three animals had grossly visible lymph node abscesses (2 
gastrohepatic and 1 sternal).  One animal had multiple pleural and mesenteric adhesions 
and abscesses.  Five animals had multifocal, raised, firm hepatic nodules which were 
consistent with larval migrans tracts.  Thirty-three animals had marked proliferation of 
the ureter and periureteral tissue which contained numerous adult nematodes consistent 
with Stephanurus dentatus.   
Histologic Lesions 
 Histologic lesions are summarized in Table 2.  There was no statistically 
significant correlation of any lesions with Brucella culture status.  Five animals in the 
study had no significant lesions.  Interstitial nephritis was the most common lesion found 
and was present in 37 animals.  This ranged from multifocal to coalescing areas of 
lymphoplasmacytic infiltrates to large lymphofollicular aggregates in the renal 
interstitium (Figure 1A).  Hepatitis was present in 34 animals.  There were three general 
forms of hepatic inflammation:  multifocal, random, lymphocytic hepatitis; multifocal, 
lymphoplasmacytic and purulent pericholangitis; and multifocal, random, 
pyogranulomatous hepatitis with necrosis (Figure 1B).  Some of the pyogranulomas were 
associated with nematode larvae.  Lymphadenitis was present in 29 animals.  The 
lymphadenitis was often multicentric and ranged from diffuse, purulent lymphadenitis to 
multifocal pyogranulomas often with necrotic cores (Figure 1C).   
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 Histologic lesions within male reproductive organs were common findings.  
Orchitis was present in 11 males and was characterized by multifocal to diffuse 
lymphocytic (Figure 1D) or multifocal to diffuse granulomatous inflammatory infiltrates.  
All cases of orchitis were associated with significant seminiferous tubular atrophy.  
Seminal vessiculitis was observed in 6 males and was exhibited in 3 patterns:  multifocal, 
lymphoplasmacytic seminal vessiculitis; diffuse, purulent and lymphoplasmacytic 
seminal vessiculitis with fibrosis (Figure 1E); and diffuse, granulomatous seminal 
vessiculitis with marked fibrosis.  Multifocal lymphocytic prostatitis was also present in 3 
males (Figure 1F). 
 Multifocal renal granulomas were present in 2 animals.  Marked epididymal 
fibrosis was present in 2 males.  One animal exhibited multifocal-coalescing, purulent 
splenitis, and one female exhibited diffuse purulent endometritis.  No pyogranulomatous 
or granulomatous lesions in any tissues were associated with fungi or acid-fast bacteria. 
 Lesions which were not consistent with swine brucellosis were also present.  
Thirty-four animals had eosinophilic and granulomatous ureteritis and periureteritis with 
intralesional trichostrongyles consistent with Stephanurus dentatus.  Moderate to marked 
interstitial cell hyperplasia was present in the testes of 21 males.  Eleven animals 
exhibited eosinophilic and granulomatous interstitial pneumonia with intralesional 
metastrongyles, and one animal had amyloidosis of the liver, kidney, and spleen. 
Bacteriologic Culture 
 Brucella was isolated from a total of 62 (77.5%) feral swine in this study.  A 
multiplex PCR which could distinguish among B. suis, B. abortus field strains, S19, and 
RB51 was used in these studies because of the history of using RB51 in this population 
for vaccine studies.  The multiplex PCR assay revealed that not only was B. suis and 
RB51 present in the population but also B. abortus field strains and S19 were present 
(Figure 2).  The results of the multiplex PCR assay correlated 100% with traditional 
Brucella biotyping methods.  All B. suis isolates were biovar 1 and all B. abortus field 
strain isolates were also biovar 1.  Table 3 lists the species of Brucella isolated on a per 
animal basis.  Isolation of B. suis only was the most common finding; however, multiple 
species were isolated from 21 animals (26.3% of the total population; 33.9% of the 
  51 
culture positive animals).  B. suis was isolated from 55 animals (68.8% of the total 
population; 88.7% of the culture positive animals).  B. abortus was isolated from 28 
animals (35.0% of the total population; 45.2% of the culture positive population).  Of 
these 28 B. abortus positive animals, biovar 1 field strains were isolated from 21 animals 
(26.3% of the total population; 33.9% of the culture positive population); S19 was 
isolated from 8 animals (10.0% of the total population; 12.9% of the culture positive 
population); and RB51 was isolated from 6 animals (7.5% of the total population; 9.7% 
of the culture positive population).  Table 4 lists the number of isolates made for the 
various species on a per tissue basis.  In general there tended to be a dominant species in 
each tissue even in animals which were infected with multiple tissues.  However, 
isolation of multiple species of Brucella in particular tissues was achieved. 
 Males were significantly more likely to be Brucella culture positive than females 
(P<0.001).  The culture positivity rate was 92.9% (39/42) for males and 60.5% (23/38) 
for females.  There was no statistically significant difference between males and females 
in the culture positivity rates for any individual species of Brucella found in this study 
when the results were compared among culture positive animals only or among the entire 
population.  Among culture positive animals, females were more often infected with 
multiple Brucella species than males (60.9% for females vs. 20.5% for males; P<0.01); 
however, there was no significant difference when the data was compared among the 
entire population. 
 The HOOF-Prints (VNTR) assay suggested that the B. suis isolates were not 
highly heterogeneous (Table 5).  The number of alleles was conserved in the entire group 
of isolates at loci 2, 3, and 4; however, differences were found at all other loci.  The 
isolates from a given animal tended to have identical patterns; however, occasionally 
patterns from isolates from different tissues from the same animal had different patterns.  
This is evidenced in isolates pairs 1688-3/1690-1 and 1803-1/1819-1 in table 5.    
Selected VNTR patterns for B. abortus isolates are given in Table 6.  All B. abortus 
biovar 1 field strains had conserved patterns at loci 1, 2, and 3; however there were single 
or double allelic differences at all other loci.  All RB51 isolated from feral swine had 
identical patterns as the laboratory reference strain of RB51.  Most S19 feral swine 
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isolates had identical patterns to the laboratory reference strain of S19; however, 2 
isolates had VNTR patterns which differed from the S19 laboratory reference strain.  The 
isolate 7-pop (Table 6) differed by 3 alleles at locus 3 from the S19 reference strain, and 
the isolate 1665-1 differed from the S19 reference strain at loci  1, 6, and 7 by 1, 1, and 4 
alleles respectively. 
S19 Sequencing 
 Four isolates which typed as S19 by the multiplex PCR assay and by traditional 
biotyping were selected for sequencing of the eri gene in order to determine if the 
deletion within the eri gene matched the laboratory reference strain of S19.  All 4 isolates 
and the S19 laboratory strain yielded the expected PCR product of approximately 361 bp.  
The resulting sequences from all 4 of the feral swine isolates were 100% homologous to 
the sequence obtained from the S19 laboratory strain. 
Serology 
 The results of the serologic assays are listed in Table 7.  The seropositivity rates 
were 48.8% for the entire population, 61.9% for males, and 34.2% for females.  Males 
were significantly more likely to be seropositive among the entire population (P<0.05); 
however, there was no difference in seropositivity rates between males and females 
among culture positive animals.   
 Relative sensitivity rates for each assay and a combination of the three assays are 
also listed in Table 7.  To estimate the sensitivity the number of seropositive animals 
from the culture positive group was divided by the number of culture positive animals.  
One animal yielded only RB51 on bacteriologic culture, and that animal was excluded 
from the sensitivity estimates as RB51, being O-polysaccharide deficient, does not induce 
detectable immune responses by the three assays utilized in this study.21, 29  The 
sensitivity rates of both the STT (P<0.0001) and FPA (P<0.005) assays were significantly 
higher than the Card Test but did not differ from each other.    
Discussion 
 In this study 80 feral swine from an area of enzootic feral swine brucellosis on the 
Atlantic coast of South Carolina were trapped, euthanized, and necropsied to determine 
Brucella culture, serologic, and lesion profiles.  It was found that not only were the feral 
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swine in this herd infected with biovar 1 of B. suis but also with biovar 1 field strains of 
B. abortus and the vaccine strains B. abortus S19 and B. abortus RB51.  This is the first 
report of B. abortus in feral swine and the first report of a wildlife reservoir of B. abortus 
outside the Greater Yellowstone National Park Area of Wyoming, Montana, and Idaho.   
 The finding of well established B. abortus infection in this feral swine herd was 
surprising not only because it had never been reported but also due to experimental 
evidence which shows that swine become only briefly infected with B. abortus when 
experimentally challenged with B. abortus.30  Previous studies in domestic swine have 
shown that RB51 is cleared quickly and persists only to four weeks in lymph nodes 
draining the site of infection.30  In the current study, however, B. abortus was found in a 
variety of tissues including whole blood suggesting that bacteremia and systemic 
distribution of the B. abortus occurs in feral swine. 
 The introduction of B. abortus S19 and biovar 1 field strains in this feral swine 
herd was possibly due to scavenging of aborted fetuses of dead, B. abortus infected cattle 
at a time when cattle were kept on the same property or in the vicinity.  The introduction 
of RB51 is easily explained by the use of this herd in experiments evaluating the potential 
usage of this vaccine in feral swine.  However, no such experiments were ever conducted 
in this herd with the S19 vaccine strain.  Examination of property records suggests the 
possibility of longstanding B. abortus infection in this feral swine herd.  No cattle have 
been kept in the area of the feral swine since at least 1970.  The property is bordered by 
the Atlantic Ocean, the Winyah Bay, and a coastal housing development and country club 
which greatly limit the migration of feral swine into and out of the area.  The VNTR data 
supported long standing infections of B. suis, B. abortus biovar 1 field strain, and B. 
abortus S19 since these isolates had allelic differences at multiple loci.  However, all 
RB51 isolates examined showed the same pattern as the reference strain of RB51. 
 The Brucella culture positivity rate in this feral swine herd was high which 
reflects the tendency of swine to develop chronic Brucella infections.  The serologic 
sensitivity rates were much lower than those previously reported for the assays used in 
this study.  The results of this study serve as an example for the lack of sensitivity of 
serological assays for diagnosing brucellosis in individual feral swine.  When necropsy 
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culture results were compared to necropsy serology results, the sensitivity of a 
combination of the three serological assays which were used was 54.1%.  Previously 
published sensitivity rates for these assays in domestic swine were 20-67% for the card 
test, 83-100% for the standard tube test, and 80-94% for the FPA test.12, 19, 22  The 
sensitivity rates for individual assays calculated in this study, however, were 13.1% for 
the card test, 44.6% for the standard tube test, and 42.6% for the fluorescence 
polarization assay.  Antigens used in these assays are from B.abortus which may at least 
partially account for the lack of sensitivity when evaluating swine presumably infected 
with B. suis.  The lack of sensitivity may also be reflected in the chronicity of infection in 
the animals in this study.  Samples used to determine sensitivity rates in previously 
published reports were obtained from acute outbreaks of swine brucellosis.  The relative 
sensitivity rates of these serologic assays have not been previously investigated in 
enzootically infected herds.  Antibody decay may occur despite the persistence of 
culturable bacteria in tissues. 
 This study utilized a multiplex PCR assay for the identification of Brucella 
species.  The assay could definitively identify B. suis, B. abortus RB51, and B. abortus 
S19.  The assay could also identify Brucella species other than B. suis and the two B. 
abortus vaccine strains; however, it could not differentiate among the other species.  
Within this assay, a single primer pair was utilized to differentiate between B. suis and 
other Brucella species (B. abortus and B. melitensis).  These primers (42797 forward and 
reverse) were targeted to a location on chromosome II at which B. suis has a 189 bp 
insertion.  This size difference allowed easy discrimination of B. suis from the other 
Brucella species on agarose gels.  Bricker has previously reported on the use of multiplex 
PCR (AMOS assay) to discriminate Brucella species.4, 5  The AMOS assay utilized 
species differences in the IS711 insertion sequence and required individual primers for 
species identification.4  Fayazi and colleagues have also reported on the use of a PCR 
assay with a single primer pair which can distinguish B. suis from B. abortus.11  The 
primer pairs used by Fayazi were unsuccessful in identifying either Brucella species in 
the studies reported in this paper.  Upon examination of the genetic sequence used to 
design Fayazi’s primers, it was found that the sequence was an assembly of 4 unique, 
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nonlinked MboI fragments.  The corresponding sequences are as follows:  1)  Nucleotides 
1-149 of the Fayzi sequence align to nucleotides 1595585-1595734 of chromosome I of 
B. abortus 9-941; 2)  nucleotides 146-200 of the Fayazi sequence align to nucleotides 
225993-225939 of chromosome I of Brucella abortus; 3)  Nucleotides 195-330 of the 
Fayazi sequence align to nucleotides 582796-582668 of Chromosome II B. abortus; and 
4)  Nucleotides 336-482 of the Fayazi sequence align to nucleotides 53279-538430 of 
chromosome II of B. abortus.16  The forward primer used in Fayazi’s assay corresponds 
to positions 1595587-1595611 of chromosome I of B. abortus, and the reverse primer 
corresponds to positions 538397-538421 of chromosome II of B. abortus.  In light of the 
sequence data, it is easily explained that the primers used in the Fayazi PCR assay could 
not identify either Brucella species in the current study.  It also appears that the current 
study is the first report of a single primer pair which can distinguish B. suis from other 
Brucella species. 
 Animals within this herd had histologic lesions in multiple organs which were 
consistent with swine brucellosis20; however, none of these lesions could be significantly 
correlated to Brucella infection within the animal or within the tissue containing the 
lesion.  Despite a high culture positivity rate, the number of animals with reproductive 
lesions was surprisingly low.  Of the 39 culture positive males in this study, only 14 had 
lesions in reproductive tissues, and of the 23 culture positive females in this study, only 
one exhibited endometritis and 2 exhibited placental necrosis.  In the face of a high level 
of Brucella within this population, these feral swine manage to maintain a level of 
reproductive efficiency which supports significant population growth and warrants 
regular population control strategies in order to control the amount of environmental 
damage imposed by the feral swine herd.   
 The results of this study have identified a feral swine herd which is enzootically 
infected with B. suis as well as multiple strains of B. abortus.  This study shows that 
within an enzootically infected feral swine population, the seroprevalance rates may be 
significantly lower than the true infection rate.  The results of this study also reiterate the 
possibility of feral swine to serve as reservoirs of Brucella spp. for both domestic 
livestock and human infections.   
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Table 1.  Primer Sequences used in PCR and sequencing assays for the 
identification of Brucella isolates obtained from feral swine. 
Primer Nucleotide Sequence 5’-3’ 
Omp2A Forward GCAACGGTGTTCTTCCACTC 
Omp2A Reverse GTATCAGGCTACGCAGAAGG 
IS711 specific TGCCGATCACTTAAGGGCCTTCATTGCCAG
RB51-3  GCCAACCAACCCAAATGCTCACAA 
eri Multiplex Forward GCGCCGCGAAGAACTTATCAA 
eri MultiplexReverse CGCCATGTTAGCGGCGGTGA 
42797 Forward CGATGTGCTGGCGCGAACCTTGTAC 
42797 Reverse CCATCGCCGATGAAATTGAAGCCCA 
eri Sequencing Forward TTGGCGGCAAGTCCGTCGGT 
eri Sequencing Reverse CCCAGAAGCGAGACGAAACG 
 
  60 
Table 2.  Summary of histologic lesions observed in 80 feral swine (42 males, 38 
females) trapped from a herd enzootically infected with Brucella spp. 
 Total # Animals Culture +a Organ +b
Lesions Consistent with  
Brucella infection 
  
Interstitial Nephritisc 37 (46.3%) 29 (78.4%) 1 (2.7%) 
Hepatitisd 34 (42.5%) 29 (85.3%) 7 (20.6%) 
Lymphadenitise 29 (36.3%) 25 (86.2%) 4 (13.8%) 
Orchitisf 11 (26.2%) 11 (100%) 5 (45.5%) 
Seminal Vessiculitisg 6 (14.3%) 6 (100%) 3 (50.0%) 
Prostatitish 3 (7.1%)      2 (66.7%) 0 
Renal Granulomas 2 (2.5%) 2 (100%) 0 
Epididymal fibrosis 2 (2.5%) 2 (100%) 1 (50.0%) 
Placental necrosis 2 (2.5%) 1 (50.0%) 0 
Splenitis, purulent 1 (1.3%) 1 (100%) 1 (100%) 
Endometritis, purulent 1 (1.3%) 1 (100%) 0 
Lesions not consistent with  
Brucella infection 
  
Granulomatous ureteritisi 34 (42.5%)   
Interstitial cell hyperplasia 21 (50.0%)   
Verminous pneumoniaj 11 (13.8%)   
Multicentric Amyloidosis 1 (1.3%)   
aNumber of animals with the lesion which were culture + for Brucella. 
bNumber of animals with the lesion which were culture + for Brucella in the organ with 
the lesion 
cMultifocal, lymphoplasmacytic to lymphofollicular interstitial nephritis. 
dLesions included multifocal, random, lymphocytic hepatitis; multifocal, 
lymphoplasmacytic and purulent pericholangitis; and multifocal, random, 
pyogranulomatous hepatitis with necrosis. 
eLesions included diffuse, purulent lymphadenitis and multifocal, pyogranulomatous 
lymphadenitis with necrosis. 
fLesions included multifocal to diffuse lymphocytic orchitis and multifocal to diffuse 
granulomatous orchitis; both included seminiferous tubular atrophy. 
gLesions included multifocal, lymphoplasmacytic seminal vessiculitis; diffuse, purulent 
and lymphoplasmacytic seminal vessiculitis with fibrosis; and diffuse, granulomatous 
seminal vessiculitis with marked fibrosis. 
hMultifocal, lymphocytic, prostatitis. 
iDiffuse, granulomatous and eosinophilic, ureteritis with intralesional trichostrongyles 
consistent with Stephanurus dentatus. 
jMultifocal, granulomatous and eosinophilic interstitial pneumonia with intralesional 
metastrongyles. 
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Table 3.  Bacteriologic culture results.  The species of Brucella obtained from 80 
feral swine is given on a per animal basis. 
 
Brucella species isolated Total culture positive  
feral swinea
B. suisb only 34 (42.5%, 54.8%) 
B. abortusc field strain only 5 (6.3%, 8.1%) 
B. abortus RB51 (RB51) only 1 (1.3%, 1.6%) 
B. suis and B. abortus field strain 11 (13.8%, 17.7%) 
B. suis and B. abortus S19 (S19) 4 (5.0%, 6.5%) 
B. suis and B. abortus RB51 2 (2.5%, 3.2%) 
B. abortus field strain , S19, and RB51 1 (1.3%, 1.6%) 
B. suis, B. abortus field strain, and RB51 1 (1.3%, 1.6%) 
B. suis, B. abortus field strain, and S19 2 (2.5%, 3.2%) 
B. suis, B. abortus field strain, S19, and RB51 1 (1.3%, 1.6%) 
aA total of 80 feral swine were trapped, and a total of 62 (77.5%) were culture positive 
for at least one species of Brucella.  The number reported is the total number of feral 
swine positive for the respective species of Brucella with the percentage of the total 
population followed by the percentage of culture positive animals in parentheses. 
bAll B. suis isolates were biovar 1. 
cAll B. abortus field strain isolates were biovar 1. 
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Table 4.  Brucella culture results by tissue.  The results of bacteriologic culture of 
tissues from 80 feral swine is shown on a per tissue basis as well as the number of 
each species isolated for each given tissue. 
Sample Totala + B. suisb B. abortus 
field strainc
B. abortus 
S19 
B. abortus
RB51 
Lymph nodes 38 (61.3%) 26 11 4 2 
Popliteal  18 (22.5%) 12 3 2 2 
Tracheobronchial  16 (20.0%) 11 3 2 0 
Sternal  14 (17.5%) 9 5 1 1 
Gastrohepatic  13 (16.3%) 11 2 0 0 
Mandibular  13 (16.3%) 10 3 0 0 
Prescapular  13 (16.3%) 8 4 1 0 
Parotid  13 (16.3%) 9 3 1 0 
Prefemoral  12 (15.0%) 9 3 0 0 
Medial 
retropharyngeal  
12 (15.0%) 6 6 0 0 
Male reproductive 
organs 
22 (56.4%) 17 5 3 0 
Seminal Vessicled 16 (38.1%) 12 2 2 0 
Bulbourethral glandd 13 (31.0%) 11 2 1 0 
Prostated 12 (28.6% 10 1 1 0 
Testisd 8 (19.1%) 4 3 2 0 
Nasal Swab 27 (33.8%) 20 5 0 2 
Blood 25 (31.3%) 24 4 0 2 
Urine 15 (18.8%) 15 1 0 0 
Vaginal Swabe 7 (18.4%) 6 1 1 0 
Liver 13 (16.3%) 9 3 1 0 
Spleen 13 (16.3%) 7 5 2 0 
Mammarye 6 (15.8%) 5 1 1 0 
Lung 12 (15.0%) 9 3 1 0 
Uteruse 4 (10.5%) 3 0 1 0 
Kidney 6 (7.5%) 3 3 0 0 
aA total of 80 feral swine were trapped, and a total of 62 (77.5%) were culture positive 
for at least one species of Brucella. 
bAll B. suis isolates were biovar 1. 
cAll B. abortus field strain isolates were biovar 1. 
dThere were 42 total males; 39 (60.6%) were Brucella culture +. 
eThere were 38 total females; 23 (92.9%) were Brucella culture +. 
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Table 5. VNTR Patterns of Selected B. suis  biovar 1 isolates from feral swine. 
Isolate or 
Strain 
Designatio
n 
VNTR-
1 
VNTR-
2 
VNTR-
3 
VNTR-
4 
VNTR-
5 
VNTR-
6 
VNTR-
7 
VNTR-
8 
1330 
(biovar 1 
reference) 
2 2 4 2 8 5 11 4 
686 (biovar 
3 reference) 
8 4 10 2 10 6 5 9 
760-1a, 3 2 3 1 6 4 7 4 
782-1a 3 2 3 1 6 4 7 4 
1688-3a,c 3 2 3 1 6 4 7 4 
1714-2b 3 2 3 1 7 4 7 4 
344-1b 3 2 3 1 6 4 8 4 
401-1 3 2 3 1 9 4 6 6 
1690-1c 3 2 3 1 8 4 7 6 
353-1d 3 2 3 1 9 3 8 7 
389-1d 3 2 3 1 9 3 8 7 
1857-1 4 2 3 1 9 3 7 6 
1803-1e 2 2 3 1 8 4 8 6 
1819-1e 2 2 3 1 8 4 7 6 
aIdentical pattern 
bDiffers from pattern a by 1 allele at a single locus 
cIsolates from the same animal (#52).  1688-3 isolated from the popliteal lymph node.  
1690-1 isolated from the bulbourethral gland 
dIdentical pattern 
eIsolates from the same animal (#216).  1803-1 isolated from the liver. 1819-1 isolated 
from the seminal vesicle 
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Table 6.  VNTR Patterns of Selected B. abortus isolates from feral swine. 
Isolate or 
Strain 
Designation 
VNTR-
1 
VNTR-
2 
VNTR-
3 
VNTR-
4 
VNTR-
5 
VNTR-
6 
VNTR-
7 
VNTR-
8 
544a (biovar 
1 reference 
strain) 
3 4 6 5 2 2 4 2 
9-941a (B. 
abortus 
sequence 
strain) 
2 5 4 4 2 2 11 2 
399-1bc 5 4 5 2 2 2 8 2 
400-1bch 5 4 5 2 2 2 10 2 
402-1bch 5 4 5 2 2 2 10 2 
431-1c 5 4 5 3 3 3 9 3 
RB51ai 5 4 4 2 2 2 11 2 
1671-1di 5 4 4 2 2 2 11 2 
S19a 5 4 4 2 2 2 8 2 
1678-1efj 5 4 4 2 2 2 8 2 
1679efj 5 4 4 2 2 2 8 2 
1684ej 5 4 4 2 2 2 8 2 
7-popegj 5 4 7 2 2 2 8 2 
1665-1eg 6 4 4 2 2 3 12 2 
 
aLaboratory reference culture. 
 bIsolates from the same animal (#10).  Isolate 399-1 was isolated from the kidney.  
Isolate 400-1 was isolated from the liver, and 401-1 was isolated from the mandibular 
lymph node. 
c Isolates are B. abortus biovar 1 field strains. 
dB. abortus RB51. 
eB. abortus S19. 
fIsolates from the same animal (#50).  Isolate 1678-1 was isolated form the liver, and 
1679 was isolated from the mammary. 
gIsolates from the same animal (#7).  Isolate 7-pop was isolated from the popliteal lymph 
node, and 1665-1 was isolated from the prostate. 
hIdentical patterns. 
iIdentical patterns. 
jIdentical patterns.
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Table 7.   Serologic Results.  Results of serologic assays from necropsy sera from 80 
feral swine. 
 Total 
Seropositive 
Total Seropositive from 
Culture Positive Groupa
Totalb 39/80 (48.8%) 33/61 (54.1%) 
Card Test 9/80 (11.3%) 8/61 (13.1%) 
Standard Tube Test 31/80 (38.8%) 27/61 (44.6%) 
Fluorescence Polarization Assay 30/80 (37.5%) 26/61 (42.6%) 
aThere were 62 culture positive animals; however, from one animal only RB51 was 
isolated.  Because RB51 does not induce a serologic response which can be detected 
by the assays used, that animal was excluded from the sensitivity calculations. 
bAn animal was considered seropositive if there was a positive reaction on at least one 
serologic assay examined. 
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Figure 1A.  Lymphofollicular interstitial nephritis.  The renal interstitium is markedly 
expanded due to abundant numbers of lymphocytes which are organized into follicle-like 
structures.  HE. 
 
 
Figure 1B.  Liver microgranulomas.  The Hepatic parenchyma is replaced by multiple 
granulomas with necrotic centers.  The area between the microgranulomas contains 
abundant collagen as well as scattered lymphocytes and plasma cells.  HE. 
 
  67 
 
Figure 1C.  Lymph node, poorly organized pyogranuloma. Abundant neutrophils are 
surrounded by macrophages and lymphocytes as well as loosely organized fibrous tissue.  
Numerous multinucleated giant cells also segmentally surround the pyogranuloma.  HE. 
 
 
Figure 1D.  Lymphocytic orchitis with atrophy of the seminiferous tubules.  Seminiferous 
tubules are greatly separated from one another due to abundant numbers of small 
lymphocytes.  The remaining seminiferous tubules are completely devoid of maturing 
spermatogonia; only Sertoli cells remain within the seminiferous tubules.  HE. 
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Figure 1E.  Purulent and lymphoplasmacytic seminal vessiculitis with fibrosis.  
Periglandular interstitial areas are expanded due to abundant numbers of lymphocytes 
and plasma cells as well as fibrous tissue.  The glandular lumena contain numerous 
neutrophils and are lacking normal secretory fluid.  HE. 
 
 
Figure 1F.  Lymphocytic prostatitis.  Periglandular interstitial areas contain abundant 
numbers of small lymphocytes.  HE. 
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Figure 2.  2% agarose ethidium bromide stained gel containing products from the 
multiplex PCR reactions from feral swine Brucella isolates. The lanes contain the 
following:  1.  100 bp ladder, 2.  Negative control, 3-8.  Feral swine Brucella isolates, 9.  
S19 positive control, 10.  B. abortus 2308 positive control, 11.  RB51 positive control, 
12.  B. suis 3B positive control. 
 
 
 
  70 
CHAPTER 4.  RESULTS OF A VACCINE TRIAL USING BRUCELLA 
ABORTUS RB51 IN A FERAL SWINE HERD ENZOOTICALLY 
INFECTED WITH BRUCELLA 
 
A paper submitted to Research in Veterinary Science 
 
William C. Stoffregen, Steven C. Olsen, C. Jack. Wheeler, and Betsy J. Bricker 
 
Abstract 
The objective of this study was to evaluate the effect on transmission of Brucella 
and clearance of Brucella abortus strain RB51 (SRB51) vaccine in a feral swine herd 
with enzootic brucellosis.  Feral swine (Sus scrofa) were trapped and injected 
intramuscularly with either 2 X 1010 CFU (2 ml) SRB51 (n=122) or 2 ml of saline 
(n=122).  At the time of initial trapping blood was obtained to determine serologic status, 
and the animals were identified by eartags and microchip implants prior to being 
released. Ten to 14 months after initial capture 80 animals were recaptured.  Animals 
were euthanized and necropsies were performed.  Samples to determine serologic status 
and Brucella culture status were collected at the time of necropsy.  There was no 
significant difference observed in seroconversion or in Brucella culture positivity rate 
between vaccinates and nonvaccinates.  Also, there was no significant difference in anti-
SRB51 dot blot titers between vaccinates and controls.  SRB51 was isolated from 
necropsy samples from eight of forty-four vaccinated animals.  The results of this study 
indicate that parenteral Brucella abortus strain RB51 has no effect in preventing 
transmission of Brucella within an enzootically infected feral swine herd. 
 
Introduction 
Feral swine herds have been reported in 26 of 50 states in the USA (Gipson, 1999; 
Gipson et al., 1999).  With increasing popularity of these animals as a game species, the 
geographic distribution and number of these populations are increasing. Brucellosis has 
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been documented in feral swine populations in 14 states (Zygmont et al., 1982). The 
transmission of Brucella from feral swine to domestic livestock has also been 
documented (Ewalt et al., 1997).  With brucellosis nearly eradicated from domestic 
livestock in the USA, recent attention has been given to dealing with wildlife reservoirs, 
including feral swine.  Currently, due to hunting and trapping and processing of these 
animals for the “wild boar meat” market, feral swine serve as a source of infection for 
human brucellosis in the USA (Starnes et al., 2004).  Particular interest has developed in 
determining control strategies for brucellosis within wild swine populations in order to 
prevent further outbreaks of this disease in domestic livestock and humans.   
Brucella abortus strain RB51 (SRB51) is a laboratory derived lipopolysaccharide 
O-side chain-deficient mutant (Schurig et al., 1991) of B. abortus strain 2308.  SRB51 
induces protective immunologic responses in cattle and bison against challenge-exposure 
with virulent B. abortus strains (Cheville et al., 1993; Cheville et al., 1996; Olsen et al., 
2003).   Initial reports suggested SRB51 induces an immune response (Edmonds et al., 
2001) and prevents transmission of B. suis in swine (Lord et al., 1998).  However, this 
has never been investigated in an enzootically infected feral swine population.   
This study was designed to characterize the effect of SRB51 vaccination in 
preventing  Brucella transmission in a feral swine population with a high prevalence of 
brucellosis; determine if serologic status influences efficacy of SRB51 under field 
conditions; and determine if feral swine stay persistently infected with RB51 after 
vaccination.  
 
Materials and Methods 
 This study was conducted on a 7,100 hectare tract of land on a peninsula between 
the Atlantic Ocean and the Winyah Bay in Georgetown County, South Carolina, USA 
(33° 20’ N, 79° 13’ W).  The study was conducted between September 2001 and 
February 2003. 
Trapping and Vaccination of Feral Swine 
 Feral swine were trapped in wooden box traps with drop doors which were baited 
with fermented shelled corn.  Initial trapping occurred weekly between September 2001 
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and May 2002.  Upon trapping animals were snared and 10 ml of blood was obtained by 
cranial vena caval puncture for serologic assays.  Plastic ear tags were placed in each ear 
and a digital identification chip (Digital Angel, South Saint Paul, MN) was placed 
subcutaneously at the base of one ear.  Animals were injected with either 2.0 ml of a 
suspension containing approximately 2 X 1010 CFU of freshly reconstituted lyophilized 
SRB51 (n=122) (Colorado Serum Company, Denver, CO, USA) or 2.0 ml saline 
(n=122).  Adult and postweaning juvenile swine were utilized.  Juvenile swine which 
were nursing were excluded due to possible passive maternal antibodies against Brucella 
spp. 
 Between October 2002 and February 2003, as many of the 244 original animals as 
possible were recaptured.  A total of 80 feral swine from the original group of 244 were 
recaptured over a total of 20 individual days of trapping.  These animals were euthanized 
and necropsied.   
Necropsies 
After euthanasia, 30 ml of blood was obtained via cardiac puncture.  Blood was 
divided for serology (10 ml) and for Brucella culture (20 ml).  The following tissues, 
fluids, and swabs were harvested for bacteriological culture: liver, spleen, lung, kidney, 
uterus, mammary tissue, testis, seminal vesicle, bulbourethral gland, prostate, urine, nasal 
swab, vaginal swab, and lymph nodes including prescapular, medial retropharyngeal, 
sternal, tracheobronchial, gastrohepatic, prefemoral, popliteal, mandibular, and parotid. 
All tissues were frozen at -70° C until processed for bacteriological evaluation.  
Serologic Evaluation 
 After collection, blood samples were allowed to clot and serum was separated by 
centrifugation.  Serum was divided into 1 ml aliquots, and stored at -70° C until assays 
were performed.  Brucella serologic status of all animals was determined by fluorescence 
polarization (Pauolo et al., 2000), standard tube agglutination, and card agglutination 
assays (Alton et al., 1988) by previously described methods. Animals which had a 
positive reaction on at least one of the three serologic assays were considered positive 
seroreactors.  Serological titers to SRB51 were determined in the 80 recaptured animals 
by a previously described dot blot assay (Olsen et al., 1997) in which γ-irradiated SRB51 
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was used as the antigen and peroxidase-labeled rabbit anti swine IgG (Sigma, St. Louis, 
MO, USA) was used as the secondary antibody at a dilution of 1:500. 
Bacteriologic Culture 
After thawing, tissues were individually ground in approximately 10% (w/v) 
sterile PBS (pH=7.2) using sterile glass grinders. Aliquots (100 μl) of each tissue 
homogenate were plated on 4 Brucella selective media.  Media included tryptose agar 
containing 5% bovine serum; brilliant green agar (BGB132; tryptose agar base with 5% 
bovine serum, .001 μg/ml brilliant green, 25 U/ml Bacitracin, 100 μg/ml cycloheximide, 
100 U/L Nystatin, 20 μg/ml vancomycin, 50 μg/ml trimethoprim, and 100 μg/ml EDTA), 
Kudzas Morse agar (KM; tryptose agar base with 5% bovine serum, 25 U/ml bacitracin, 6 
U/ml polymyxin B, 100 μg/ml cycloheximide, and 1.4 μg/ml ethyl violet), and RBM 
agar, a selective medium for SRB51 (Hornsby et al., 2000). Inoculated plates were 
incubated at 37˚C in 5% CO2 for 7 days. 
Culture Identification 
Brucella suspect cultures were identified on the basis of colony morphology, 
growth characteristics (Alton et al., 1988), and growth on selective media.  Isolates were 
identified as Brucella spp. by a polymerase chain reaction technique (PCR) using 
Brucella-specific primers to the omp2A region of the Brucella genome.  Reactions 
consisted of 50μl and contained 5 μl of suspect culture in tris-EDTA and 45 μl of 
reaction mixture consisting of 200 μM each of dATP, dCTP, dGTP, and dTTP 
(Boehringer Mannheim, Indianapolis, IN), 1 X PCR Buffer II (Perkin Elmer, Branchburg, 
NJ), 1.5 mM MgCl2, 1.25 U AmpliTaq Gold polymerase (Perkin Elmer, Branchburg, 
NJ), and 0.2 mM of each upstream (5’-GCAACGGTGTTCTTCCACTC-3’) and 
downstream (5’-GTATCAGGCTACGCAGAAGG-3’) primers selected from the omp2A 
sequences of Brucella abortus (Ficht et al., 1989).  The primers had 100% conservancy 
within the genomes of Brucella suis and Brucella melitensis according to BLAST 
analysis.  Tris-EDTA and a culture of Yersinia enterocolitica O:9 served as negative 
controls, and Brucella suis strain 3B, a biovar 1 laboratory challenge strain, served as a 
positive control. Following a 10 minute activation at 95˚C reaction preparations were 
cycled in a thermocycler (MJ Research Inc., Watertown, MA) for 40 cycles consisting of 
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30 sec. at 95˚ C, 30 sec. at 44˚ C, and 60 sec. at 72˚ C.  Products were analyzed by 
electrophoresis on 1.5% agarose gels stained with ethidium bromide.  Animals were 
considered culture positive if at least one sample yielded a positive Brucella culture. 
 Cultures which were positive by the omp2A PCR assay were run in a second PCR 
assay in order to determine if they were SRB51.  This PCR assay utilized SRB51 specific 
primers targeted toward the insertion sequence 711 (IS711) (Vemulpalli et al., 1999; 
Bricker and Halling, 1995).  Each reaction mixture consisted of a volume of 25 μl 
containing 2.5 μl of suspect culture in Tris-EDTA, 1X PCR reaction buffer containing 50 
mM Tris, 1.5 mM MgCl2, 10 mM KCl, 50 mM (NH4)2SO4, pH=8.3 (Roche Molecular 
Biochemicals, Indianapolis, IN), 200 μM each of dATP, dCTP, dGTP, and dTTP 
(Boehringer Mannheim, Indianapolis, IN); 1X GC rich solution (Roche Molecular 
Biochemicals, Indianapolis, IN); 1.0 U of FastStart DNA polymerase (Roche 
Diagnostics, Basel, Switzerland); and 0.2 μM of each upstream (5’-
TGCCGATCACTTAAGGGCCTTCATTGCCAG-3’) and downstream (5’-
GCCAACCAACCCAAATGCTCACAA-3’) primer.  Thermocycling consisted of a 
single 5 min. incubation at 95˚ C followed by 40 cycles consisting of 15 sec. at 95°C, 30 
sec. at 52°C, and 90 sec. at 72°C.  Tris-EDTA and B. suis strain 3B served as negative 
controls, and SRB51 served as the positive control.  Products were analyzed by 
electrophoresis on 2.0% agarose gels stained with ethidium bromide. 
Statistical Analysis 
Seroconversion and Brucella culture positivity rates between vaccinates which 
were initially seronegative and nonvaccinates which were initially seronegative were 
used to evaluate efficacy of RB51.  Chi-square analysis was used to determine 
significance with significance defined as P<0.05 (PROC FREQ CHISQ, SAS Statistical 
Software, SAS Institute, Inc., Cary, NC). 
Serologic responses to SRB51 were evaluated on a fold-difference basis.  The 
quotients of the necropsy SRB51 dot blot titers divided by the prevaccination titers were 
converted to logarithmic values and compared between vaccinates and controls using  
Student’s t-test (PROC MEANS T, SAS Statistical Software, SAS Institute, Inc., Cary, 
NC). 
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The immugenicity of SRB51 was also evaluated using Chi-square analysis.  
Positive dot blot titers were defined as a four-fold or greater increase in titer between day 
0 and necropsy samples.  Vaccinates were compared to nonvaccinates.  
 
Results 
Serology 
 The seroprevalance rate for Brucella of all initially captured animals was 34.5% 
(84/244).  The overall seroprevalence rate of recaptured animals was 42.5% (34/80). Data 
related to the efficacy of SRB51 are summarized in Table 1.  The seroconversion rates 
among vaccinates which were initially seronegative was 32.0% (9/28).  The 
seroconversion rate among nonvaccinated controls which were initially seronegative was 
40% (10/25). 
 Data related to SRB51 dot blot titers are summarized in figures 2 and 3.  The 
mean SRB51 titers among vaccinates were 1:226 prevaccination and 1:425 at the time of 
necropsy and 1:250 among controls upon initial capture and 1:288 at necropsy (Figure 1).  
This represented a mean of 3.28-fold increase for vaccinates and a mean 2.60-fold 
increase for controls (p=0.45) (Figure 2).  Mean SRB51 titers for animals which were 
seronegative for Brucella at the time of initial capture were 1:205 prevaccination and 
1:465 at the time of necropsy for vaccinates and 1:267 upon initial capture and 1:503 at 
the time of necropsy for controls.   This results in a mean of 5.01-fold increase for 
vaccinates and 3.90-fold increase for controls (p=0.50). 
Culture 
 Overall Brucella culture positivity rate was 77.5% (62/80).  Six animals were 
culture positive for SRB51.  Five of these animals were positive for both SRB51 and 
Brucella spp.  A single animal was positive for only SRB51.  Forty-four of the recaptured 
animals were vaccinates; therefore, SRB51 has a persistence rate of 13.6%. 
 In animals which were initially seronegative, Brucella field strains were 
recovered from 64.0% (16/25)  of nonvaccinated and 67.9% (19/28) SRB51 vaccinates 
(Table 1).   
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Discussion and Conclusions 
 This is the first reported study of a field trial of SRB51 in a feral swine herd with 
enzootic brucellosis.  The results of this study indicate that SRB51 had no effect in 
preventing seroconversion and infection with Brucella spp in seronegative feral swine 
when vaccinated with a standard vaccine dosage and returned to their natural 
environment. 
 Animals in this study were categorized into 4 groups:  vaccinates which were 
initially seronegative, controls which were initially seronegative, vaccinates which were 
initially seropositive, and controls which were initially seropositive.  Conclusions on the 
efficacy of SRB51 were made by comparing the populations of vaccinates and controls 
which were seronegative upon initial capture.  There were no statistical differences 
between these two groups with respect to seroconversion (p=0.48) and Brucella culture 
positivity rate (P=0.45).  Because SRB51 is a rough mutant which does not express the 
lipopolysaccharide O-side chain, the use of SRB51 in this feral swine herd had no effect 
on seroconversion to Brucella spp. as the 3 serologic assay used in this study utilize the 
lipopolysaccharide O-side chain of Brucella abortus as the antigen. 
 Vaccinated animals also failed to develop significant humoral immune response 
against SRB51.  While many vaccinated animals did have four fold or greater increases 
in SRB51 titers, there was no significance in the number of animals which seroconverted 
when compared to controls (P=0.12).  There were also no significant differences in 
necropsy sample SRB51 titer values between vaccinates and controls (P>0.05).  There 
was a statistically significant difference in the factor increase of SRB51 titers between 
vaccinates which were initially seronegative and vaccinates which were initially 
seropositive (P=0.02).  This may suggest that serostatus has an effect on vaccine 
immunogenicity; however, this is discredited by the lack of statistically significant 
differences in both absolute titer values and factor increase values between controls and 
vaccinates which were initially seronegative. 
 The results of this study are contrary to those of Lord and colleagues (1998).  In 
that study SRB51 was used to parenterally vaccinate domestic gilts IM and orally at 
dosages of 106-109 CFU.  That study also used purified lipopolysaccharide O-side chain 
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from B. abortus or B. suis to vaccinate animals IM or PO.  It was concluded that all 
vaccine preparations provided 100% protection based on lack of seroconversion, lack of 
abortions, and increased litter size over those of the control groups.  That study was 
similar to the feral swine study of this paper in that the challenge dosage was not defined; 
vaccinated gilts were bred to boars which were previously determined to be infected and 
shedding Brucella suis in their semen. The study by Lord et al. (1998) also did not 
examine the Brucella-culture status of all animals in the study.  Cultures were only 
performed on vaginal swabs from sows which aborted and on tissues from aborted 
fetuses.  Whereas, samples from animals which had full-term pregnancies were not 
cultured. 
 Edmonds and colleagues (2001) also examined SRB51 vaccination of domestic 
swine with 109-1012 CFU/dose.  That study concluded that some animals could develop a 
humoral immune response against SRB51 after SQ or oral vaccination.  Unlike the feral 
swine study of this paper, the study by Edmonds did not have any nonvaccinated control 
animals to which the results of the SRB51 vaccinated animals could be statistically 
compared. 
 An interesting result from this study was the persistence of SRB51 in 6 vaccinated 
animals for as long as 14 months post vaccination.  B. abortus usually produces a short-
lived infection of only the draining lymph node of the area of infection in swine (Deyoe 
1972).  From all 6 of the SRB51 culture positive animals, SRB51 was isolated from 
tissues other than lymph nodes (prescapular, sternal, and medial retropharyngeal lymph 
nodes) draining the site of vaccination.  This suggests that subsequent to vaccination, 
bacteremia and peripheral infection also occurred.  This atypical response might be due to 
an immune-mediated enhancement of infection.  Previous infection with Brucella suis in 
these animals might have allowed  an increased incidence of infection and enhanced 
persistence of the antigenically related SRB51 by similar mechanisms as previously 
described for immune-mediated enhancement of infection of antigenically similar 
organisms (Mahalingam and Lidbury, 2003; Sullivan, 2001).  The animals in this study 
were also heavily parasitized.  There was evidence of nematode infestation, notably from 
Stephanurus dentatus, in almost every necropsied animal.  Recently, it has been shown 
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that persistent helminths can down regulate TH1 cell mediated immune responses (Brady, 
et al., 1999) and allow enhancement of infection and persistence of bacteria (O’Neill et 
al., 2001).  Perhaps, a similar process may be at least partially responsible for the unusual 
persistence of the SRB51 and for the markedly high Brucella culture positivity rate 
within this feral swine population. 
 The results of this study serve as an example for the lack of sensitivity of 
serological assays for diagnosing brucellosis in feral swine.  When necropsy culture 
results were compared to necropsy serology results, the sensitivity of a combination of 
the three serological assays which were used was 54.1%.  Previously published 
sensitivity rates for these assays in domestic swine were 20-67% for the card test, 83-
100% for the standard tube test, and 80-94% for the FPA test (Paolo et al., 2000; Lord et 
al., 1997; Ferris et al., 1995).  Anitgens used in these assays are from Brucella abortus 
which may at least partially account for the lack of sensitivity when evaluating swine 
presumably infected with Brucella suis. 
 The results of this study do not support the use of SRB51 as a suitable vaccine 
candidate to be used in the control of brucellosis in feral swine.  This study also reiterates 
the lack of sensitivity of conventional serologic assays for diagnosing brucellosis in 
swine.  Control of brucellosis in feral swine will likely require an efficacious vaccine 
which can be administered orally, and management of brucellosis in feral swine could be 
aided by the development of more sensitive serologic assays. 
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Table 1.  Efficacy of SRB51 in Feral Swine.  Comparison between vaccinates and 
controls.  All animals were seronegative at the time of primary capture.   
 
     Controls (n=25)  Vaccinates (n=28)  
 
Seroconversionac   40% (10/25)   32% (9/28) 
 
 
Brucella culture +bd   64.0% (16/25)  67.9% (19/28)   
aSeroconversion defined as positive result on at least one of the following assays:  Card 
Test, Standard Tube Test, and Fluorescence Polarization assay. 
bBrucella Culture + defined as culturing Brucella spp. one or more samples. 
cP=0.28 
dP=0.45 
 
 
   82
 
Figure 1.  Serologic responses of feral swine to γ-irradiated SRB51 in a dot blot assay.  
Feral swine were vaccinated with either 1 X1010 CFU SRB51 vaccine or saline.  
Responses are presented as mean titer ±SEM.  Means with the same lowercase letter are 
significantly different (P<0.05). 
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Figure 2.  Serologic responses of feral swine to γ-irradiated SRB51 in a dot blot assay 
expressed as the factor of increase between initial capture and necropsy sera.  Feral swine 
were vaccinated with either 1 X1010 CFU SRB51 vaccine or saline at the time of initial 
capture.  Responses are presented as mean quotient  ±SEM.   
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CHAPTER 5.  PARENTERAL VACCINATION OF DOMESTIC PIGS 
WITH BRUCELLA ABORTUS STRAIN RB51 
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William C. Stoffregen, DVM, Steven C. Olsen, DVM, PhD, and Betsy J. Bricker, PhD 
 
Abstract 
Objective⎯To determine the immunogenicity and efficacy of Brucella abortus strain 
RB51 (SRB51) as a vaccine in domestic pigs. 
Animals⎯68 six-week-old crossbred domestic pigs and 24 four-month-old gilts. 
Procedures⎯In experiment 1, pigs were vaccinated IM (n = 51) with 2 × 1010 CFUs of 
SRB51 or sham inoculated (17). Periodic blood samples were obtained to perform blood 
cultures, serologic evaluations, and cell-mediated immunity assays. Necropsies were 
performed at selected times between weeks 1 and 23 after vaccination to determine 
vaccine clearance. In experiment 2, gilts were similarly vaccinated (n = 18) or sham 
inoculated (8) and similar samples obtained after vaccination. Gilts were bred and 
challenged conjunctivally with 5.0 × 107 CFUs of virulent Brucella suis strain 3B. 
Necropsies were performed on gilts and on fetuses or neonates after abortion or 
parturition, respectively. Bacterial cultures and serologic evaluations were performed on 
samples obtained at necropsy to determine vaccine efficacy. 
Results⎯Humoral and cell-mediated immune responses did not differ between 
vaccinates and controls. After vaccination, SRB51 was not isolated from blood cultures 
of either group and was isolated from lymphoid tissues of 3 pigs at 2 weeks (n = 2) and 4 
weeks (1) after vaccination. No differences were found in isolation of B suis or in 
seroconversion between vaccinated and control gilts and between their neonates or 
aborted fetuses. 
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Conclusions and Clinical Relevance⎯Parenteral vaccination with SRB51 does not 
induce humoral or cell-mediated immune responses. Vaccination with SRB51 did not 
protect gilts or their neonates and fetuses from virulent challenge with B suis. 
 
Introduction 
Swine brucellosis, which is caused by the bacterium Brucella suis, is found in 
domestic or feral pigs on all inhabited continents.1 Manifestations of swine brucellosis 
range from subclinical infection to abortions and infertility.1 In addition to its effects on 
female reproduction cycles and pregnancy, swine brucellosis may also manifest as 
infection and inflammation of primary and secondary reproductive organs of males as 
well as multicentric arthritis, diskospondylitis, and lymphadenitis in all aged pigs of both 
sexes.1 Of all the Brucella spp, B suis is most noteworthy for causing chronic and 
persistent infections.2,3 Brucella suis is a zoonotic agent that has been known to infect 
slaughter house workers, farm workers, and hunters who have been exposed to tissues 
from B suis infected pigs.4,5
In the United States the Cooperative State-Federal Brucellosis Eradication 
Program has led to the near elimination of swine brucellosis within domestic pigs. 
Currently, 49 states and Puerto Rico are classified as free of swine brucellosis (ie, stage 
III) while Texas is classified as stage II (more than 1 B. suis infected herd identified in 
the past 2 years).6 However, periodic, isolated outbreaks of swine brucellosis still occur 
within the United States. Most of these outbreaks are attributed to contact with feral pigs. 
Feral pigs have also been responsible for infecting cattle with B suis.7
The reduction and near eradication of swine brucellosis from domestic herds 
within the United States has been achieved through a systematic program of herd testing, 
slaughter testing, trace-back of reactors, and disposal of reactor herds. With the near 
complete eradication of swine brucellosis from domestic pigs in the United States, a 
reemergence of interest exists in new strategies, including candidate vaccines, to control 
swine brucellosis particularly in light of the wide distribution of Brucella-infected feral 
pigs across the United States. 
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Brucella abortus strain RB51 is a laboratory derived lipopolysaccharide O-side 
chain-deficient mutant of B abortus strain 2308.8 Brucella abortus strain RB51 induces 
protective immunologic responses in cattle and bison against challenge-exposure with 
virulent B abortus strains.9,10,11 Brucella abortus strain RB51 also does not induce 
antibody responses that react with conventional brucellosis serologic surveillance tests.12, 
13 Initial reports suggested that SRB51 induces an immune response and prevents 
transmission of B suis in pigs.14, 15 The purposes of the study reported here were to 
determine the potential of parenteral administration of SRB51 to elicit an immune 
response as well as protection from challenge with virulent B suis in domestic pigs. 
 
Materials and Methods 
Bacterial cultures 
A master seed stock of SRB51 was obtained.a  After 1 passage on TSA, the seed 
stock was designated ARS/1. For experimental use in serologic and lymphocyte 
proliferation assays, SRB51 (ARS/1) bacteria were grown on TSAb for 48 hours at 37°C. 
Resulting cultures were suspended in PBS (0.15M NaCl) solution at a concentration of 1.3 
× 1012 CFUs/mL and inactivated by γ-irradiation (1.4 × 106 rad). After irradiation, 
suspensions were washed in 0.15M NaCl solution and stored in 1.0 mL aliquots at 
−70°C. 
For vaccination of pigs, SRB51 (ARS/1) was expanded on TSA for 48 hours at 
37°C with 5% CO2. Harvested bacteria were suspended in PBS (0.15M NaCl) solution and 
then diluted to a concentration of 1.0 × 1010 CFUs/mL in PBS (0.15M NaCl) solution by 
use of an optical density method and spectrophotometerc. The final concentration was 
determined by standard plate counts on TSA after a 5-day incubation period at 37°C and 
5% CO2. 
The challenge culture Brucella suis strain 3B (biovar 1) was originally obtained 
from an aborted fetus of a sow exposed to a polyvalent suspension of 3 strains of B suis. 
The 3 strains had previously been isolated from boars originating from 3 sources. 
Brucella suis strain 3B has been maintained as a lyophilized culture since 1942. Brucella 
suis strain 3B was grown on TSA for 48 hours at 37°C with 5% CO2. Bacteria were 
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harvested and suspended in PBS (0.15M NaCl) solution and diluted to a concentration of 1 
× 109 CFUs/mL by use of an optical density method and spectrophotometerc. The final 
concentration was determined by standard plate counts on TSA after a 5-day incubation 
period at 37°C and 5% CO2. 
Swine experiments and study design 
The work reported herein was performed under the approval of the Institutional 
Animal Care and Use Committee of the National Animal Disease Center (Ames, IA). 
Vaccine clearance and induction of an immune response were initially assessed in 
weaned pigs (experiment 1). A total of sixty-eight 6-week-old, crossbred domestic pigs 
were inoculated IM in the right cervical area with either 2.0 mL of PBS (0.15M NaCl) 
solution alone (n = 17) or 2.0 mL of PBS (0.15M NaCl) solution containing 2.0 × 1010 
CFUs of SRB51 (51). All pigs were commingled in a single pen and fed ad libitum. 
Induction of an immune response and protection from virulent challenge with B 
suis strain 3B were assessed in crossbred domestic gilts (experiment 2). A total of 
twenty-four 4-month-old gilts were inoculated IM in the right cervical area with 2.0 mL 
of PBS (0.15M NaCl) solution containing 2 × 1010 CFUs of SRB51 (n = 18) or sham 
inoculated with 2.0 mL of PBS (0.15M NaCl) solution (8). At approximately 10 months of 
age, gilts were bred by artificial insemination. Pregnancy was verified by use of 
ultrasonography. Fourteen vaccinates and 8 control gilts were successfully bred and 
challenged at approximately day 75 of gestation by bilateral conjunctival administration 
of 5.0 × 107 CFUs of B suis strain 3B (volume, 50 μL/eye). 
Serologic evaluation 
Blood was collected for serologic evaluation by cranial vena cava puncture in 
experiment 1 (weaned pig group) at weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 
after vaccination and in experiment 2 (gilt group) at weeks 0, 2, 4, 8, 12, 16, 20, and 24 
after vaccination. Blood samples were allowed to clot and serum was separated by 
centrifugation. Serum was divided into 1 mL aliquots, and stored at −70°C until assays 
were performed. Serum antibody titers to SRB51 were determined by use of a previously 
described dot blot assay in which γ-irradiated SRB51 was used as the antigen and 
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peroxidase-labeled rabbit anti-swine IgGd was used as the secondary antibody at a 
dilution of 1:500.16 
 
Seroconversion as a result of challenge with the B suis strain was determined by use of 
fluorescence polarization17, standard tube agglutination18, and card agglutination assays18 
with previously described methods that use B abortus antigen. Blood was collected on 
day 0 of challenge from all gilts and at necropsy from all gilts, neonates, and fetuses. Pigs 
that had a positive reaction on ≥ 1 of the 3 serologic assays were considered seroreactors. 
PBMC proliferation assays 
Blood samples (45 mL) were collected into acid-citrate dextrose solution from the 
cranial vena cava at weeks 8, 12, 14, 16, 18, and 20 after vaccination from pigs in 
experiment 1 and at weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 after vaccination 
from the gilts in experiment 2. Peripheral blood mononuclear cells were enriched by 
density centrifugation with a Ficoll-sodium diatrizoate gradient.d
Fifty microliters of each cell suspension containing 5 × 105 PBMCs were added to 
each of 2 separate flat-bottom wells of 96-well microtiter plates that contained 100 μL of 
RPMI 1640 medium only or RPMI 1640 medium containing γ-irradiated SRB51 (105 to 
109 bacteria/well). Cell cultures were incubated for 4 days at 37°C under 5% CO2. Plates 
were then pulsed with 1.0 μCi of [3H] thymidine/well for 18 hours. Cells were harvested 
onto glass filter mats and counted for radioactivity in a liquid scintillation countere. 
Necropsy examination 
All pigs were euthanatized by administration of sodium pentobarbital into the 
cranial vena cava. Tissues collected for bacterial culture were collected with an aseptic 
technique, placed into individual containers, and immediately frozen at −70°C until 
processed. Tissues collected for histologic evaluation were immediately placed in 
neutral-buffered 10% formalin, processed by routine paraffin embedding techniques, cut 
in 4-μm-thick sections, and stained with H&E. 
In experiment 1, 4 vaccinates and 1 control pig were necropsied at weeks 1, 2, 3, 
4, 5, and 6 after vaccination Five vaccinates and 2 controls were necropsied at weeks 8, 
12, 16, and 20 after vaccination, and the remaining 7 vaccinates and 3 controls were 
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necropsied at week 23 after vaccination. Blood and urine were collected for bacterial 
culture at necropsy. The following tissues were collected for bacterial culture and 
histologic evaluation: liver, spleen, kidney, lung, pharyngeal tonsils, and lingual tonsil as 
well as prescapular, medial retropharyngeal, sternal, tracheobronchial, mediastinal, 
gastrohepatic, ileocecal, jejunal, renal, iliac, inguinal, prefemoral, popliteal, mandibular, 
and parotid lymph nodes. 
In experiment 2, all neonates or fetuses were euthanatized and necropsied within a 
few hours of parturition or abortion, respectively. Samples of whole blood, CSF, and 
stomach contents, and rectal swab specimens were obtained for bacterial culture, and 
lung, liver, spleen, and kidney tissue specimens were obtained for bacterial culture and 
histologic evaluation. Gilts were euthanatized and necropsied within 2 days of parturition 
(or abortion). Samples of whole blood, milk, and urine, and vaginal swab specimens were 
obtained for bacterial culture, and lung, liver, spleen, kidney, mammary gland, uterus, 
and placenta tissue specimens as well as tracheobronchial, prescapular, medial 
retropharyngeal, mandibular, parotid, sternal, iliac, prefemoral, popliteal, gastrohepatic, 
and ileocecal lymph nodes were obtained for bacterial culture and histologic evaluation. 
Bacterial culture 
In experiment 1, whole blood was collected for bacterial culture at days 0, 7, 10, 
14, 17, 21, 24, 28, and weeks 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, and 23 after 
vaccination. In experiment 2, whole blood was collected for bacterial culture at day 0 and 
weeks 2, 4, 8, 12, 16, 20, and 24 after vaccination. Whole blood samples and 
conjunctival, nasal, and vaginal swab specimens were collected after virulent challenge 
with B suis strain 3B on days 0, 3, 7, and 10, and weekly thereafter until parturition or 
abortion. 
Whole blood for bacterial culture was immediately placed into tryptose broth 
containing acid citrate dextrose (1:1, vol/vol) and incubated for 7 days at 37°C and 5% 
CO2 prior to plating on Brucella selective media. Urine, stomach contents, CSF, and milk 
were incubated in tryptose broth containing 5% bovine serum (1:3, vol/vol) for 7 days at 
37°C and 5% CO2 prior to plating on Brucella selective media. After thawing, tissues 
were individually ground in approximately 10% (wt/vol) sterile PBS solution (pH 7.2) 
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with sterile glass grinders. Aliquots (100 μL) of each tissue homogenate or preincubated 
tryptose broth (blood, urine, stomach contents, CSF, and milk) were plated on 4 Brucella 
selective media. Media included tryptose agar containing 5% bovine serum; brilliant 
green agar (containing tryptose agar base with 5% bovine serum, brilliant green [0.001 
μg/mL], bacitracin [25 U/mL], cycloheximide [100 μg/mL], nystatin [100 U/L], 
vancomycin [20 μg/mL], vancomycin [50 μg/mL], and EDTA [100 μg/mL]); Kuzdas-
Morse selective medium (containing tryptose agar base with 5% bovine serum, bacitracin 
[25 U/mL], polymyxin B [6 U/mL], cycloheximide [100 μg/mL], and ethyl violet [1.4 
μg/mL]); and RBM agar, a selective medium for SRB5119. Inoculated plates were 
incubated at 37°C in 5% CO2 for 7 days. 
Bacterial culture results 
Suspect cultures of Brucella spp were identified on the basis of colony 
morphology, growth characteristics18, and growth on selective media. Isolates were 
identified as Brucella spp by use of a PCR technique with Brucella-specific primers to 
the omp2A region of the Brucella genome. Reactions consisted of 50 μL and contained 5 
μL of the suspect culture of Brucella spp in tris-EDTA and 45 μL of reaction mixture 
consisting of 200μM each of dATP, dCTP, dGTP, and dTTPf, 1× PCR buffer IIf, 1.5mM 
MgCl2, 1.25units of Taq polymeraseg, and 0.2mM of each upstream (5’-
GCAACGGTGTTCTTCCACTC-3’) and downstream (5’-
GTATCAGGCTACGCAGAAGG-3’) primer selected from the omp2A sequences of 
Brucella abortus.20 Primers had 100% conservancy within the genomes of Brucella suis 
and Brucella melitensis according to the results of a basic local alignment search tool (ie, 
BLAST) analysis. Tris-EDTA and a culture of Yersinia enterocolitica O:9 served as 
negative controls, and Brucella suis strain 3B served as a positive control. Following a 
10-minute activation at 95°C, reaction preparations were cycled in a thermocyclerh for 40 
cycles consisting of 30 seconds at 95°C, 30 seconds at 44°C, and 60 seconds at 72°C. 
Products were analyzed by electrophoresis on 1.5% agarose gels stained with ethidium 
bromide. Pigs were considered infected with B suis strain 3B if ≥ 1 sample yielded a 
positive Brucella culture result. 
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Cultures that had positive results for Brucella spp by the omp2A PCR assay were run in a 
second PCR assay to determine whether they were SRB51. This PCR assay used SRB51 
specific primers targeted toward the insertion sequence 711.21, 22 Each reaction mixture 
consisted of a volume of 25 μL containing 2.5 μL of the suspect culture of Brucella spp 
in Tris-EDTA, 1× PCR reaction buffer containing 50mM Tris, 1.5mM MgCl2, 10mM 
KCl, 50mM (NH4)2SO4, pH 8.3,i and 200μM each of dATP, dCTP, dGTP, and dTTPf; 1× 
guanine-cytosine rich solutioni; 1.0 unit of DNA polymerasej; and 0.2μM of each 
upstream (5’-TGCCGATCACTTAAGGGCCTTCATTGCCAG-3’) and downstream (5’-
GCCAACCAACCCAAATGCTCACAA-3’) primer. Thermocycling consisted of a single 
5 minute incubation at 95°C followed by 40 cycles consisting of 15 seconds at 95°C, 30 
seconds at 52°C, and 90 seconds at 72°C. Tris-EDTA and B suis strain 3B served as 
negative controls, and SRB51 served as the positive control. Products were analyzed by 
electrophoresis on 2.0% agarose gels stained with ethidium bromide. 
Statistical analysis 
For all analyses a level of P < 0.05 was used to determine significant differences 
between vaccinates and controls. Serologic response data to SRB51 were converted to the 
logarithm of the titer for analysis. Resulting values were compared between vaccinates 
and controls by use of a repeated measures, general linear model procedurek. Proliferative 
responses to SRB51 were converted to the logarithm of the mean cpm and compared 
between vaccinates and controls by use of a general linear model procedure and least 
squared meansk. A χ2 test was used to determine differences in positive bacterial culture 
results and seropositivity between neonates and fetuses from vaccinated versus control 
giltsl. The Fisher exact test was used to determine differences between vaccinates and 
controls on a per litter basis and to determine differences in positive bacterial culture 
results, seroconversion, and histologic lesions between vaccinated and control gilts or 
between neonates and fetuses from vaccinated or control giltsl. 
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Results 
Serologic evaluation 
The SRB51 dot blot titers were analyzed (Figure 1 and 2) to determine serum 
antibody titers to SRB51. No significant differences in serum antibody titers to SRB51 
were found between vaccinates and controls in both experiments with the exception of 
week 22 in experiment 1; however, at this time point the mean titer of the control group 
was significantly higher than the vaccinated group. 
Seroconversion rates for control and vaccinated gilts that were challenged with B 
suis strain 3B during gestation were 7 of 8 and 11 of 14 gilts, respectively, (P = 0.40). 
Seropositivity rate was 27.8% (25/90) for neonates and fetuses from control gilts and 
35.1% (60/171) for neonates and fetuses from vaccinated gilts (P = 0.23). 
PBMC proliferation assays 
Analysis of data from PBMC proliferation assays revealed that at all time points 
in both experiments no significant difference was found in mean cpm between the 
vaccinated and control groups (Figures 3 and 4). At each time point the pokeweed 
mitogen positive control wells yielded mean cpm of > 100,000 for the control and 
vaccinated groups. 
Bacterial culture results 
In experiment 1, SRB51 was isolated from 3 of 51 vaccinated pigs at the 
following time points: the lingual tonsil and sternal lymph node in 1 pig at 2 weeks after 
vaccination; the tracheobronchial lymph node from 1 pig at 2 weeks after vaccination; 
and the prescapular lymph node from 1 pig at 4 weeks after vaccination. Brucella abortus 
strain RB51 was not isolated from blood cultures from any pigs at any time point in 
experiments 1 and 2, and SRB51 was also not isolated from samples obtained at necropsy 
from sham inoculated control pigs in experiment 1. 
Recovery of B suis after inoculation and from tissues collected at necropsy from 
control and vaccinated gilts and their neonates and fetuses were recorded (Table 1). 
Polymerase chain reaction analysis of all isolates obtained after inoculation also at 
necropsy confirmed that none were SRB51. Pigs were considered infected with B suis 
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strain 3B if ≥ 1 sample (ie, tissues, blood, swab specimens, fluids) yielded a positive 
Brucella culture result. No significant differences in positive bacterial culture result rates 
were found between control and vaccinated gilts for samples from the after inoculation-
antemortem period (P = 0.14) and from samples obtained at necropsy (P = 0.39). 
Likewise, no significant differences were found in positive bacterial culture result rates 
between neonates and fetuses from control gilts or vaccinated gilts when examined on a 
per neonate-fetus basis (P = 0.46) or on a per litter basis (P = 0.47). 
Lesions 
No gross lesions were observed in pigs of experiment 1, and with the exception of 
purulent endometrial exudate in 1 vaccinated gilt, no gross lesions were observed in gilts 
of experiment 2. No noteworthy histologic lesions were found in pigs from experiment 1. 
Histologic lesions in the gilts from experiment 2 and their neonates and fetuses were 
recorded. Purulent lymphadenitis characterized by mild to moderate numbers of 
neutrophils present within sinusoids of interfollicular areas of multiple lymph nodes was 
present in 5 pigs (5 vaccinates). Lymph nodes affected included medial retropharyngeal 
(2), mandibular (1), gastrohepatic (1), sternal (1), popliteal (1), iliac (1), and 
tracheobronchial (1). Portal hepatitis characterized by low to moderate number of 
neutrophils, lymphocytes, and plasma cells surrounding portal vessels and bile ducts was 
present in 5 pigs (2 controls and 3 vaccinates). Five gilts (2 controls and 3 vaccinates) 
had purulent endometritis characterized by low to moderate numbers of neutrophils 
within the mucosa and lamina propria of the uterus. In 1 control pig moderate numbers of 
lymphocytes and plasma cells were present in addition to neutrophils. Five pigs (1 control 
and 4 vaccinates) had interstitial nephritis characterized by multifocal areas of low to 
moderate number of neutrophils, lymphocytes, and plasma cells within cortical interstitial 
areas. No significant (P = 0.34) difference was found between the number of control and 
vaccinated pigs that had histologic lesions consistent with Brucella infection. 
Histologic lesions consistent with Brucella infection were present in 21.2% 
(19/90) of neonates and fetuses from control gilts and 23.3% (40/171) of neonates and 
fetuses from vaccinated gilts. Diffuse, mild to moderate, purulent interstitial pneumonia 
characterized by low to moderate numbers of neutrophils infiltrating alveolar septa was 
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present in 18.9% (17/90) of neonates and fetuses from control gilts and 19.9% (34/171) 
of neonates and fetuses from vaccinated gilts. Multifocal, purulent, portal hepatitis 
characterized by mild to moderate numbers of neutrophils surrounding vessels and bile 
ducts within portal areas of the liver was present in 2 neonates and fetuses from control 
gilts and 6 neonates and fetuses from vaccinates gilts. No significant (P = 0.83) 
difference was found between the number of neonates and fetuses from control gilts and 
vaccinated gilts that had histologic lesions consistent with Brucella infection. 
 
Discussion 
Results of our study indicate that single dose parenteral vaccination with SRB51 
is not sufficiently immunogenic to protect against virulent challenge with B suis strain 3B 
in domestic pigs. In experiments 1 and 2, vaccinated pigs failed to develop antibody titers 
against γ-irradiated SRB51 that were significantly higher than those of the nonvaccinated 
controls. Serum antibody titers examined in cattle in which SRB51 has been found to be 
immunogenic and efficacious were significantly higher in vaccinated pigs than in 
nonvaccinated controls at weeks 4 to 20 after vaccination23, 24 Also, no significant 
difference was found in seroconversion between control and vaccinated gilts and between 
neonates and fetuses from control and vaccinated gilts after challenge with virulent B 
suis. 
No evidence exists from our study indicating that SRB51 elicits a strong cell-
mediated immune response after parenteral vaccination in pigs. Results of PBMC 
proliferation assays after stimulation with γ-irradiated SRB51 did not significantly differ 
between controls and vaccinated pigs in experiments 1 and 2. Brucella abortus strain 
RB51 has been shown to elicit robust proliferative responses in other species. Bison 
parenterally vaccinated with 1.2 to 6.1 × 1010 CFUs of SRB51 have significantly higher 
PBMC proliferation responses than nonvaccinated controls at weeks 12 and 18 after 
vaccination,25 and the same dosage of SRB51 in a subsequent study11 was demonstrated 
to be protective in bison . Likewise, cattle parenterally vaccinated with 1 × 1010 CFUs of 
SRB51 had PBMC proliferative responses that were significantly higher than those of 
controls at weeks 10, 12, 14, and 16 after vaccination, and cattle parenterally vaccinated 
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with 3 × 109 CFUs of SRB51 had PBMC proliferative responses that were significantly 
higher than those of controls at weeks 14 and 18 after vaccination.23,24 Both doses were 
associated with protection from virulent B abortus challenge.23,24 It has been shown that 
pigs that are infected with B suis are capable of eliciting a significantly higher PBMC 
proliferative response over noninfected controls.26
Data from the weaned pigs of experiment 1 suggest that SRB51 is cleared quickly 
in pigs. Isolation of SRB51 was achieved in only 3 pigs (2 at week 2 after vaccination 
and 1 at week 4 after vaccination). The elicitation of a protective immune response has 
been associated with longer persistence of SRB51 within regional lymph nodes. In bison 
bacterial titers of SRB51 were found to peak at week 2 after vaccination and steadily 
decline through week 18 after vaccination with total vaccine clearance achieved by week 
24 after vaccination25, 27, 28 In cattle, SRB51 has been shown to persist until week 14 after 
vaccination within the regional lymph nodes of some cattle that were vaccinated with 
protective doses.29
The hallmark of Brucella vaccine efficacy has long been the reduction in recovery 
of Brucella organisms in maternal and fetal tissues after virulent challenge.11, 24, 29 Our 
study failed to show a significant reduction in the recovery of B suis organisms on a per 
gilt, per neonate-fetus, or per litter basis. 
Results of our study are contrary to those reported by Lord et al.15 In their study 
SRB51 was used to parenterally vaccinate domestic gilts IM and also PO at doses of 106 
to 109 CFUs. In that study the lipopolysaccharide O-side chain from B abortus or B suis 
was also used to vaccinate pigs IM or PO. It was concluded that all vaccine preparations 
provided 100% protection on the basis of the lack of seroconversion, lack of abortions, 
and increased litter size over those of the control groups. A major difference between the 
study by Lord et al15 and our study is that in their study the challenge dose was not 
defined; vaccinated gilts were bred to boars previously determined to be shedding B suis 
in their semen; however, the culture status of the semen from the boars used for sire was 
not determined on the days of insemination. Our study used a defined challenge dose of a 
single strain of virulent B suis for conjunctival administration. In the study by Lord et al15 
the Brucella-culture status of all pigs was not examined.15 Cultures were only performed 
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on vaginal swab specimens from sows that aborted and on tissues from aborted fetuses. 
Samples from pigs that had full-term pregnancies were not cultured. In our study we 
determined the culture status on the basis of a full complement of tissues from vaccinated 
and control gilts as well as from their neonates and fetuses to assess the efficacy of 
vaccination with SRB51. 
Edmonds et al14 also examined SRB51 vaccination of domestic pigs with 109 to 
1012 CFUs/dose.14 Results of that study indicate that some pigs can develop a humoral 
immune response against SRB51 after SC or oral vaccination. Unlike our study, the study 
by Edmonds et. al14 did not have any nonvaccinated control pigs to which the results of 
the SRB51 vaccinated pigs could be compared. 
Results of our study are similar to those of other studies30,31 in which B abortus 
strain 19 was examined as a vaccine candidate for control of swine brucellosis. Brucella 
abortus strain 19 was found to not confer demonstrable immunity and protection against 
virulent challenge with B suis.30, 31 Cedro et al,32,33 however, reported efficacy of a live B 
abortus vaccine strain when coadminister with heat-killed B suis and lipopolysaccharide 
from B suis.32, 33 This compound vaccine was found to decrease abortion rates as well as 
culture recovery of B suis. 
Although Brucella vaccines traditionally have not been 100% efficacious under 
experimental conditions in preventing maternal infection, fetal infection, and lesions, the 
SRB51 and B abortus strain 19 vaccines greatly reduce the occurrence of all of these 
after virulent challenge in cattle. In our study none of these conditions were met; 
therefore, SRB51 does not appear to be a suitable vaccine candidate for the control of B 
suis infection in pigs. 
  
aDr. Gerhardt Schurig, Virginia Tech, Blacksburg, VA USA 
bDifco Laboratories, Detroit, MI , USA 
cBeckman, Palo Alto, CA, USA 
dSigma, St. Louis, MO, USA 
e1450 Microbeta scintillation counter, Wallac, Inc., Gaithersburg, MD, USA 
fBoehringer Mannheim, Indianapolis, IN, USA 
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Table 1⎯Recovery of Brucella suis from individual neonates and farrowed litters at 
necropsy and gilts after inoculation and at necropsy.* 
 Culture results 
Variables Positive Negative 
Neonates and fetuses   
No. from vaccinates 96 (56.1%) 75 (43.9%) 
No. from control gilts 55( 61.1%) 35 (38.9%) 
   
Litters   
No. from vaccinates 12 (85.7%) 2 (14.3%) 
No. from control gilts 7 (87.5%) 1 (12.5%) 
   
Gilts after inoculation, antemortem   
No. of vaccinates 8 (57.1%) 6 (42.9%) 
No. of control gilts 7 (87.5%) 1 (12.5%) 
   
Gilts at necropsy   
No. of vaccinates 12 (85.7%) 2 (14.3%) 
No. of control gilts 8 (100%)               0 (0%) 
*Gilts were challenged with 5.0 × 107 CFUs of B suis strain 3B on day 75 of gestation. 
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Figure 1⎯Mean ± SEM serum antibody titer to SRB51 in vaccinated or control weaned 
pigs on the basis of γ-irradiated SRB51 dot-blot assay results. Pigs were vaccinated with 
2.0 × 1010 CFUs of SRB51 (closed bars; n = 51) or sham inoculated with an equal volume 
of PBS solution (open bars; n = 17). 
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Figure 2⎯Mean ± SEM serum antibody titer to SRB51 in vaccinated or control gilts on 
the basis of γ-irradiated SRB51 dot-blot assay results. Gilts were vaccinated with 2.0 × 
1010 CFUs of SRB51 (closed bars; n = 18) or sham inoculated with an equal volume of 
PBS solution (open bars; n = 8). 
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Figure 3⎯Mean cpm ± SEM in PBMC blastogenesis assays of weaned pigs vaccinated 
with 2.0 × 1010 CFUs of SRB51 (closed bars [stimulated], gray bar [not stimulated]; n = 
9) or sham inoculated with an equal volume of PBS solution (open bars [stimulated], 
hatched bar [not stimulated]; n = 6). 
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Figure 4⎯Mean cpm ± SEM in PBMC blastogenesis assays of gilts vaccinated with 2.0 
× 1010 CFUs of SRB51 (closed bars [stimulated], gray bar [not stimulated]; n = 18) or 
sham inoculated with an equal volume of PBS solution (open bars [stimulated], hatched 
bar [not stimulated]; n = 8). 
0
5000
10000
15000
20000
25000
30000
35000
40000
8 12 16 20 24
After vaccination (wk.)
M
ea
n 
cp
m
 
 103
 
 
CHAPTER 6.  RESULTS OF VACCINE TRIALS USING A 
NATURALLY ROUGH MUTANT OF BRUCELLA SUIS IN SWINE 
 
A paper submitted to the American Journal of Veterinary Research 
 
William C. Stoffregen, DVM and Steven C. Olsen, DVM, PhD 
 
Abstract 
Objective – To determine the safety, immunogenicity, clearance, and efficacy of Brucella 
suis strain 353-1, a naturally rough mutant, as a vaccine in domestic swine. 
Animals – Experiment 1 contained 21 inoculated, domestic swine and 6 age-matched, 
controls.  Experiment 2 contained 84 vaccinated, domestic swine, 9 age-matched 
controls, and 4 age-matched sentinels. 
Procedures – In experiment 1, pigs were conjunctivally inoculated with 5 X 107 CFU of 
353-1.  Periodic bleedings were performed for blood culture, serology, and cell-mediated 
immunity assays.  Necropsies were performed at selected time periods between weeks 1 
and 18 after inoculation to determine pathogenicity, distribution, and clearance of 353-1.  
In experiment 2, pigs were vaccinated orally or parenterally with live 353-1 or 
parenterally with adjuvanted, heat-killed 353-1 and similar postvaccination samples 
taken.  Vaccinated, control, and sentinel pigs were challenged conjunctivally with 5.0 X 
107 CFU virulent B. suis strain 3B.  Necropsies were performed, and bacterial culture was 
performed on necropsy samples to determine vaccine efficacy. 
Results – B. suis 353-1 was nonpathogenic and cleared by week 20 in inoculated and 
vaccinated swine.  Parenteral and oral vaccination induced significant cell-mediated 
immune responses, and parenteral vaccination elicited a significant humoral response.  
There appeared to be no shedding of 353-1 from parenterally vaccinated animals.  
Recovery of the virulent challenge strain B. suis 3B was significantly lower in some 
tissue from orally and parenterally vaccinated animals compared to controls.       
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Conclusions – B. suis 353-1 is a stable, rough mutant which when used as a parenteral or 
oral vaccine can induce a significant immune response and confer a partial level of 
protection from challenge with virulent B. suis. 
 
Introduction 
 The Brucellae compose a group of genetically homogenous, facultative, 
intracellular pathogens which infect dozens of terrestrial and marine mammal species 
worldwide.1, 2  Brucellae have been conventionally divided into 8 genera based on the 
primary animal species which they infect; however, due to the high degree of genetic 
similarity, it has been proposed that all Brucellae are members of a single genus (B. 
melitensis).3, 4  The specie Brucella suis is divided into 5 biovars:  biovars 1 and 3 infect 
primarily swine and are found in North America; biovar 2 is primarily a European biovar 
which infects swine and has also been found to be maintained in European hares; biovar 
4 is enzootically found in many reindeer and caribou herds; and biovar 5 infects murine 
species.5
Swine brucellosis was first described in the United States by Traum in 1914.6  
The disease syndrome in swine is characterized by abortions, stillbirths, and infertility in 
sows.5  Chronically infected boars may also suffer from decreased fertility and libido due 
to infections associated with pyogranulomatous and fibrosing lesions of the testis, 
epididymis, seminal vesicle, prostate, and bulbourethral gland.  Other lesions associated 
with Brucella infection in swine are pyogranulomatous lymphadenitis, splenitis, hepatitis, 
arthritis, and diskospondilitis.5, 7, 8   
Swine brucellosis still occurs enzootically in parts of South America, sub-Saharan 
Africa, and Asia, but it has essentially been eradicated from domestic swine in the US 
with only sporadic outbreaks which are associated with feral swine contact.9, 10, 11, 12  
Elimination of swine brucellosis from the US is the result of the Cooperative State-
Federal Brucellosis Eradication Program which relied on the principles of serological 
herd testing and elimination of seroreactive herds.  The efforts of this program were 
undoubtedly aided by the drastic changes in swine production and swine farm 
management and biosecurity.  Brucellosis is enzootic in feral swine herds within the US 
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and other parts of the world.13, 14  Feral swine not only threaten the stability of the 
brucellosis eradication campaign but also serve as a reservoir of pseudorabies virus.15  
Feral swine associated outbreaks of brucellosis have not only occurred in swine but also 
cattle16 and humans.17  With feral swine becoming an increasingly popular game animal 
its distribution and numbers have dramatically increased in recent decades.  This has lead 
to an increased interest in dealing with brucellosis in feral swine in order to prevent 
further transmission to domestic livestock and humans. 
There have been limited studies dealing with the prevention of swine brucellosis 
with vaccines.  Early studies with the smooth strain B.  abortus S19 showed a lack of 
immunologic response and protection.18, 19  Initial studies with the rough vaccine strain B. 
abortus RB51 reported that this vaccine induced a humoral immune response in swine 
and protected vaccinated swine 100% from challenge with B.suis.20, 21  However, more 
controlled studies failed to agree with these initial reports.22  The later studies showed 
that swine parenterally vaccinated with RB51 failed to develop a cell-mediated and 
humoral immune response, and these lack of responses were associated with a failure of 
protection in a pregnant gilt challenge model.22  Despite its failure to induce immune 
responses in swine, RB51 has been shown to induce significant immune responses in 
cattle and bison and protect these species from challenge with virulent B. abortus.23, 24, 25  
RB51 induces these protective immune responses despite being deficient of the 
lipopolysaccharide O-side chain, a property which has the advantage of not inducing 
humoral immune responses which would make vaccinated animals reactors to standard 
Brucella serological assay.26, 27
Herein, studies dealing with a natural rough mutant of B. suis are reported.  These 
experiments were performed to determine the potential of this new rough B. suis strain as 
a vaccine which might serve as a tool for the control of brucellosis in domestic and feral 
swine populations.  The studies were designed to assess pathogenicity, distribution, and 
clearance as well as the ability of live oral and parenteral and adjuvanted, heat-killed 
preparations of this rough B. suis strain to induce significant immune responses and 
confer protection from challenge with virulent B. suis.  The in vitro and in vivo stability 
of the rough phenotype were also assessed.   
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Materials and Methods 
Bacterial Cultures and Vaccine Preparation 
 The natural rough mutant of B. suis used in the vaccine trials reported herein was 
isolated from the urine of a feral boar from Georgetown County, South Carolina and 
given the arbitrary designation B. suis 353-1 (353-1).  A master seed stock of 353-1 was 
prepared by the propagation of a single colony from the original isolation plate on 
tryptose agara containing 5% bovine serum (TSA) and stored at -80° C until vaccine or 
reagent preparation.  For experimental use in serology and lymphocyte proliferation 
assays and for killed vaccine preparation, 353-1 bacteria were grown on TSA for 48 
hours at 37˚ C.  The resulting cultures were suspended in 0.15 M phosphate buffered 
saline (PBS), and the bacterial concentration was determined by serial dilutions and plate 
counts on TSA.  The culture was then inactivated by incubation at 60° C for 2 hours.  
Inactivation was confirmed by plating the culture suspension on TSA.  After inactivation, 
culture suspensions were stored at -80° C.   
 For conjunctival inoculation and parenteral and oral vaccination of swine, 353-1 
was expanded on TSA for 48 hours at 37˚ C with 5% CO2.  The harvested bacteria were 
suspended in 0.15 M PBS and then diluted to a concentration of 1.0 X 109 CFU/ml for 
conjunctival inoculation or 1.0 X 1010 CFU/ml in 0.15 M PBS using an optical density 
method and spectrophotometerb.  The final concentration was determined by standard 
plate counts on TSA after 5 days incubation at 37˚ C and 5% CO2.  For the preparation of 
killed vaccines, aliquots of heat inactivated 353-1 were adjusted to a concentration of 2.0 
X 1010 CFU/ml in 0.15 M PBS and mixed with equal parts of a Quil Ac (1.0 mg/ml in 
0.15 M PBS) or a squalened/Pluronic F127d adjuvant which was prepared as previously 
described.28
 The challenge culture B. suis strain 3B (biovar 1) was prepared as previously 
reported.22  In order to assess the in vitro stability of the rough phenotype of 353-1, the 
culture was passaged weekly on TSA for the duration of experiment 2 for a total of 35 
passages. 
Swine experiments and study design 
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 The pathogenicity and clearance of 353-1 were evaluated in weaned swine 
(experiment 1).  A total of 21, 6 week old, cross-bred domestic swine were inoculated 
conjunctivally with 50 μl of 5.0 X 107 CFU of 353-1 in 0.15 M PBS.  Six age-matched 
swine were sham inoculated with 50 μl of 0.15 M PBS.  Inoculated and control swine 
were housed separately in biolevel 3 large animal containment facility and fed ad lib.   
 Induction of an immune responses, clearance, and protection from virulent 
challenge were also assessed in cross-bred domestic swine (experiment 2).  A total of 44 
6 week old swine were inoculated intramuscularly in the right cervical area with 2.0 ml of 
0.15 M PBS containing 2 X1010 CFU of 353-1.  An additional 30 age-matched swine 
were orally inoculated with an average of 5.0 X 1011 CFU of 353-1/ animal which was 
top-dressed onto their normal ration prior to feeding.  Adjuvanted, heat-killed 353-1 
vaccines were evaluated each in 5 age-matched swine which were vaccinated in both the 
right and left cervical areas with 2.0 ml of either the Quil A or squalene/Pluronic F127 
adjuvanted vaccines which contained an equivalent of 2.0 X 1010 CFU of 353-1.  Nine 
age-matched swine served as controls and were sham inoculated with 2.0 ml of 0.15 M 
PBS in the right cervical area.  In addition, 4 age-matched, nonvaccinated swine were 
commingled with the parenterally vaccinated group to serve as sentinels to detect 
shedding of 353-1.  All animals in experiment 2 were challenged at approximately week 
30 after vaccination for the oral and parenteral group and week 16 after vaccination for 
the adjuvanted, killed vaccine groups by conjunctival administration of 5.0 X 107 CFU 
(volume=50 μl) of B. suis 3B.  The colonial phenotype was determined by direct 
observation and crystal violet staining.29 
Serological Evaluation 
Blood was collected for serologic evaluation by cranial vena cava puncture in 
experiment 2 at weeks 0, 2, 4, 6, 8, 12, 14, 16, 18, 20, 24, 28, and 30 after vaccination 
and weeks 1, 2, 3, and 4 after challenge for the orally vaccinated and control groups; 
weeks 0, 3, 5, 7, 9, 11, 13, 17, 21, 25, 29, and 30 after vaccination and weeks 1, 2, 3, and 
4 after challenge for the parenterally vaccinated and control groups; and weeks 0, 2, 4, 6, 
8, 12, 14, and 16 after vaccination and weeks 1, 2, 3, and 4 after challenge for the killed 
vaccine and controls groups. After collection, blood samples were allowed to clot and 
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serum was separated by centrifugation.  Serum was divided into 1 ml aliquots, and stored 
at -70° C until assays were performed.  Seroconversion to 353-1 was determined by a 
microtiter plate ELISA assay.  B. suis 353-1 used in ELISA assays was inactivated by 
treatment with 0.5% neutral buffered formalin for 24 h. at 4 C.  Ninety-six well platese 
were coated with 100 μl of 1.0 X 1010 CFU/ml of formalin-inactivated 353-1 in 0.1 M 
sodium carbonate/sodium bicarbonate buffer (pH 9.6) overnight at 4° C.  After discarding 
the coating solution, plates were then blocked with 100 μl of 0.55% fish gelatin in 0.15 M 
phosphate buffered saline (PBS) at room temperature for 2 h.  Plates were then washed 8 
times with  300 μl of 0.15 M PBS containing 0.05% Tween 20 (PBS-T, pH 7.4).  Plates 
were then coated with 100 μl of test sera at a dilution of 1:100 in PBS containing 0.55% 
fish gelatin .  All samples were run in quadruplicate.  After incubation for 2 h. at room 
temperature, test sera was discarded and plates were washed 8 times with 300 μl of PBS-
T.  Plates were then incubated with 100 μl of peroxidase-labeled rabbit anti swine IgGd  
at a dilution of 1:500 in PBS containing 0.55% fish gelatin.  After a 2 h. incubation at 
room temperature, the secondary antibody solution was discarded and plates were washed 
8 times with 300 ml of PBS-T.  Colorimetric reactions were developed with 0.0075% 3, 
3’, 5, 5’-tetramethylbenzidine in 0.10 M citrate buffer containing 0.015% hydrogen 
peroxide for 30 min. at room temperature.  Reactions were stopped by the addition of 100 
μl of 0.18 M sulfuric acid, and the optical density was read using an automated 
spectrophotometric plate at 450nm and 550 nm.  The optical density at 550 nm was 
subtracted from the optical density at 450 nm and the 4 resulting values from each sample 
were averaged prior to statistical analysis. 
 Seroconversion to the B. suis challenge strain was determined by standard tube 
agglutination and card agglutination assays by previously described methods.29 Blood 
was collected on day 0 of challenge and weeks 1, 2, 3, and 4 after challenge from all 
swine.   
Peripheral blood mononuclear cell proliferation assays 
 Blood (45 ml) was obtained in acid-citrate dextrose solution from the cranial vena 
cava at weeks 0, 6, 10, 14, and 18 after intraconjunctival inoculation with 353-1  from 
animals in experiment 1.  In experiment 2 blood was similarly obtained at the following 
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time points:  weeks 0, 2, 4, 6, 8, 12, 14, 16, 20, 24, 28, and 30 after vaccination from 
controls and oral vaccinates;  weeks 0, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 
and 30 after vaccination from controls and parenteral vaccinates; and weeks 0, 2, 4, 6, 8, 
10, 12, 14, and 16 from controls and pigs vaccinates with adjuvanted, killed vaccines.  
Peripheral blood mononuclear cells (PBMCs) were enriched by density centrifugation 
using a Ficoll-sodium diatrizoate gradient.g Fifty μl of each cell suspension containing 
5.0 X 105 peripheral blood mononuclear cells were added to each of two separate flat-
bottom wells of 96-well microtiter plates that contained 100 μl of RPMI 1640 medium 
only, 1640 medium containing 1.0 X 108 cells of heat-killed 353-1, or 1640 medium 
containing 1.2 μg of pokeweed mitogen (PWM).  Cell cultures were incubated for 3 days 
at 37˚ C under 5% CO2.  The plates were then pulsed with 1.0 mCi of [3H] thymidine per 
well for 18 hours.  Cells were harvested onto glass filter mats and counted for 
radioactivity in a liquid scintillation counterh.  Radioactivity was expressed as mean 
counts per minute (cpm), and stimulation indexes were obtained by dividing the mean 
cpm from antigen stimulated (1640 medium plus heat-killed 353-1) cells by the mean 
cpm from the nonstimulated (1640 medium only), control cell wells.   
Cytokine Assays 
 In order to assess cytokine production of antigen stimulated PBMCs, duplicate 
plates to those prepared for proliferation assays were incubated for 4 days  at 37˚ C under 
5% CO2.  Plates were then frozen at -20º C until cytokine ELISAs were performed.  A 
commercially available ELISAi was used according to manufacturer’s instruction to 
assay interferon-gamma (IFN-γ) production of cultured PBMCs in experiment 2 at the 
following time points:  weeks 0, 2, 4, 8, 10, 12, 14, 16, 20, 22, 24, 26, 28, and 30 after 
vaccination as well as weeks 1, 2, and 3 after virulent challenge for controls and orally 
vaccinated animals; weeks 0, 3, 5, 7, 8, 11, 15, 17, 19, 21, 23, 25, 27, 29, and 30 after 
vaccination and weeks 1, 2, and 3 after virulent challenge for controls and parenterally 
vaccinated animals; and weeks 0, 2, 6, 8, 10, 12, 14, and 16 after vaccination as well as 
weeks 1 and 3 after virulent challenge for controls and animals vaccinated with 
adjuvanted killed preparations.  Inlterleukin-4 (IL-4) was also assayed from the same 
culture supernatant using a commercially available ELISAj  at weeks 0, 2, 6, 10, 14, and 
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16 for controls as well as oral and killed vaccine groups and weeks 0, 3, 7, 11, 15, and 17 
for the control and parenteral group.  Concentrations of the respective cytokines from the 
culture supernatants were determined by a log-log regressions analysis obtained from 
standard concentrations of IL-4 or IFN-γ.  The concentration of the respective cytokines 
in the nonstimulated culture supernatant was subtracted from the antigen stimulated 
culture supernatant and means of the resulting differences were used to compare cytokine 
concentrations between controls and treatment groups. 
Necropsy 
 All swine were euthanized by intra-cranial vena caval administration of sodium 
pentobarbital. Tissues collected for bacteriologic culture were collected using aseptic 
technique, placed into individual containers, and immediately frozen at -70˚ C until 
processed.  Tissues collected for histologic evaluation were immediately placed in 
neutral-buffered 10% formalin, processed by routine paraffin embedding techniques, cut 
in 4 μm sections, and stained with hematoxylin and eosin. 
In experiment 1, 2 inoculated pigs were necropsied at weeks 1, 2, and 3 after 
inoculation.  Three inoculated pigs were necropsied at week 4 after inoculation.  Five 
pigs were necropsied at weeks 10 and 14 after inoculation, and 8 inoculated pigs and the 
6 control pigs were necropsied at week 18 after inoculation.  Blood and urine were 
collected for bacteriologic culture at necropsy.  The following tissues were collected for 
bacteriologic culture and histologic analysis:  lung, liver, spleen, kidney, uterus, testis, 
seminal vesicle, bulbourethral gland, and prostate as well as medial retropharyngeal, 
mandibular, parotid, prescapular, prefemoral, popliteal, inguinal, iliac, ileocecal, sternal, 
and gastric hepatic lymph nodes. 
 In experiment 2, 4 orally vaccinated pigs were necropsied at weeks 4, 8, 16, 20, 
and 24 after vaccination.  Four parenterally vaccinated pigs were necropsied at weeks 2 
and 4 weeks after vaccination.  Five parenterally vaccinated pigs were necropsied at 
weeks 6, 8, and 12 after vaccination, and 4 parenterally vaccinated pigs were necropsied 
at weeks 16, 20, and 24 after vaccination.  Nine control pigs, 10 orally vaccinated pigs, 9 
parenterally vaccinated pigs, 4 pigs which were sentinels to the parenterally vaccinated 
group, and 10 pigs vaccinated with the adjuvanted, killed vaccines were necropsied 30-32 
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days after virulent challenge.  Whole blood, and urine were taken for culture, and lung, 
liver, spleen, kidney, uterus, testis, seminal vesicle, bulbourethral gland, and prostate as 
well as tracheobronchial, prescapular, medial retropharyngeal, mandibular, parotid, 
sternal, popliteal, and gastrohepatic, lymph nodes were taken for bacteriologic culture 
and histology. 
Bacteriologic culture 
In Experiment 1 whole blood as well as conjunctival, nasal, and vaginal swabs 
were collected for bacteriologic culture at day 0 and weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 
and 18 after infection.  In Experiment 2 whole blood, conjunctival and nasal swabs, and 
environmental room swabs were collected for bacteriologic culture at day 0 and weekly 
after infection until necropsy.  Whole blood and conjunctival and nasal swabs were 
collected at day 0 and weeks 1, 2, 3, and 4 after virulent challenge. 
Whole blood for bacteriologic culture was immediately placed into tryptose broth 
containing acid citrate dextrose (1:1 v:v) and incubated for 7 days at 37˚ C and 5% CO2 
prior to plating on Brucella selective media.  Urine was incubated in tryptose broth 
containing 5% bovine serum (1:3 v:v) for 7 days at 37˚ C and 5% CO2 prior to plating on 
Brucella selective media.  Environmental room swabs were incubated for 7 days at 37˚ C 
and 5% CO2  in 300 ml of Kudzas Morse broth (Tryptose base with 5% bovine serum, 25 
U/ml bacitracin, 6 U/ml polymyxin B, 100 μg/ml cycloheximide, and 1.4 μg/ml ethyl 
violet).  All other swabs were plated directly onto TSA and Kudzas Morse agar (KM; 
tryptose agar base with 5% bovine serum, 25 U/ml bacitracin, 6 U/ml polymyxin B, 100 
μg/ml cycloheximide, and 1.4 μg/ml ethyl violet) and incubated for 7 days at 37˚ C and 
5% CO2.  After thawing, tissues were individually ground in approximately 10% (w/v) 
sterile PBS (pH=7.2) using sterile glass grinders. Aliquots (100 μl) of each tissue 
homogenate or preincubated tryptose or KM broth (blood, urine, and environmental room 
swabs) were plated onto TSA and KM plates and were incubated at 37˚C in 5% CO2 for 7 
days. 
Culture identification: 
Brucella suspect cultures were identified on the basis of colony morphology, 
growth characteristics,29 and growth on selective media.  All suspect Brucella cultures 
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recovered were especially checked for smooth of rough colony morphology.  Isolates 
were identified as Brucella spp. by a real time polymerase chain reaction technique 
(PCR) using Brucella-specific primers and probe to the omp2A region of the Brucella 
genome.30  Reactions consisted of 20 μl and contained 2 μl of suspect culture in tris-
EDTA and 18 μl of reaction mixture consisting of 200 μM each of dATP, dCTP, dGTP, 
and dTTPk, 1 X PCR Buffer IIl, 3.0 mM MgCl2, 1.25 U AmpliTaq Gold polymerasel, 
0.5 μM of each upstream (5’-CCCAAGCATTGTCTTCAGCAACAG-3’) and 
downstream (5’-TGGTCTGAAGTATCAGGCTACGCA-3’) primers, and 0.1 mM of 
probe (5’-ACCTTGGTGTAGGAAACTTCCGGCGT-3’) which was labeled with 6-
FAM on the 5’ end and Black Hole Quencher 1 on the 3’ end.  The primers had 100% 
conservancy within the genomes of B. suis, B. abortus, and B. melitensis according to 
BLAST analysis.  Tris-EDTA and a culture of Yersinia enterocolitica O:9 served as 
negative controls, and Brucella suis strain 3B and 353-1 served as a positive control. 
Samples were cycled in a Rotor Gene 3000m real time PCR thermal cycler under the 
following conditions:  a single 10 minute activation at 95˚C, followed by 40 cycles 
consisting of 60 sec. at 60˚ C and 20 sec. at 95˚ C.  Mean fluorescence was recorded each 
cycle after the 60° C step.  Thresholds were determined for each individual run using the 
positive control reactions, and test samples were considered positive if the mean change 
in fluorescence went above the threshold..   
Statistical Analysis 
 For all statistical analyses a level of P<0.05 was used to determine differences 
between vaccinates and controls.  Serologic response data to 353-1 were compared 
between vaccinates and controls using Student’s t-testn.  Stimulation indexes of 
proliferative responses to 353-1 were compared between vaccinated and controls using a 
general linear model procedure and least squared meanso.  Fisher’s exact testp was used to 
determine differences in culture positivity on a per tissue basis between vaccinates and 
controls.  Bacterial culture concentrations from tissues which were quantified were 
converted to the logarithm of the resulting CFU/g and compared between vaccinates and 
controls using Student’s t-testn.  Fisher’s Exact Testp was also used to determine 
differences between vaccinates and controls for histologic lesions. 
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Results 
Bacterial Cultures 
 In experiment 1, plate counts yielded a culture concentration of 7.3 X 108 CFU/ml 
of 353-1 which equaled a per animal dosage of 3.65 X 107 CFU.  In experiment 2 plate 
counts of 353-1 yielded culture concentrations of 0.97 X 1010 CFU/ml which equaled a 
per animal dosage of 1.94 X 1010 CFU for parenteral vaccinates and 1.46 X 1011 CFU for 
oral vaccinates.  Plate counts for the challenge strain B. suis 3B yielded a culture 
concentration of 6.7 X 108 CFU/ml which equaled a per animal dosage of 3.35 X 107 
CFU.  All passages (n=35) of 353-1 produced cultures with rough phenotype colonies as 
observed by direct observation and by crystal violet colony staining. 
Serological evaluation 
 There were no significant differences in Experiment 1 between 353-1 inoculated 
pigs and controls on 353-1 ELISAs.  All sera samples in Experiment 1 were also negative 
by the Brucella card test and STT serological assays.  The results of 353-1 ELISAs in 
Experiment 2 are given in Figure 1 for parenterally vaccinated pigs and Figure 2 for pigs 
vaccinated with adjuvanted.  Briefly, there were statistically significant differences 
between controls and parenterally vaccinated pigs as well as pigs vaccinated with 
adjuvanted, heat-killed vaccines at certain weeks after vaccination; however, there were 
no significant differences between controls and orally vaccinated pigs.  All prechallenge, 
postvaccination sera samples in Experiment 2 were also negative by the Brucella card 
and STT serologic assays. 
Peripheral blood mononuclear cell proliferation assays 
 The results of PBMC proliferation assays from Experiment 1 are shown in Figure 
3.  Inoculated pigs had significantly higher stimulation indexes at weeks 10 and 18 after 
inoculation.  All vaccine preparations induced significant PBMC proliferation from 
vaccinated animals compared to controls.  Parenterally vaccinated animals had 
significantly higher stimulation indexes compared to controls at weeks 7, 9, 11, 15, 17, 
19, 21, 23, 25, 27, 29, and 30 (Figure 4).  Orally vaccinated animals  had significantly 
higher stimulation indexed compared to controls at weeks 2, 4, 6, 8, 14, 16, 18, 20, 22, 
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24, 26, 28, and 30 (Figure 5).  Pigs vaccinated with heat-killed 353-1 adjuvanted with 
squalene/Pluronic F127 had significantly higher stimulation indexes at weeks 6, 8, 10, 
and 14 compared to controls, and animals in the Quil A adjuvant group had significantly 
higher stimulation indexes at weeks 4, 6, 8, and 10 compared to controls (Figure 6).   
Cytokine ELISAs 
 In Experiment 2 there was no significant IL-4 production in 353-1 antigen 
stimulated PBMCs from vaccinated animals compared to controls at all weeks assayed.  
PBMCs from parenterally vaccinated pigs had significantly higher IFN-γ production at 
weeks 3, 5, 7, 15, 17, 21, 29, and 30 after vaccination as well as weeks 1 and 2 after 
challenge compared to controls (Figure 7).  IFN-γ production was significantly higher at 
weeks 8, 16, 20, 22, 26, 28, and 30 after vaccination as well as week 1 after challenge in 
the orally vaccinated group compared to the control group (Figure 8).  In the adjuvanted, 
heat-killed vaccine groups, only the squalene/Pluronic F127 preparation induced 
significant IFN-γ production at weeks 8 and 10 after vaccination (Figure 9).  
Distribution, shedding, clearance, and pathogenicity of 353-1 
 Table 1 lists the postinoculation, antemortem culture results of Experiment 1.  B. 
suis 353-1 was only isolated from the blood (n=7) and conjunctival swabs (n=2).   In 
Experiment 2, 353-1 was only isolated from blood (Table 2) from both parenteral (n=30) 
and oral (n=26) vaccinates.  Weekly environmental swabs from the rooms housing the 
parenteral and oral vaccine groups in Experiment 2 yielded no growth of 353-1 at all 
weeks.   Bacterial culture results from necropsy samples from Experiment 1 (Table 3) 
and postvaccination, prechallenge necropsy samples from Experiment 2 (Tables 4 and 5) 
showed that 353-1 was first isolated from draining lymph nodes followed by isolation 
from peripheral lymphoreticular tissues.  All postinoculation isolates from Experiment 1 
and postvaccination, prechallenge isolates from Experiment 2 exhibited the rough 
phenotype by direct observation and crystal violet staining of all colonies examined.  
Most isolations were clustered between weeks 1 to 12; however, a single animal was 
positive at week 18 after inoculation in Experiment 1.  In Experiment 2 there were no 
bacterial culture isolations of 353-1 at all time points from the 4 sentinel pigs 
commingled with the parenteral vaccinates.  In Experiment 1 there were no significant 
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histological lesions in inoculated animals compared to controls.  In Experiment 2 mild, 
multifocal lymphoplasmacytic interstitial nephritis was the only histological lesion noted 
in postvaccination, prechallenge necropsy samples.  Small aggregates of small 
lymphocytes and lesser numbers of plasma cells were present between tubules, mostly in 
the cortex, and adjacent to some glomeruli in 1 oral vaccinate at 4 weeks after 
vaccination and in 4 parenteral vaccinates, one each at 4, 6, 16, and 24 weeks after 
vaccination.  
Postvaccination challenge studies 
 Postchallenge serology and postchallenge, antemortem culture results for 
Experiment 2 are listed in Table 6.  All animals seroconverted to Brucella as 
demonstrated by the Brucella card and STT assays; however seroconversion was delayed 
in all vaccine groups.  All B. suis isolates from postchallenge swine from all groups at all 
time points were smooth as examined by direct observation and crystal violet staining. 
Postchallenge blood culture isolation of smooth B. suis was also lower in parenteral, oral 
and squalene groups, however, there was no statistical significance.  Swab cultures 
(conjunctival and nasal) were lower in parenteral and oral groups compared to 
nonvaccinated controls.  Table 7 lists the percentage of animals culture positive for 
smooth B. suis for each vaccine treatment group for each tissue examined.  There was a 
statistically lower percentage of positive isolations from the spleen for oral and parenteral 
vaccinates and the medial retropharyngeal lymph node for oral vaccinates.  Parenteral 
vaccinates also had significantly lower recovery of smooth B. suis on a CFU/g of tissue 
basis for the spleen and gastrohepatic, mandibular, and parotid lymph nodes (Figure 10).  
Likewise, there was significantly lower recovery of smooth B. suis on a CFU/g of tissue 
basis for oral vaccinates from the spleen and gastrohepatic, mandibular, medial 
retropharyngeal, and parotid lymph nodes (Figure 11).  From both the squalene/Pluronic 
F127 and Quil A adjuvant groups, there was a significantly lower recovery of smooth B. 
suis from the spleen on a CFU/g of tissue basis (Figure 12). 
 Table 8 summarizes histological lesions found in all treatment groups after 
challenge with B. suis 3B.  There was a significant difference in the number of animals 
with no significant lesions in the orally vaccinated and Quil A adjuvant groups compared 
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to nonvaccinated controls.  There was also a significant difference in the number of 
animals exhibiting hepatitis in the orally vaccinated groups compared to controls.  
Hepatitis in affected animals was characterized by portal to random distribution of 
aggregates of lymphocytes and plasma cells with lesser numbers of neutrophils (Figure 
13A).  Other histological lesions found in control and vaccine groups after challenge 
included purulent to pyogranulomatous lymphadenitis (Figures 13B & 13C) and 
interstitial nephritis (13D).  A single nonvaccinated, sentinel animal developed bilateral 
prostatitis and seminal vesiculitis characterized by a marked increase in space between 
ductules due to marked fibrosis and high numbers of lymphocytes, plasma cells, and 
neutrophils.  Ductular lumena were also markedly dilated due to large numbers of 
neutrophils and sloughed, necrotic epithelial cells.  There was segmental denudement of 
epithelial cells from the ductular epithelial surfaces and segmental epithelial hyperplasia. 
 
Discussion 
 The studies reported here examined B. suis 353-1, a natural, rough mutant, with 
the goal of determining its potential as a vaccine candidate.  The studies were designed to 
determine 1) if 353-1 is pathogenic to swine, 2) the clearance time of 353-1 in swine 
when given as a parenteral or oral vaccine 3) the immunogenicity of 353-1 and its ability 
the determine a cell-mediated immune response, and 4) the ability of 353-1 to protect 
from virulent B. suis challenge.  B. suis 353-1 was examined in live vaccine preparations 
which were considered to be applicable to both domestic (parenteral administration) or 
feral (oral administration) swine.  In addition, heat-killed preparations of 353-1 were also 
examined in adjuvant preparations of squalene/Pluronic F127 and Quil A which have 
been shown to enhance type 1-T helper lymphocyte (Th-1) cytokine responses.28, 31
 Rough strains of Brucella are attractive as vaccine strains due to their general lack 
of virulence and their inabilility to cause seroconversion to standard Brucella serological 
assays.27, 32, 33 B. suis 353-1 induced no lesions when administered at a low dose 
(Experiment 1).  Lymphoplasmacytic interstitial nephritis was the only histological lesion 
observed in swine administered a vaccine dose either orally or parenterally (Experiment 
2).  The results of these studies showed that 353-1 first colonized draining lymph nodes 
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and then was systemically distributed throughout the lymphoreticular system.  Total 
clearance of 353-1 appears to be achieved by 20 weeks after inoculation/vaccination as 
the latest tissue isolation of 353-1 was at 18 weeks postinoculation in Experiment 1, and 
the last blood culture isolation of 353-1 was week 17 after parenteral vaccination.  In 
addition no swine which were inoculated with a low dose by conjunctival administration 
or vaccine dose of 353-1 by parenteral or oral administration developed positive 
serological reactions to standard Brucella serological detection assays which rely on 
detecting antibodies to the O-polysacchiride side chain of LPS.   
 B. suis 353-1 also appears to not be shed by vaccinated animals.  There was no 
isolation of 353-1 from weekly environmental swabs.  Also, there were no nasal or 
conjunctival swabs culture positive for 353-1 after vaccination.  In addition, 4 
nonvaccinated swine were used as sentinel animals which were commingled with the 
group parenterally vaccinated with live 353-1.  These animals were commingled from 
day 0 of vaccination, and none of these sentinels were blood culture positive for 353-1 at 
any of the weekly postvaccination sampling times.   
 Proliferation of antigen-stimulated PBMCs from postvaccination animals has 
been associated with protective immunity with B. abortus RB51 in both cattle and 
bison.25, 34 Parenteral and oral vaccination with live 353-1 as well as vaccination with 
adjuvanted, heat-killed 353-1 induced proliferative responses in cultured PBMCs which 
were stimulated with heat-killed 353-1 antigen.  These responses occurred sooner and 
were more robust than those associated with the lower dosage of 353-1 administered via 
conjunctival administration in Experiment 1.  
 IFN-γ has also been reported to be necessary for clearance of B. abortus in 
murine models,35 and IFN-γ production by antigen stimulated lymphoid cells has also 
been associated with protective immunity in B. abortus murine models.26, 36  In swine, 
IFN-γ gene transcription has been found to be associated with intracellular Toxplasma 
gondii infection and has been recognized as a key marker of a Th-1 polarized immune 
response.37, 38   In the current study, IFN-γ was significantly elevated at multiple time 
points after vaccination in the parenterally and orally vaccinated groups as well as the 
squalene/Pluronic F127 adjuvant group.  There was also a lack of production of 
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interleukin-4 (IL-4) by the same antigen stimulated PBMCs.  IL-4 upregulation has been 
associated with Th-2 polarized cell-mediated immune processes in swine.37  Murine 
models of brucellosis suggest that the lack of an IL-4 response is advantageous in 
allowing maximal production of Th-1 cytokines39 and in the clearance of Brucella 
abortus.40, 41
Humoral immune responses were also significantly higher in swine parenterally 
vaccinated with live 353-1 or adjuvanted heat killed 353-1.  The orally vaccinated group 
had no differences in humoral responses to 353-1 as measured by ELISA compared to the 
control group.  Although humoral responses are commonly observed against Brucella 
vaccine strains which induce protective immunity,34, 42 humoral immune responses 
themselves are not necessarily a correlate of protection in Brucella vaccine models.43
B. suis 353-1 conferred partial protection to challenge with the virulent strain B. 
suis 3B.  Protection was assessed in these studies by bacterial recovery.  Decreases in 
recovery of B. suis 3B was most noteworthy in the groups parenterally and orally 
vaccinated with live 353-1 in these groups there was a significant decrease in the log 
CFU/g of tissue recovery of B. suis 3B in multiple tissues.  There was also a significant 
decrease in the number of animals being splenic culture positive from those two groups 
and a decrease in the number of animals which were culture positive from the medial 
retropharyngeal lymph node in the orally vaccinated group.  Both adjuvant groups also 
had a significant decrease in recovery of B. suis 3B from the spleen on a log CFU/g of 
tissue basis.  Antemortem, postchallenge recovery of B. suis 3B was significantly lower 1 
week after challenge in both live vaccine groups.  All vaccinated groups also exhibited a 
delay in seroconversion to B. suis 3B by one week compared to controls.   
Histological lesions consistent with those previously reported for B. suis5 were 
present in postchallenge necropsy samples.  Although there was a decrease in lesions in 
all vaccine groups, there was a statistically significant decrease in total lesions in the 
orally vaccinated group and the group vaccinated with Quil A adjuvanted heat-killed 353-
1 and a statistically significant decrease in hepatitis in the orally vaccinated group. 
 The results of these studies suggest that 353-1 is a stable, rough mutant of B. suis 
which may have promise in the prevention of swine brucellosis.  B. suis 353-1 was shown 
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to induce a Th-1 polarized immune response in vaccinated swine and confer partial 
protection to challenge with virulent B. suis.  The preliminary studies reported here 
suggest that further investigations into applications of 353-1 could be beneficial to 
develop tools for aiding efforts in controlling swine brucellosis in domestic and feral 
populations. 
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Table 1.  Experiment 1, postinoculation, antemortem recovery of B. suis 353-1.  Twenty-
one 6 week old, crossbred domestic swine were conjunctivally inoculated with 5.0 X 107 
B. suis 353-1 and sampled weekly 1 to 18 weeks after inoculation. 
 Week after inoculation  
Sample 1 2 3 18* Total 
Whole Blood 0/21 6/19 1/17 1/7 7/21 
Conjunctival swab 1/21 0/19 1/17 0/7 2/21 
Nasal swab 0/21 0/19 0/17 0/7 0/21 
Vaginal swab 0/7 0/7 0/7 0/2 0/7 
*There were no positive samples in any groups weeks 4 to 17 after inoculation. 
 
 
 
Table 2.  Experiment 2, postvaccination, antemortem blood culture recovery of B. suis 
353-1.  Six week old, crossbred, domestic swine were either parenterally vaccinated with 
2.0 X 1010 CFU of B. suis 353-1 or orally vaccinated with an average dose of 5.0 X 1011 
B. suis 353-1. 
 Week after vaccination  
 1 2 3 4 5 6 7 8 9 17* Total 
Parenteral 
Vaccinates 25/44 13/44 0/40 0/40 0/36 0/36 0/31 2/31 1/26 1/17 30/44 
Oral 
Vaccinates 18/30 17/30 2/30 0/30 1/26 0/26/ 0/26 1/26 0/22 0/22 26/30 
*No animals were blood culture positive for B. suis 353-1 between weeks 9 and 17 or 
after week 17 after vaccination. 
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Table 3.  Experiment 1, postinoculation recovery of B. suis 353-1.  A total of 21 
crossbred, domestic swine were conjunctivally inoculated with 5.0 X 107 CFU B. suis 
353-1 and necropsied 1-18 weeks after inoculation.  
 
 Week after inoculation 
Tissue 1 2 3 4 10 18 
Lung  0/2 0/2 0/2 0/3 1/5 0/7 
Liver 0/2 0/2 1/2 0/3 0/5 0/7 
Spleen 0/2 1/2 0/2 0/3 0/5 1/7 
Kidney 0/2 1/2 0/2 0/3 0/5 0/7 
Medial Retropharyngeal LN 1/2 1/2 1/2 1/3 1/5 0/7 
Mandibular LN 0/2 2/2 0/2 1/3 0/5 0/7 
Parotid LN 0/2 1/2 1/2 0/3 1/5 0/7 
Prescapular LN 0/2 0/2 0/2 0/3 0/5 0/7 
Prefemoral LN 0/2 0/2 1/2 0/3 0/5 0/7 
Popliteal LN 0/2 0/2 1/2 0/3 0/5 1/7 
Inguinal LN 0/2 0/2 0/2 0/3 1/5 0/7 
Ileocecal LN 0/2 0/2 1/2 0/3 0/5 0/7 
Sternal LN 0/2 0/2 0/2 0/3 0/5 0/7 
Tracheobronchial LN 0/2 0/2 0/2 0/3 0/5 0/7 
Gastrohepatic LN 0/2 0/2 0/2 3/3 1/5 0/7 
Uterus NA NA 0/1 NA 0/4 0/2 
Testis 0/2 0/2 0/1 0/3 0/1 0/5 
Male Accessory Sex Glands 0/2 0/2 0/1 0/3 0/1 0/5 
Urine 0/2 0/2 0/2 0/3 0/5 0/7 
Total number of swine 
culture positive 1/2 2/2 2/2 3/3 2/5 1/7 
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Table 4.  Experiment 2, postvaccination recovery of B. suis 353-1 from samples obtained 
at necropsy from crossbred, domestic swine parenterally vaccinated with 2.0 X 1010 CFU 
of B. suis 353-1. 
 Week after vaccination 
Tissue 2 4 6 8 12 16 20 24 
Lung 0/4 1/4 0/5 0/5 0/5 0/4 0/4 0/4 
Liver 0/4 1/4 0/5 1/5 0/5 0/4 0/4 0/4 
Spleen 0/4 1/4 0/5 1/5 0/5 0/4 0/4 0/4 
Kidney 0/4 1/4 0/5 1/5 0/5 0/4 0/4 0/4 
Gastrohepatic LN 3/4 1/4 0/5 0/5 0/5 0/4 0/4 0/4 
Mandibular LN 1/4 1/4 1/5 0/5 0/5 0/4 0/4 0/4 
Medial Retropharyngeal LN 0/4 2/4 0/5 0/5 1/5 0/4 0/4 0/4 
Prescapular LN 1/4 1/4 0/5 0/5 0/5 0/4 0/4 0/4 
Parotid LN 1/4 2/4 0/5 1/5 0/5 0/4 0/4 0/4 
Popliteal LN 1/4 0/4 0/5 0/5 0/5 0/4 0/4 0/4 
Sternal LN 2/4 3/4 0/5 1/5 0/5 0/4 0/4 0/4 
Tracheobronchial LN 2/4 1/4 1/5 1/5 0/5 0/4 0/4 0/4 
Uterus 0/2 0/2 0/2 0/3 0/3 0/2 0/2 0/2 
Testis 0/2 0/2 0/3 0/2 0/2 0/2 0/2 0/2 
Male Accessory Sex Organs 0/2 0/2 0/3 0/2 0/2 0/2 0/2 0/2 
Urine 0/4 0/4 0/5 0/5 0/5 0/4 0/4 0/4 
Total number of swine 
culture positive 4/4 3/4 1/5 1/5 1/5 0/4 0/4 0/4 
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Table 5.  Experiment 2, postvaccination recovery of B. suis 353-1 from samples obtained 
at necropsy from crossbred, domestic swine orally vaccinated with an average dose of 5.0 
X 1011 CFU of B. suis 353-1. 
 Week after inoculation 
Tissue 4 8 16 20 24 
Lung 1/4 0/4 0/4 0/4 0/4 
Liver 0/4 0/4 0/4 0/4 0/4 
Spleen 0/4 2/4 0/4 0/4 0/4 
Kidney 0/4 0/4 0/4 0/4 0/4 
Gastrohepatic LN 0/4 0/4 0/4 0/4 0/4 
Mandibular LN 1/4 3/4 0/4 0/4 0/4 
Medial Retropharyngeal LN 0/4 0/4 0/4 0/4 0/4 
Prescapular LN 0/4 0/4 0/4 0/4 0/4 
Parotid LN 0/4 0/4 0/4 0/4 0/4 
Popliteal LN 0/4 1/4 0/4 0/4 0/4 
Sternal LN 0/4 0/4 0/4 0/4 0/4 
Tracheobronchial LN 1/4 0/4 0/4 0/4 0/4 
Uterus 0/2 0/2 0/2 0/2 0/2 
Testis 0/2 0/2 0/2 0/2 0/2 
Male Accessory Sex Organs 0/2 0/2 0/2 0/2 0/2 
Urine 0/4 0/4 0/4 0/4 0/4 
Total number of swine 
culture positive 1/4 4/4 0/4 0/4 0/4 
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Table 6.  Postchallenge seroconversion and antemortem bacterial culture results of 
control swine and swine vaccinates with B. suis 353-1.  Swine were conjunctivally 
challenged with 5.0 X 107 CFU of B. suis 3B 30 weeks (parenteral and oral groups) or 16 
weeks (adjuvanted, heat-killed vaccine groups) after vaccination. 
 Week after virulent challenge  
 1 2 3 4 Total 
Serology      
Controls 9/9 9/9 9/9 9/9 9/9 
Parenteral Vaccinates 3/9* 8/9 9/9 9/9 9/9 
Oral Vaccinates 5/10* 9/10 9/10 9/10 10/10 
Squalene Vaccinates 0/5* 5/5 5/5 5/5 5/5 
Quil A Vaccinates 0/5* 5/5 5/5 5/5 5/5 
Blood Culture      
Controls 4/9 0/9 1/9 0/9 5/9 
Parenteral Vaccinates 2/9 1/9 0/9 9/9 3/9 
Oral Vaccinates 2/10 0/10 0/10 0/10 2/10 
Squalene Vaccinates 1/5 0/5 0/5 0/5 1/5 
Quil A Vaccinates 5/5 3/5 3/5 2/5 5/5 
Swab Culture      
Controls 4/9 2/9 0/9 0/9 5/9 
Parenteral Vaccinates 0/9* 1/9 1/9 0/0 1/9 
Oral Vaccinates 0/10* 1/10 0/10 0/10 1/10* 
Squalene Vaccinates 2/5 2/5 2/5 0/5 3/5 
Quil A Vaccinates 2/5 1/5 3/5 2/5 5/5 
*P<0.05 
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Table 7. Experiment 2, postchallenge recovery of B. suis 3B. Results are expressed as the 
percentage of animals from which B. suis 3B was recovered from controls (n=9), pigs 
orally vaccinated with an average dose of 5.0 X 1011 B. suis 353-1 (n=10), pigs 
intramuscularly vaccinated with 2.0 X 1010 CFU B. suis 353-1 (n=9), and pigs 
intramuscularly vaccinated with 2.0 X 1010 CFU of heat-killed B. suis 353-1 which was 
adjuvanted with squalene/Pluronic F127 (n=5) or Quil A (n=5).  Animals were 
challenged with 5.0 X 107 CFU B. suis 3B via conjunctival administration 30 weeks (oral 
and parenteral groups) or 16 weeks (heat-killed vaccine groups) after vaccination. 
 Controls Oral 
Vaccinates 
Parenteral 
Vaccinates 
Squalene 
Vaccinates 
Quil A 
Vaccinates 
Blood 0.0 0.0 0.0 0.0 0.0 
Urine 11.1 10.0 0.0 0.0 0.0 
Lung 22.2 0.0 0.0 0.0 0.0 
Liver 22.2 0.0 11.1 0.0 0.0 
Spleen 66.7 10.0* 0.0* 20.0 20.0 
Kidney 11.1 0.0 0.0 0.0 0.0 
Gastric Hepatic 
L.N. 
100 70.0 88.9 100 100 
Mandibular L.N. 100 60.0 88.9 100 100 
Medial 
Retropharyngeal 
L.N. 
77.8 20.0* 66.7 80.0 100 
Prescapular L.N. 55.6 40.0 44.4 80.0 100 
Parotid L.N. 100 60.0 88.9 100 100 
Popliteal L.N. 33.3 30.0 22.2 80.0 60.0 
Sternal L.N. 33.3 20.0 0.0 40.0 60.0 
Tracheobronchial 
L.N. 
88.9 50.0 44.4 60.0 40.0 
*P<0.05 
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Table 8.  Summary of histological lesions by treatment group observed after challenge 
with 5.0 X 107 CFU B. suis 3B via conjunctival route 30 weeks (parenteral and oral 
group) or 16 weeks (squalene and Quil A group) after vaccination. 
 Hepatitis1
 
Lymphadenitis2 Interstitial 
Nepritis3
Inflammation 
of Male 
Accessory Sex 
Gland4
NSL5
Control 4/9 4/9 4/9 0/9 2/9 
Sentinel 2/4 2/4 0/4 1/4 1/4 
Parenteral 3/9 1/9 1/9 0/9 6/9 
Oral 0/10* 0/10 1/10 0/10 9/10* 
Squalene 0/5 0/5 2/5 0/5 3/5 
Quil A 0/5 0/5 0/5 0/5 5/5* 
1Multifocal, lymphoplasmacytic and purulent portal to random hepatitis 
2Multifocal to locally extensive purulent to pyogranulomatous lymphadenitis 
3Multifocal, lymphocytic interstitial nephritis 
4Diffuse, lymphoplasmacytic and purulent prostatitis and seminal vessiculitis with 
marked fibrosis 
5No significant lesions 
*P<0.05 
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Figure 1.  Serologic responses of negative control pigs (dark boxes, n=9) and pigs 
intramuscularly vaccinated with 2.0 X 1010 CFU B. suis 353-1 (light boxes, n=9) to heat-
killed B. suis 353-1 ELISAs.  Responses are reported as mean optical density (OD) ± 
SEM.  
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Figure 2.  Serologic responses of negative control pigs (dark boxes, n=9) and pigs 
intramuscularly vaccinated with 2.0 X 1010 CFU of heat-killed B. suis 353-1 adjuvanted 
with either squalene/Pluronic F127 (light boxes, n=5) or Quil A (open boxes, n=5) to 
heat-killed B. suis 353-1 ELISAs.  Responses are reported as mean optical density (OD) 
± SEM.  
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aP<0.05 squalene/pluronic F127 adjuvant group 
bP<0.05 Quil A adjuvant group 
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 Figure 3.  Experiment 1, peripheral blood mononuclear cell (PBMC) blastogenesis 
assays of negative control pigs (dark boxes) and pigs conjunctivally inoculated with 5.0 
X 107 CFU B. suis 353-1. Proliferative responses are expressed as stimulation indexes ± 
SEM.  Data was obtained from 6 (week 18) or 10 (weeks 0, 6, 10, and 15) inoculated pigs 
and 6 control pigs per time period. 
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Figure 4.  Experiment 2, peripheral blood mononuclear cell (PBMC) blastogenesis assays 
of parenterally vaccinated (light boxes) and sham vaccinated controls (dark boxes). 
Proliferative responses obtained after intramuscular vaccination with 2.0 X1010 CFU B. 
suis 353-1.  Results are expressed as stimulation indexes ± SEM.  Data was obtained 
from 9 vaccinates and 9 control animals per time period. 
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Figure 5.  Experiment 2, peripheral blood mononuclear cell (PBMC) blastogenesis assays 
of orally vaccinated (light boxes) and nonvaccinated controls (dark boxes). Proliferative 
responses obtained after oral vaccination with an average dose of 5.0 X 1011 CFU B. suis 
353-1.  Results are expressed as stimulation indexes ± SEM.  Data was obtained from 10 
vaccinates and 9 control animals per time period. 
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Figure 6.  Experiment 2, peripheral blood mononuclear cell (PBMC) blastogenesis assays 
of swine intramuscularly vaccinated with 2.0 X 1010 CFU of heat-killed B. suis 353-1.  
Proliferative responses of controls (dark boxes, n=9), pigs vaccinated with 
squalene/Pluronic F127 adjuvanted vaccine (light boxes, n=5), and Quil A adjuvanted 
vaccine (open boxes n=5) are expressed as stimulation indexes ± SEM.   
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aP<0.05, squalene/Pluronic F127 adjuvant group 
bP<0.05, Quil A adjuvant group 
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Figure 7.  Experiment 2, results of interferon-gamma (IFN-γ) ELISAs from culture 
supernatant of antigen-stimulated peripheral blood mononuclear cells (PBMCs) from 
controls (dark boxes, n=9) and pigs intramuscularly vaccinated with 2.0 X1010 CFU B. 
suis 353-1.  Results are expressed as mean IFN-γ concentration ± SEM. 
0
200
400
600
800
1000
1200
1400
0 3* 5* 7* 9 11 15* 17* 19 21* 23 25* 27* 29* 30* p.c. w.
1*
p.c. w.
2*
p.c. w.
3*
Week
In
te
rf
er
on
-g
am
m
a 
(p
g/
m
l)
 
*P<0.05 
 
 137
Figure 8.  Experiment 2, results of interferon-gamma (IFN-γ) ELISAs from culture 
supernatant of antigen-stimulated peripheral blood mononuclear cells (PBMCs) from 
controls (dark boxes, n=9) and pigs orally vaccinated with an average dose of 5.0 X 1011 
CFU of B. suis 353-1 (light boxes. n=10).  Results are expressed as mean IFN-γ 
concentration ± SEM.  
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Figure 9.  Experiment 2, results of interferon-gamma (IFN-γ) ELISAs from culture 
supernatant of antigen-stimulated peripheral blood mononuclear cells (PBMCs) from 
controls (dark boxes, n=9) and pigs intramuscularly vaccinated with 2.0 X 1010 CFU of 
heat-killed B. suis 353-1 adjuvanted with either squalene/Pluronic F127 (light boxes) or 
Quil A (open boxes).  Results are expressed as mean IFN-γ concentration ± SEM.  
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aP<0.05, squalene/Pluronic F127 group. 
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 Figure 10.  Experiment 2, postchallenge recovery of B. suis 3B from tissues obtained at 
necropsy 30-32 days after challenge with 5.0 X 107 CFU B. suis 3B.  Bacterial recovery 
is expressed as log CFU/g of tissue ± SEM for controls (dark boxes, n=9) and pigs 
intramuscularly vaccinated with 2.0 X 1010 CFU of B. suis 353-1 (light boxes. n=9) 30 
weeks prior to challenge. 
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Figure 11.  Experiment 2, postchallenge recovery of B. suis 3B from tissues obtained at 
necropsy 30-32 days after challenge with 5.0 X 107 CFU B. suis 3B.  Bacterial recovery 
is expressed as log CFU/g of tissue ± SEM for controls (dark boxes, n=9) and pigs orally 
vaccinated with an average dose of 5.0 X 1011 CFU of B. suis 353-1 (light boxes. n=10) 
30 weeks prior to challenge. 
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Figure 12.  Experiment 2, postchallenge recovery of B. suis 3B from tissues obtained at 
necropsy 30-32 days after challenge with 5.0 X 107 CFU B. suis 3B.  Bacterial recovery 
is expressed as log CFU/g of tissue ± SEM for controls (dark boxes, n=9) and pigs 
intramuscularly vaccinated with 2.0 X 1010 CFU of heat-killed B. suis 353-1 adjuvanted 
with either squalene/Pluronic F127 (light boxes, n=5) or Quil A (open boxes, n=5) 16 
weeks prior to challenge.  
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Figure 13A.  Portal hepatitis in a nonvaccinated, control animals 32 days after challenge 
with 5.0 X 107 CFU B. suis 353-1.  The portal area is expanded with lymphocytes, 
plasma cells, and neutrophils which extend beyond the limiting plate.   
 
Figure 13B.  Purulent and histiocytic lymphadenitis in a nonvaccinated, control animal 32 
days after challenge with 5.0 X 107 CFU B. suis 3B.  Sinuses are expanded by large 
numbers of neutrophils and moderate numbers of macrophages. 
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Figure 13C.  Granulomatous lymphadenitis in a nonvaccinated, control animal 32 days 
after challenge with 5.0 X 107 CFU B. suis 3B.  The perifollicular area contains dense 
aggregates of multinucleated giant cells and epithelioid macrophages.   
 
Figure 13D.  Lymphoplasmacytic interstitial nephritis in a nonvaccinated, control animal 
32 days after challenged with 5.0 X CFU 107 B. suis 3B.  Aggregates of lymphocytes and 
plasma cells are found segmentally around a glomerulus and between cortical tubules. 
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CHAPTER 7.  GENERAL CONCLUSIONS 
 
Due to the near eradication of brucellosis in domestic livestock within the US, 
there has been increased interest in developing control efforts for brucellosis in wildlife 
reservoirs of Brucella.  Feral swine, which are continually penetrating new areas in the 
US and growing in population, serve as a reservoir for Brucella in at least 15 states.  
USDA Animal and Plant Health Inspection Service (APHIS) and Wildlife Services (WS) 
have expressed great interest in utilizing vaccines to control brucellosis in feral swine 
populations.  Early reports of immunogenicity and efficacy of the vaccine B. abortus 
RB51 (RB51)9, 12 within the research and regulatory community prompted an effort to 
further characterize RB51 as well as other potential vaccine candidates.   The work 
reported within this dissertation attempted to contribute to the knowledge base which will 
aid in dealing with feral swine brucellosis by characterizing Brucella infection and 
diagnostics within an enzootically feral swine population as well as characterizing 
candidate vaccines within feral and domestic swine. 
 The studies reported within Chapter 3 examined an isolated feral swine herd on an 
island on the Atlantic coast of South Carolina.  This herd had been previously 
documented to be enzootically infected with Brucella based on serological 
assessments.10, 23  It was found in the current study that this population is harboring 
multiple strains of both B. suis and B. abortus.  Strain differences among the biovar 1 
isolates of B. suis were found using an assay which assessed 8 loci of a variable 
nucleotide tandem repeat (VNTR) within the Brucella genome.3, 4  A VNTR assay was 
also used to examine the B. abortus isolates; however, isolate differences were more 
pronounced as the B. abortus strain 19 (S19) vaccine was found to be enzootic within the 
population.  This was the first report of a feral swine population enzootically infected 
with B. abortus.  The vaccine strain RB51 was also found within the population.  RB51 
was introduced into the population as part of the studies reported in Chapter 4.  The 
establishment of chronic infections with B. abortus was unexpected, as most 
experimental infection studies with B. abortus in swine have found that there is only a 
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short term infection of only several weeks duration of the lymph nodes which drains the 
site of infection.1, 8, 14, 15  Indeed studies with RB51 in domestic swine reported in Chapter 
5 found that RB51 could only be isolated from the draining lymph node within a few 
weeks after experimental infection.  No animals became bacteremic or systemically 
infected with RB51 in the domestic swine trials reported in Chapter 5.  This interesting 
discrepancy between experimental infection and field observation has several possible 
explanations.  First, the B. abortus isolates from the feral swine could be swine adapted 
exhibiting particular tropism for swine tissues which enhances their infection.  
Experimental infections were conducted with these isolates in domestic swine 
(unpublished data), and the results were highly similar to other experimental infections 
with B. abortus in swine; these isolates only established a short-lived infection of the 
draining lymph nodes.  Second, perhaps prior infection with B. suis allows enhancement 
of infection with B. abortus in swine.  This type of immune-mediated enhancement of 
infection has been reported with other species of antigenically similar bacteria.13, 21 
Although many animals harbored both B. abortus and B. suis, B. abortus was the only 
species isolated from seven of 62 culture positive animals.  However, making individual 
species isolations in the face of a mixed Brucella infection is tedious; therefore, the lack 
of a B. suis culture does not totally exclude its presence, particularly within this herd with 
such a high culture prevalence of Brucella.  Another interesting possibility is the down 
regulation of a typical Th1 response by other pathogens.  This herd had a very high 
prevalence rate of nematode infestation particularly from Stephanurus dentatus.  
Helminth infestation has been shown to down regulate the Th1 response and enhance 
infection with bacteria.2, 5, 18, 20  However, further investigations into how this process 
may enhance Brucella infections have not been undertaken.   
 The extremely high prevalence of Brucella infection in this feral swine herd 
reiterates the predisposition which has been documented in the literature for swine to 
become chronically infected with B. suis.  This high culture positivity rate allowed some 
general assessments of serological assays to be made.  The apparent sensitivity rate of the 
three assays investigated in these studies was quite low.  When these tests were used in 
parallel, the overall sensitivity was 54.1% and individual assay sensitivity rates ranged 
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from 13.1% to 44.6%.  This is contrasted with the seroconversion rates observed in the 
experiments from Chapters 5 and 6.  Using the same three assays in parallel, the 
sensitivity rate was 100% when sera from swine challenged with B. suis 3B were used.  
This extreme difference suggests that the sensitivity for these assays is excellent in the 
case of acute infection and extremely poor in the case of chronic infection and that these 
assays are unreliable for determining individual infected animals.   
 The results from the studies reported in Chapters 4 and 5 fail to support the 
immunogenicity and efficacy of RB51.  Contrary to what was previously published, 
RB51 did not induce a cell-mediated or humoral immune response in vaccinated, 
domestic swine.  Total clearance of RB51 was achieved quickly without first establishing 
a systemic distribution of the bacterium.  This lack of immune responses and systemic 
distribution was associated with a lack of protection in a pregnant gilt challenge model 
based on bacterial recovery from maternal and fetal tissues.  A field trial with RB51 in 
feral swine also had no effect on preventing further infection and seroconversion to 
Brucella within the vaccinated population.  Furthermore, as previously mentioned, RB51 
established a chronic infection in 13.6% of the recapture vaccinated animals.  There were 
major differences in the study designs which could explain the incongruity among the 
results of the current study and those of the previously reported studies dealing with 
RB51 in swine.  Within the Lord study, there was no defined challenge dose; gilts were 
bred to boars which were previously determined to be shedding B. suis in their semen.12  
However, there was no attempt to validate and quantitated Brucella shedding rates within 
semen on the days of breeding; therefore, there was an undefined challenge dose.  
Furthermore, the criteria for determining protection centered on the abortion rate.  
Cultures from fetal tissues and gilt vaginal swabs were only performed on animals which 
were deemed to have aborted, which in the vaccine groups was 0%.  As previously 
demonstrated in the literature, abortion is a relatively rare event in a Brucella infected 
swine herd particularly in chronically infected herds.11, 15  Edmond’s study determined 
that swine vaccinated with RB51 developed significant humoral immune responses;9 
however, there was no nonvaccinated, age-matched control group within that study.  
Therefore, that determination seems invalid.   
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 The studies reported in Chapter 6 examined a naturally rough mutant of B. suis, B. 
suis 353-1 (353-1) as a vaccine candidate in swine.  The original isolate of 353-1 was 
made from the urine of a feral pig; therefore, there was initial skepticism on the potential 
for it to be a vaccine because of the possibility of urinary shedding in vaccinated animals.  
As well as being nonpathogenic in domestic swine, 353-1 was found to not be shed from 
vaccinated animals.  Both cell-mediated and humoral immune responses were found to be 
elicited by vaccination with 353-1.  Although there are no established correlates of 
protection in the Brucella vaccinology field, proliferation of antigen stimulated peripheral 
blood mononuclear cells (PBMCs) has repeatedly been associated with vaccine efficacy 
in cattle and bison.16, 17  Proliferation was induced with antigen stimulation of PBMCs of 
353-1 vaccinated animals.  There were also significant differences in interferon gamma 
(IFN-γ) production by antigen stimulated PBMCs from vaccinated animals compared to 
controls.  IFN-γ has been shown to be pivotal in the demonstration of a Th1 polarized 
cell-mediated immune response which is associated with clearance of intracellular 
pathogens in pigs.6, 7  The PBMC proliferation and IFN-γ responses were associated with 
reduced recovery of virulent B. suis from necropsy tissues four weeks after vaccinated 
pigs were challenged.  Therefore, 353-1 possesses several characteristics of a favorable 
vaccine candidate:  1) It is nonpathogenic for the target species.  2)  It is not shed into the 
environment from vaccinated animals.  3)  After redistribution and systemic lymphoid 
infection, it is cleared from the body.  4)  It is immunogenic.  5)  It reduces colonization 
of virulent B. suis after challenge.   
 Although the initial trials with 353-1 are promising, there are still major hurdles to 
using a live vaccine in a feral swine population.  B. suis is zoonotic, and is more virulent 
for humans than B. abortus.  All work with 353-1 thus far has been conducted in a 
biosafety level 3 (BSL-3) environment.  Further virulence trials are warranted before 
conducting work outside of a BSL-3 facility.  Inoculation studies in mice and guinea pigs 
have been the hallmark of assessing virulence of Brucella strains,19, 22  and such studies 
are warranted with 353-1.  Effects on nontarget species should also be determined.  
Because of these safety issues, live 353-1 may be a better vaccine candidate for domestic 
swine than feral swine.  However, 353-1 is proof of the concept that swine can develop 
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protective immunity with Brucella vaccination and is a model for further investigations 
into Brucella infection and immunity in swine.    
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